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Introduction
Cervical cancer is the fourth most common cancer and the fourth leading cause 
of cancer death among women worldwide. It is a significant health care problem, 
particularly in the developing countries; almost nine out of ten cervical cancer deaths 
occur in the less developed regions.1 Since the introduction of cytological screening 
for cervical cancer in many developed countries, the incidence and mortality rate 
of cervical cancer have markedly diminished.2 Although the Netherlands has a good 
program for cervical cancer screening, there are ways in which cervical cancer 
prevention can be improved to further reduce the numbers of newly diagnosed cases 
(700 a year) and deaths due to cervical cancer (200–250 a year).3 Recently, the Dutch 
Minister of Health decided to reshape the Dutch screening program for cervical 
cancer.4 Testing for high-risk human papillomavirus (hrHPV) will replace cytology 
testing as the primary screening method in 2016.
This introduction gives a brief outline of the considerations that led to the 
implementation of primary HPV screening for cervical cancer and moreover of 
the opportunities for its further improvement, which is the main objective of the 
research described in this thesis. Chapter 2 provides a thorough overview of all 
aspects of HPV screening.
From cytology to HPV screening
Cervical cancer screening started in the Netherlands in the early 1970s. Since the 
restructuring of the Dutch screening program in 1988 and 1996, there has been 
a nationwide program targeting women aged 30–60 years. They are invited at 
5-year intervals for cervical smears, often taken by their physician or the practice 
assistants.5,6 The smears are used for cytology testing. The aim of cytology screening 
is to detect morphological abnormalities in the cells, which can be cancerous or 
precancerous lesions. 
However, such a morphological abnormality is the result of an earlier event: an 
infection with hrHPV. There is no longer any doubt that infection with hrHPV is a 
prerequisite for the development of precancerous or cancerous cervical lesions.7 
This etiological role of hrHPV in the development of cervical cancer was discovered 
in the early 1980s.8-10 Human papillomavirus is a very common, sexually transmitted 
virus, and the lifetime risk exceeds 50%.11,12 Approximately 80% of all HPV infections 
clear within 24 months without clinical signs or symptoms (transient infections).13,14 
However, some infections may become persistent and significantly increase the 
risk of premalignant or malignant changes in the cervix (persistent infections). The 
time lag between the peak of the HPV infection and cancer incidence is 2–4 decades. 
This makes HPV an appropriate target for screening and early detection of cervical 
precancer and cancer.15
So far, this knowledge about HPV has led to several changes in the Dutch program 
for cervical cancer screening. Since 2006, Dutch guidelines recommend that when 
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borderline cytological abnormalities or mild dyskaryosis are found, a repeat smear 
should be tested for hrHPV after 6 months.16 A recent breakthrough in the prevention 
of cervical cancer is the development of an HPV vaccine (primary prevention). Since 
2009, a bivalent HPV vaccine has been included in the Dutch National Immunization 
Program, which targets 12-year-old girls.17 In March 2009, a catch-up campaign was 
organized for girls aged 13 to 16 years. From 2010 onward, girls who reach the age 
of 12 are invited for immunization. Most recently, in 2013, the Minister of Health 
decided to implement primary hrHPV testing in the Dutch program for cervical 
screening (secondary prevention), where it replaces cytology testing.4 This switch 
has no practical consequences for the participants; the physician will collect the 
smear to be tested for HPV, as before.
Advantages and disadvantages of HPV screening
The main reason for the change from cytology to HPV testing is its higher sensitivity: 
HPV testing detects high-grade precancerous lesions better and earlier than cytology 
testing does. This increases the likelihood of treatment before precancerous lesions 
transform to cervical cancer.18-23 In addition, this high sensitivity and the high 
negative predictive value of HPV testing make longer screening intervals possible: if 
an HPV test is negative, the probability is greater that a woman is truly not infected. 
Altogether, there is a firm basis for the implementation of primary HPV testing in 
cervical screening. 
The main concern, however, is that the specificity and positive predictive value 
of HPV testing for detecting high-grade precancerous lesions are lower than those of 
cytology testing, since an HPV test does not discern between transient and persistent 
infections.21,24,25 To prevent unnecessary colposcopy referrals, psychosocial distress, 
and possible overtreatment,21, 25, 26 a positive hrHPV test needs an additional reflex 
or follow-up triage test.27 A triage test sorts and selects women whose hrHPV test 
results are positive with greater specificity before referral for colposcopy. The Dutch 
minister decided to use cytology testing for this purpose.4 However, other tests might 
better fulfill this role. This thesis investigates several of these tests.
Furthermore, the reshaped screening program will make it possible for 
women who do not attend regular screening to order a device for self-collection 
of cervicovaginal material. Although HPV self-sampling in cervical screening is 
relatively new and unknown, it is a promising method. This thesis elaborates several 
aspects of screening with HPV self-sampling.
Factors in the effectiveness of a screening program
Apart from the aspects already mentioned, there are many other factors on which 
the effectiveness of a screening program depends. Several of these factors play a role 
in this thesis, which aims to improve the effectiveness of the HPV screening program. 
In general, the effectiveness of any screening program depends on factors such as:28
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1  The organization of screening and the participation of the targeted population: only 
screening programs carefully organized to reach a large proportion of the at-risk 
population are likely to be fully successful.
2  Characteristics of the screening test: the aims of a screening test are (a) to identify 
as many patients with the disease as possible while ensuring that as few as 
possible remain undetected (high sensitivity) and (b) to correctly identify as many 
patients without the disease as possible, in order to prevent them from undergoing 
unnecessary further diagnostic tests (high specificity). The likelihood that the result 
of a positive screening test is correct is called the positive predictive value. This 
strongly depends on the prevalence of the disease within the population. 
3  Test procedures should be acceptable. Acceptability of a test is the extent to which 
those for whom the test is designed agree to be tested. Apart from being acceptable, 
test procedures should be safe and relatively inexpensive.
4  Frequency of screening and age ranges have to be determined in a screening program; 
benefits, harms, and costs must be taken into account. 
5  Early treatment and follow-up compliance: when a disease is detected in a screening 
program, early treatment should be available and effective, and it should be capable 
of reducing morbidity and mortality. Besides that, all patients with precancer and 
cancer should receive follow-up care, which is necessary to identify recurrence. 
Aims and outline of the thesis: opportunities for improvement of HPV screening
This thesis starts with an overview of the efficacy of the current cervical cancer 
screening and describes the future perspectives of promising new screening 
strategies (Chapter 2). In the chapters that follow, several aspects concerning the 
effectiveness of the HPV screening program are investigated.
One of the factors essential to the success of any screening program, as already 
mentioned, is participation.29 The participation rates of the current programs for 
population-based cervical screening are not optimal.30 In the Netherlands, 30% of 
the women invited annually do not participate in the cervical cancer screening.31 
The reasons for non-participation in the Dutch screening population remain unclear. 
Offering self-sampling for hrHPV testing appears to be a feasible method to reach 
non-participants of the regular cervical cancer screening and thereby to improve 
the screening effectiveness.32-35 One of the aims of this thesis is to examine women’s 
reasons for not participating in regular screening more closely and to investigate why 
women do or still do not participate in screening when offered a self-sampling device. 
A questionnaire study on these topics is presented in Chapter 3. It shows the results 
of 10,166 questionnaires completed by non-responders to the regular screening 
program. 
Various self-sampling devices for hrHPV testing have been developed with 
various designs; for example, brushes, swabs, tampons, and lavage devices.34,35 
The important criteria for evaluation in a user population are acceptability, user-
friendliness, and performance. Only when these criteria have been reasonably 
| Chapter 1
C
H
A
P
T
E
R
.1
14
met can self-sampling devices be implemented on a large scale. This thesis aims to 
evaluate some new generation self-sampling devices on the above-mentioned criteria. 
Chapter 4 investigates the agreement of hrHPV detection with two PCR methods 
between physician-obtained samples and self-samples taken with an improved 
cervicovaginal brush-based device, and it evaluates women’s acceptance of this self-
sampling device.
Furthermore, in Chapter 5, we have compared a cervicovaginal lavage-based 
device with an improved, brush-based, self-sampling device. This chapter describes 
the findings of the PROHTECT (PRotection by Offering HPV TEsting on Cervicovaginal 
specimens Trial) 3B study. We used data from 30,130 non-responders to the regular 
screening program to determine whether the participation rate with a new brush-
based self-sampling device is non-inferior to the participation rate with a lavage-
based self-sampling device for hrHPV testing.  Additionally, we determined the 
efficacy of the clinical performance and the acceptability of both self-sampling 
methods. 
Whereas HPV self-sampling has obvious advantages, such as the easy accessibility 
that leads to a higher participation rate, there are still some difficulties to overcome. 
Primary hrHPV screening leads to increased referral rates for colposcopy and to 
overtreatment, since hrHPV testing of both physician-sampled and self-sampled 
specimens has a lower specificity and a lower positive predictive value than cytology 
screening for detecting high-grade cervical lesions.24,25 Therefore, a positive hrHPV 
test needs an additional reflex or follow-up triage test with greater specificity before 
referral for colposcopy.27 Cytology testing is the prescribed triage tool for hrHPV-
positive women.4 However, the use of additional or alternative markers on physician-
taken smears might improve the accuracy of triage. This thesis aims to explore new 
and more effective triage methods for smears taken by physicians from HPV-positive 
women (Chapters 6 and 7).
Chapter 6 presents the results of a study in which we determined the additional 
or alternative value of HPV genotyping in the triage of hrHPV-positive women for 
the identification of cervical intraepithelial neoplasia (CIN) 2 or worse and CIN3 
or worse in the physician-taken triage samples from the PROHTECT 3B. Chapter 7 
investigates another triage method. Here we compared DNA methylation analysis 
for the genes C13ORF18, EPB41L3, JAM3 and TERT to cytology as a triage test on 
physician-taken triage samples. We also assessed the feasibility of direct triage testing 
with DNA methylation analysis on the hrHPV-positive material self-sampled with the 
brush-based device and compared the results to the DNA methylation results in the 
matched physician-taken samples. 
Both HPV and cytology can be tested on the same physician-taken smear. 
Unfortunately, in the case of primary HPV screening with self-sampling, triage 
cytology cannot be tested on the same self-sample. It has been proven that cytology 
directly tested on self-sampled material does not yield reliable results.36,37 Thus, triage 
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by cytology requires an extra visit to a physician for a cervical smear to be taken. 
For the effectiveness of the screening, it is critical that the follow-up and further 
management are acceptable to the participants, especially when the participants are 
reluctant. If HPV-positive women need their physician to take an extra triage smear, 
this may lead to delay or losing these women to follow-up. An extra triage smear can 
be circumvented and the loss to follow-up prevented with a direct triage test on self-
collected cervicovaginal material. Therefore, the last aim of this thesis is to explore the 
possibilities for direct triage on the self-sampled specimens (Chapters 7 and 8). 
As mentioned before, we assessed in Chapter 7 the feasibility of direct triage 
testing on hrHPV-positive brush-based self-sampled material with DNA methylation 
analysis for the genes C13ORF18, EPB41L3, JAM3 and TERT. Chapter 8 describes 
the findings of the randomized PROHTECT 3 study in a population of 46,001 non-
responders to the regular screening program in the Netherlands. We assessed 
whether direct DNA methylation-based molecular triage with MAL and miR-124-2 
genes on self-sampled lavage specimens is non-inferior to indirect cytology triage on 
physician-taken cervical samples in the detection of CIN2 or worse.
Finally, Chapter 9 puts the data from the various chapters into perspective, 
describes the implications of our findings in more detail, and gives future perspectives 
on further implementation of self-sampling for hrHPV in primary cervical screening 
and on improving triage for hrHPV-positive women. A summary follows this general 
discussion.
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Chapter 2
The current position and the future 
perspectives of cervical cancer 
screening
R.P. Bosgraaf, A.G. Siebers, J.A. de Hullu, L.F.A.G. Massuger,  
J. Bulten, R.L.M. Bekkers, W.J.G. Melchers
Expert Review of Anticancer Therapy. 2014;14:75-92
Summary
Cervical screening programs for detecting cancer and precancer have dramatically 
reduced the incidence and mortality rates of cervical cancer since the 1960s. The 
efficacy of the screening programs depends on participation and the accuracy of 
the screening tests. Unfortunately, the participation rates are suboptimal; more 
than half the women with cervical cancer have not or have only sporadically been 
screened. Increasing participation is the best way of maximizing the program’s 
benefit. Furthermore, cytology screening lacks high sensitivity for high-grade 
cervical intraepithelial neoplasia (≥CIN2). High-risk human papillomavirus (hrHPV) 
screening is more sensitive in the detection of ≥CIN2 than cytology screening, but less 
specific, so that additional triage testing is still mandatory. The aim of this article is to 
reflect on the efficacy of current cervical cancer screening and on promising future 
screening strategies with primary hrHPV testing and additional triage strategies for 
hrHPV-positive screening results.
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Introduction
Cervical cancer is the fourth most common cancer and the fourth leading cause of 
cancer death of women worldwide. It accounted for 529,000 new cases and 275,000 
deaths in 2008. About 88% of all cervical cancer deaths occur in developing countries, 
where it accounts for 13% of all cancers in women. High-risk regions include Africa, 
southern Central Asia, and South America. The risks are lowest in parts of northern 
and western Europe, western Asia, North America, Australia and New Zealand.1
In the early 1980s, zur Hausen discovered that human papillomavirus (HPV) plays 
an important role in the development of cervical cancer, a finding for which he co-
received the Nobel Prize in Physiology or Medicine in 2008.2-4 In 1999, Walboomers 
and colleagues first described how infection with high-risk HPV (hrHPV) is necessary 
for the development of precancerous or cancerous cervical lesions (Figure 1).5 
Over 150 HPV genotypes have been identified; they can be classed as high risk or 
low risk. Twelve HPV genotypes (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, and 59) are 
classed as high risk for developing cervical cancer, while the additional types 68 
and 73 are recognized as possibly cancer causing.6-9 The HPV types 16 and 18 cause 
approximately 70% of all cervical cancer.7,10,11 Low-risk types do not cause cervical 
cancer, but can give rise to papillomatosis in the genital tract.
Human papilloma virus is a very common, sexually transmitted virus and the 
life-time risk exceeds 50%.10,12 Approximately 80% of the HPV infections clear within 
24 months (median time: 11 months) without clinical signs or symptoms (transient 
infections).13,14 However, some infections become persistent and increase the risk of 
premalignant or malignant changes of the cervix. The time lag between the peak of 
the HPV infection and cancer incidence is 2–4 decades. This makes cervical precancer 
and cancer an appropriate target for screening and early detection (secondary 
prevention).15  
The most widely used cervical cancer screening test in the developed countries 
for detecting such lesions is based on the concept of cytological examination of 
exfoliated cervical cells (Pap test), which Papanicolaou introduced in the 1940s.16 The 
introduction of screening programs in the 1960s and 1970s with the Pap test has 
led to low cervical cancer incidences and mortality rates in most western countries. 
For example, the current mortality rate of cervical cancer in the Netherlands is less 
than 40% of the rate around 1960.17 Before the introduction of screening, the cervical 
cancer incidences in western countries were similar to the current incidences in the 
developing countries.18 
There are several differences in the cervical cancer screening programs of the 
various countries, in terms of invitation methodology, target population, screening 
intervals, organization and quality assurance methodology. Table 1 summarizes 
the organization of cervical cancer screening and cervical cancer incidence rates in 
European countries, Australia, the USA and Canada.1,19 
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Figure 1. Human papillomavirus-mediated progression to cervical cancer.
  
Basal cells in the cervical epithelium rest on the basement membrane, which is supported by the 
dermis. Human papillomavirus (HPV) is thought to access the basal cells through micro-abrasions 
in the cervical epithelium. Following infection, the early HPV genes E1, E2, E4, E5, E6, and E7 are 
expressed and the viral DNA replicates from episomal DNA (purple nuclei). In the upper layers of 
epithelium (the midzone and superficial zone) the viral genome is replicated further, and the late 
genes L1 and L2, and E4 are expressed. L1 and L2 encapsidate the viral genomes to form progeny 
virions in the nucleus. The shed virus can then initiate a new infection. Low-grade intraepithelial 
lesions support productive viral replication. The progression of untreated lesions to micro invasive 
and invasive cancer is associated with the integration of the HPV genome into the host chromosomes 
(red nuclei), with associated loss or disruption of E2, and subsequent up-regulation of E6 and E7 
oncogene expression. LCR = long control region. Reprinted by permission from Macmillan Publishers: 
Nature Reviews. Cancer.110 Copyright 2007
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Table 1. Organization of cervical cancer screening and cervical cancer incidence 
in various European countries, Australia, the USA and Canada.
Country Target range 
(in years)
Screening 
interval in 
years
Smears per 
woman life 
long
Cervical 
cancer 
incidence*
Belgium 25–64 3 14 8.4
Denmark 23–59 3 13 12.1
Finland 30–60 5 7 4.5
France 25–65 3 14 7.1
Germany ≥20 1 50+ 6.9
Italy 25–64 3 14 6.7
Netherlands 30–60 5 7 6.8
Sweden 20–59 5 14 7.8
UK (England) 20–65 3 or 5 16–10 7.2
Australia 18–70 2 43 4.9
USA 21–65 3 16 5.7
Canada 30–69 3 14 6.6
*Age-standardized incidence rates per 100,000.
For example, in the Netherlands, cervical cancer screening started in the early 
1970s. Since the restructuring of the Dutch screening program in 1988 and 1996, 
the nationwide program had targeted women aged 30–60 years. At 5-year intervals, 
they are invited for conventional cervical smears, often taken by their family 
physician or practice assistants. The indication for direct referral for colposcopy 
in the Netherlands is cytological HSIL or worse. For atypical squamous cells of 
undertermined significance (ASC-US), atypical glandular cells (AGC) or low-grade 
squamous intraepithelial lesion (LSIL) cases, a cervical smear is repeated with 
or without hrHPV triage (6 months later) (Figure 2). An overview of the various 
cytological and histological terminology is provided in Table 2.
The most recent breakthrough in primary prevention of cervical cancer is an HPV 
vaccine. Vaccines against the most oncogenic hrHPV types 16 and 18 became available 
in the period 2006–2007. It is assumed that vaccinating girls before they become 
sexually active might prevent cervical cancers caused by these genotypes.20,21 It will 
take many years before the vaccination program affects the incidence of cervical 
cancer, during which time screening will remain necessary. 
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Table 2. Histological and cytological terminology and classification systems.
Histology Cytology
Dysplasia 
terminology (WHO)
CIN terminology 
(Richart)
Papanicolaou (PAP) Bethesda 2001
(TBS 2001)
Normal Normal 1 Negative for 
intraepithelial lesion 
or malignancy
Atypia Koilocytic atypia 2 ASC-US
ASC-H
AGC
Mild dysplasia CIN 1 3a LSIL
Moderate dysplasia CIN 2 3a HSIL
Severe dysplasia CIN 3 3b HSIL
Carcinoma in situ CIN 3 4 HSIL
Invasive carcinoma Invasive carcinoma 5 Carcinoma
AGC: Atypical glandular cells; ASC-H: Atypical squamous cells-cannot exclude high-grade 
squamous intraepithelial lesion; ASC-US: Atypical squamous cells of undertermined significance; 
CIN: Cervical intraepithelial neoplasia; HSIL: High-grade squamous intraepithelial lesion; LSIL: 
Low-grade squamous intraepithelial lesion.
This review gives an outline of the efficacy of current cervical cancer screening and 
of promising future screening strategies. These include primary hrHPV screening 
and additional triage strategies for cases with positive screening results. First, 
we describe screening modalities (organized vs opportunistic), reasons for non-
participation and ways of improving participation. Second, we describe the accuracy 
of the current cytology screening (Figure 2) and visual inspection. The latter is used 
mainly in undeveloped countries. In several European countries, trials on primary 
HPV screening are being conducted and, in the near future, these countries may 
convert from cytology screening to primary hrHPV screening, due to its higher 
sensitivity for high-grade cervical intraepithelial neoplasia (CIN). Third, we describe 
the accuracy of hrHPV testing as a primary screening test (Figure 3). Because a 
positive hrHPV test has relatively little specificity for high-grade CIN, an additional 
reflex- or follow-up triage test with more specificity is needed for considering 
referral to colposcopy. Sensitivity, specificity and predictive values throughout this 
paper refer to the histological end point of ≥CIN2, unless otherwise specified. Fourth, 
we describe several promising tests that might be used for additional hrHPV testing 
in future screening. Fifth, we describe the applicability of the HPV self-sampling test 
and the triage of self-sampled material. 
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Efficacy of cervical cancer screening
Participation rate
The efficacy of cervical cancer screening depends on several factors (Box 1).22-24 
Participation is the most important factor in the success of a screening program. 
Increasing the participation rate is the simplest and best way of improving the 
screening effectiveness. For example, the predicted lifetime risk of cervical cancer 
in a previously unscreened Dutch population dropped from 2.9 to 0.4% after cervical 
screening.22
Box 1. Efficacy of cervical screening.
 - Screening modality (organized screening vs opportunistic screening)
 - Participation rate
 - Accuracy of the screening test
 - Number of screening tests offered during life (screening interval)
 - Age group to be targeted
 - Compliance to follow-up
 - Effectiveness of early treatment
Screening modalities
Screening programs can be classed as organized or opportunistic. Organized 
screening programs invite all eligible women personally to participate and re-
invite the non-participants (call/recall system). Quality at all levels of the program is 
assured in an organized setting with continuous monitoring. These programs have a 
high standard and are effective in for example the UK, the Nordic countries and the 
Netherlands.23,24 
Opportunistic screening depends on motivating each woman and each healthcare 
provider. There is no central data collection and no monitoring of the program. 
Screening intervals are accordingly variable. Screening programs in the USA, France, 
Germany and the southern European countries are more or less opportunistic, with 
lower participation rates than those of organized screening programs. Opportunistic 
screening may achieve high participation rates (as in Australia), but may cause 
unnecessary negative health effects and may thus not be the first choice. 
Several studies have shown that more than half the women who presented with 
cervical cancer were unscreened, despite the organized screening programs.25-29 
Reasons for non-participation
Reasons for non-participation are hard to study, and non-response to studies is high 
in this specific group. Screening participation rates are low among younger women, 
immigrants and women in more urbanized areas. Financial issues can play an 
important role in whether or not women are screened. Women with lower incomes 
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and those without health insurance are less likely to be screened.30-34 The reasons for 
non-participation are sometimes medical, but usually practical: forgetting to schedule 
an appointment, being unable to make a suitable appointment or not speaking the 
language well enough. Furthermore, there may be emotional barriers: shame or 
fear, previous unpleasant experiences with having a smear taken or dissatisfaction 
with the physician.31,35,36 Additionally, both in responders and in non-responders 
have little knowledge about cervical cancer and the advantages and disadvantages 
of screening.36,37
How to increase participation 
There are opportunities in organized screening to increase the participation rate (Box 
2).38-51 For example, the physician’s setting a fixed appointment with a date and time 
achieved a 13% greater participation rate than providing an open appointment did.38-40 
Moreover, the participation rates increase when their own physician invites 
patients, especially if they are immigrants, young women, urban residents and those 
with low socio-economic status.39,41-44 If the physician sends a reminder to initial non-
responders, this also adds to the participation rate.44,45 
Other approaches to lower the threshold for participation include arranging 
more flexible physicians’ office hours,46 sending reminder invitations sooner or 
more frequently after the regular invitation, or phoning the non-participants.47,48,52 
In the PROHTECT studies, some of the non-participants were randomized for a 
second reminder invitation; 6.5–16.6% of these non-participants decided to visit their 
physician for cervical cytology.47,48  
Offering self-sampling for hrHPV testing is a feasible method of reaching the non-
participants in the regular cervical screening.47-51 Women can take a cervicovaginal 
sample themselves with a self-sample device. The materials can be offered by regular 
mail and the test kit can be returned to the laboratory by regular mail for hrHPV testing. 
 
Box 2. Ways of increasing participation in cervical screening programs.
 - Physician’s invitation instead of a national of regional organization
 - Fixed appointment with date and time
 - Flexible office hours
 - Sending a reminder invitation sooner after the regular invitation
 - Sending more frequent reminder invitations
 - Telephone contact with the non-responders
 - Offering self-sampling for hrHPV testing
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Accuracy of the screening test
The success of screening depends on the accuracy, sensitivity and specificity of the 
screening test.24 Low sensitivity gives false reassurance to those with false-negative 
test results. Low specificity gives rise to very many false-positive cases, resulting in 
overtreatment, unnecessary anxiety and excess costs. 
Current screening: primary cytology screening
The markedly reduced incidence and mortality rate of cervical cancer after the 
introduction of screening programs in various developed countries were interpreted 
as strong non-experimental reasons for using organized programs for cervical cancer 
screening. The routine use of cytology screening has led to a dramatic decrease of 
cervical cancer incidence and mortality rates in the developed countries.53 Since its 
introduction, conventional cytology has been used for screening: the cervical cells 
are smeared on a glass slide immediately after sampling. The cells must be fixed 
within a few seconds to prevent air-drying artifacts. Despite the success of cervical 
cytology, its sensitivity is only moderate: 30–87%.54 This is mainly due to sampling 
and/or interpretation errors. Failures to comply with follow-up after cytological 
abnormalities have been found, and failures in treatment and follow-up after 
treatment further compromise the overall efficacy of cervical screening programs.55 
Smear taking (sampling errors) and smear reading or laboratory errors (screening or 
interpretation errors) represent only 12–23% of the failures and are less important 
than lack of compliance.26,28,29
Liquid-based cytology (LBC) was introduced in the mid-1990s to improve the 
performance of cervical cytology. In contrast to conventional cytology, the cells are 
immersed in a vial by thoroughly rinsing the sampling device within a preservation 
fluid. Then, the microscopic slide is prepared with a thin monolayer-like sample 
of well-preserved cells without obscuring blood, mucus or inflammatory cells. 
The advantages of the LBC techniques are the availability of residual material for 
preparation of multiple smears and additional molecular testing. Comparing the 
performance of LBC and conventional cytology showed that LBC improved specimen 
adequacy and reduced screening time relative to conventional cytology. In general, 
LBC does not better detect premalignant cervical lesions,56,57 however, in countries 
with less quality for reading conventional smears, there is some evidence that LBC 
performs better than conventional cytology.58 
Because of the repetitive nature of screening (at least once every 5 years) and 
the long interval between HPV infection and the development of cervical cancer, 
the moderate sensitivity of either conventional cytology or LBC generates greater 
cumulative sensitivity. This reduces the incidence and mortality rates of cervical 
cancer to a low residual.41,59 
In the USA, co-testing with cervical cytology screening and HPV testing is 
recommended for screening. The increased sensitivity of co-testing compared with 
cytology screening alone allows for greater detection of ≥CIN3.60,61 However, the 
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decreased specificity results in the need for more follow-up testing with subsequently 
more costs, higher risk for overtreatment and anxiety for women participating in 
cervical screening programs. For women younger than 30 years, co-testing is not 
recommended, because of the very high prevalence of hrHPV infections and the low 
incidence of cervical cancer in sexually active women in this age group.62
The most recent breakthrough in cytology screening is computer-assisted 
screening,  which specifically aims at increasing (i) the sensitivity of the cervical 
smear by reducing screening errors (false-negative results) and (ii) the productivity 
by reducing the screening time. Automatic screening devices help cytotechnologists 
focus on any abnormal cells on the slide, which facilitates a correct diagnosing. 
Furthermore, automatic screening should increase productivity by excluding normal 
parts of the slides from manual reading by selecting only the most abnormal cells for 
the cytotechnologist’s interpretation.
Currently, there are two commercially available US FDA-approved automated 
screening systems. No significant differences in sensitivity in these tests have 
been identified.63 Computer-assisted screening is thought to be at least as good 
as conventional screening, and it may be valuable in a sub-optimal screening 
environment where it could improve the sensitivity. By contrast, it may have no 
advantage in a high-quality setting other than a greater productivity.63-67 However, 
it is a rather expensive method and therefore infeasible for developing countries.
Current screening: visual inspection 
Another method of screening, most often used in low-resource settings, is visual 
inspection of the cervix after application of diluted acetic acid (3–5%) with a cotton 
swab (VIA or visual inspection with acetic acid), or visual inspection with Lugol’s 
iodine (VILI), eventually combined with low-level magnification (VIAM or VIA 
magnified). Test positivity is based on the appearance of acetowhite in VIA or non-
staining areas in or near the transformation zone (VILI). The sensitivity of VIA for 
the detection of ≥CIN2 has been reported to be similar to that of cervical cytology, 
but it has less specificity.68,69 A recent meta-analysis has reported that the sensitivity 
of VILI is greater than that of VIA with an equal specificity for ≥CIN2. Although VIA 
and VIAM have equal specificity for ≥CIN2, greater sensitivity has been reported for 
VIAM.69 The advantages of these methods are that they help in immediately detecting 
and treating cervical precancer or cancer and they can be used as simple, rapid and 
cost-effective screening techniques in low-resource regions. A disadvantage of these 
screenings methods is their subjectivity; the accuracy is highly provider-dependent.
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Promising future screening strategies
The discovery of the causal relationship between persistent cervical hrHPV infection 
and the occurrence of cervical cancer led to the development of a series of HPV 
DNA tests. These tests are potentially useful for primary screening to detect cervical 
precancer or cancer. The great advantages are that these detection assays are 
automated and objective; they therefore have a greater reproducibility than cytology. 
DNA HPV testing
DNA-based tests detect the presence or absence of the HPV genome. The hrHPV DNA 
test is very sensitive in detecting high-grade CIN or worse (≥CIN2). It is therefore 
a promising screening test. The recent meta-analysis by Arbyn et al. shows that 
the sensitivities of hybrid capture 2 (HC2) HPV DNA test (the most frequently used 
HPV test worldwide) for detecting underlying ≥CIN2 and ≥CIN3 are 90 and 95%, 
respectively.70 Other HPV assays evaluated in primary screening appear to be 
consistently very sensitive (>92%) in detecting ≥CIN3.70,71 In primary screening, this 
great clinical sensitivity may lead to earlier diagnosis of high-grade cervical lesions 
and prevent cervical cancer from appearing in the next screening round.72-74 
Furthermore, the negative predictive value (NPV) of a double negative test, that 
is, normal cytology and a negative hrHPV test, is close to 100%.61,75 A negative hrHPV 
test result provides a greater reassurance against ≥CIN2 than a negative cytology 
test result; the ≥CIN3 yield 5 years after a negative hrHPV test is 0.2%, compared 
with 0.8% after a negative cytology test.76 All these test characteristics and the test’s 
reproducibility have great advantages over cytology –  the current primary screening 
test.
The main concern, however, is that the specificity and positive predictive value 
(PPV) of HPV DNA testing for detecting ≥CIN2 are lower than those in conventional 
cytology.70,71,74 The large prevalence of transient HPV infections may explain the 
lower specificity, especially in young women. These transient infections cannot be 
distinguished from persistent infections with hrHPV testing. Only persistent infections 
are associated with an increased risk of high-grade CIN and cervical cancer.77 Low 
specificity of an HPV DNA test may lead to increased numbers of follow-up tests, 
unnecessary colposcopies, psychosocial distress and possible overtreatment.71,72,74 
Therefore, a positive hrHPV test needs an additional reflex- or follow-up triage test 
with greater specificity before referral for colposcopy.78 
Clinical equivalency criteria79 for hrHPV DNA testing have been defined to ensure 
high clinical sensitivity and specificity for CIN2/3 and cervical cancer in screening. 
High specificity is important for minimizing unnecessary follow-up procedures. 
According to the guidelines, candidate assays should exhibit clinical non-inferiority 
to general primer (GP) 5+/6+ PCR, the second most often evaluated HPV test in clinical 
trials, or HC2 (i.e., a relative sensitivity for ≥CIN2 of ≥0.90 and a specificity for ≥CIN2 
of ≥0.98). Further, these assays should show sufficiently high intralaboratory and 
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interlaboratory agreements, that is, both have agreement with a lower confidence 
bound not less than 87% (k ≥0.5). Such values should be clinically validated.79,80 
Currently, more than 100 commercially HPV tests are available. However, the 
HPV DNA tests of a small subset have documented clinical performance in primary 
screening and fulfill the criteria we have described. The number of HPV DNA tests 
fulfilling these criteria is still rising.81 
What the most optimal triage strategy is remains unclear when it comes to 
identifying hrHPV-positive women with cervical precancer or cancer requiring 
treatment, while at the same time limiting unnecessary referrals of women with 
transient infections.82 Cytological triage is now the approach that is most advocated, 
but other tests (such as HPV genotyping and identifying various biomarkers 
being expressed during transforming infections) could also fulfill this role. While 
knowledge about the molecular oncogenesis of cervical precancer and cancer 
is expanding, the clinical utility of a wide variety of novel biomarkers as a triage 
test is being extensively studied. At present, it would be premature to integrate 
these strategies into the standard of care for cervical cancer screening because of 
insufficient evidence.60,83
As different approaches may be useful in the triage of hrHPV-positive cases, it 
is very important to formally compare these approaches or tests within the same 
population and/or healthcare settings. An organized screening program likely needs 
a different triage algorithm than a clinical setting with opportunistic screening.60,82 
Therefore, proper evaluation of potential screening strategies, including the 
evaluation of benefits and harms, is imperative before implementation is considered.84 
Triage is possible in the form of direct triage after a primary hrHPV test or 
sequential triage with one or more triage tests and/or follow-up. Direct triage is 
preferable because costs are lower and there is less loss of follow-up than with 
sequential triage. 
Triage of hrHPV-positive cases: cytology
Several studies have found that cytological triage improves the specificity of primary 
hrHPV screening, which results in fewer colposcopy referrals and follow-up tests.85-90 
Ogilvie et al.90 have recently found increased ≥CIN2 detection with HPV testing. 
Further, the preliminary results show that cytology triage reduces the number of 
potential referrals to colposcopy on the basis of a single hrHPV test. 
Rijkaart et al.91 studied 14 triage strategies for HPV DNA-positive women within 
the setting of an organized population-based program for cervical cancer screening, 
using the VUSA-Screen cohort.92 Cytology triage followed by repeat cytology at 12 
months for negative cytology results showed that the colposcopy referral rate was 
the lowest of the tested strategies, with an NPV of 99.3%. This appears to be the 
most feasible management strategy. A recent sub study of the POBASCAM trial has 
confirmed these results.93
The systematic review by Whitlock et al.89 concludes that detailed reporting from 
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more large, comparative, randomized controlled trials (RCTs) is needed to determine 
evidence-based management strategies for primary HPV screening coupled with 
reflex cytology. By contrast, Dillner et al.94 argues that direct referral and cytological 
triage for hrHPV-positive women can readily be compared with the current data 
of several RCTs. Triaging hrHPV-positive women with cytology is preferable, 
specifically in populations with low hrHPV prevalences. Then the predictive value of 
the screening procedures will not be impaired, and the number of referrals will not 
increase. Primary hrHPV testing with cytology triage has been shown to be the most 
cost-effective strategy for women aged 32 years or older when it is combined with a 
longer interval between screening rounds.95
A potential problem in primary hrHPV screening followed by cytology triage for 
hrHPV-positive women is that the hrHPV test result is known to the cytotechnologist. 
This may affect the interpretation of the cytology, which is subjective by nature.91 
However, it is unclear to what extent the clinical performance of cytology would 
be affected by prior knowledge of the hrHPV status.60 Additional cytology testing or 
separate testing for other biomarkers may be useful in this context.
Triage of hrHPV-positive cases: hrHPV genotyping
The evidence that HPV16 and HPV18 are the most oncogenic hrHPV genotypes is 
convincing.96 HPV16 is found in most (50–60%) cervical cancers, and the prevalence 
is high in the general population worldwide. Infections with HPV16 are more likely to 
persist and the risk of high-grade CIN is much greater than with other oncogenic HPV 
types. HPV18 has been identified in 10–15% of the cervical cancer cases, especially 
in adenocarcinoma or in its precursor lesions. Other genotypes have also been 
identified as carcinogenic, but are much less common in cervical cancers.97
Immediate triage strategies for hrHPV-positive women are very attractive and 
needed, as loss to follow-up at the 1-year interval negated the greater sensitivity of 
HPV-testing in the ARTISTIC trial.98 In the large, clinical ATHENA trial, the detection 
of HPV16 (50.4%), or both HPV 16/18 (59.5%), as a triage test for HPV-positive women 
was equivalent to detecting ASC-US or worse (52.8%) in terms of sensitivity to CIN3.99 
A post hoc analysis of data emerging from this trial100 reports 10 screening strategies 
for the sensitivity and specificity in detecting CIN3. Potential harm was estimated 
with the number of tests and colposcopies. Initial screening with HPV and triage of 
HPV-positive women with combined genotyping and cytology were found to provide 
maximal sensitivity and specificity by limiting the number of colposcopies. However, 
the publication includes only the baseline data and reports no estimates of the overall 
colposcopy referral rates. 
Genotyping may also prove to be a suitable immediate triage strategy for hrHPV-
positive women with negative cytology results. Cases that are hrHPV-positive and 
triage cytology-result-negative can be further stratified according to ≥CIN3 risk. 
More aggressive management of HPV16/18-positive women (i.e., direct referral for 
colposcopy) is advisable, as is less aggressive management of women with other HPV 
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genotypes (follow-up with either cytology, HPV testing or the advice to participate in 
the next screening round).60,96,101,102
In addition, Arbyn et al.70 state that genotyping for HPV types 16 and 18, or such 
genotyping combined with cytology, stratifies the risk of ≥CIN3 and can be used in 
triage for hrHPV-positive women. However, the relative balance between benefit 
and harm of cytology versus HPV16/18 genotyping has yet to be determined.
Triage of hrHPV-positive cases: mRNA HPV testing
While DNA-based tests detect the presence or absence of the HPV genome, RNA tests 
detect the gene expression (mRNA), which is related to cancer development. HPV E6 
and E7 are viral gene products identified as deregulated and overexpressed following 
viral integration in the host genome. Overexpression of E6 and E7 is strictly required 
for malignant transformation in HPV-related cancers.103 The two viral oncogenes 
promote irregular cell growth by inactivating the tumor suppressor proteins p53 and 
pRb. It is argued that the detection of the E6 and E7 may facilitate a better distinction 
of transient HPV infections (low expression of E6/E7) and those that will progress 
to cancer (overexpression of E6/E7), which would improve triage for women with 
abnormal primary screening.104
Various studies have shown that testing for HPV mRNA can be clinically useful 
due to its high clinical specificity for the detection of ≥CIN2.70,105-109 However, studies 
determining the reproducibility of the test are lacking. Furthermore, longitudinal 
studies and economic evaluations should be conducted so that we can draw solid 
conclusions with regard to the clinical applicability of the HPV mRNA test as a 
secondary triage test or as a primary screening test. 
Triage of hrHPV-positive cases: molecular markers
At present, several molecular markers that may be helpful in the detection of CIN 
and cervical cancer have been identified. Some of these biomarkers are proteins 
involved in cell-cycle regulation, cell proliferation and DNA replication. Interaction 
of viral E6/E7 oncoproteins with host cell targets can alter the expression of these 
proteins, resulting in abrogated cell-cycle control and apoptosis mechanisms (Figure 
1).110 Other biomarkers focus on cellular DNA expression and yet others on viral 
protein or RNA expression. These biomarkers reportedly increase specificity for the 
detection of ≥CIN2 while being used (i) as an adjunct to cytological triage for hrHPV-
positive women and also (ii) as an immediate reflex test within a primary hrHPV 
screening setting. 
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Protein biomarkers for transforming hrHPV infections
p16INK4a 
Immunochemical staining for p16INK4a can be used as a diagnostic adjunct in histolo-
gical and cytological evaluation. Inactivation of pRb by E7 finally leads – via a 
negative feedback loop mechanism within the cell cycle – to enhanced and continuous 
overexpression of a cellular tumor suppressor protein, namely the cyclin-dependent 
kinase inhibitor 2A (p16INK4a).111 Overexpression of p16INK4a may also be used as 
a progression marker for low-grade CIN, as it has been shown that most p16INK4a-
negative lesions regress while most of the p16INK4a-positive CIN1 lesions progress.77  
The mere presence of p16INK4a positive-staining cells is not enough to classify 
cytological specimens. Under normal physiological circumstances, squamous 
metaplastic and endocervical cells occasionally show overexpression of p16INK4a. Thus, 
the immunocytological interpretation also requires morphological interpretation 
to distinguish intraepithelial lesions from cancer and occasionally positive normal 
endocervical cells. Therefore, the interpretation of p16INK4a remains a subjective 
method with problems similar to those of cytological interpretation.112 
The performance of p16INK4a immunocytochemistry as an adjunct to triage of low-
grade cytological lesions has been studied extensively. The meta-analysis by Roelens 
et al.113 compared p16INK4a immunocytochemistry with HPV DNA testing in triage for 
women with cytological evidence of ASC-US and LSIL. They report that p16INK4a had a 
sensitivity for the detection of ≥CIN2 (relative sensitivity 0.95 [0.89–1.01]) similar to 
HPV DNA testing, but greater specificity (relative specificity 1.82 [1.57–2.12]) than HPV 
DNA testing in the triage of ASC-US. For LSIL, p16INK4a had significantly less sensitivity 
(relative sensitivity 0.87 [0.81–0.94]) but greater specificity (relative specificity 2.74 
[1.99–3.76]) than HPV DNA testing for the detection of ≥CIN2. Carozzi et al.114 studied 
the performance of p16INK4a in triage for women testing positive for hrHPV. They report 
a strong association between p16INK4a detection and histologically confirmed CIN2 
and CIN3. The sensitivity was greater for hrHPV testing with adjunct p16INK4a triage 
than for cytological screening, but the referral rates for colposcopy were similar. The 
first longitudinal data from this trial have been published recently.115 The authors 
conclude that p16INK4a could be used as a triage method for HPV-positive women and 
that p16INK4a-negative women can safely manage with retesting after 2–3 years. 
Dual staining with p16/Ki-67 
A double-label immunostain for p16INK4a and Ki-67 for LBC preparations facilitates 
recognition of positive cells on co-staining of both markers in de same cell without 
the need to take the morphology of the positive cells into consideration. 
The nuclear protein Ki-67 is expressed during all cell-cycle phases, but not in 
resting cells (G0 phase). Therefore, it is used as a measure of cell proliferation. In 
normal cervical epithelium Ki-67, expression is limited to the basal or parabasal 
layers, whereas Ki-67 expression in CIN lesions extends above the first one-third of 
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the epithelium. Thus, p16INK4a and Ki-67 should be mutually exclusive in normal cells, 
and concomitant expression of p16INK4a and Ki-67 in the same cell should identify 
deregulated cells during hrHPV-induced oncogenic transformation independently of 
morphological criteria. 
The clinical performance of p16/Ki-67 dual staining has been studied in several 
trials, mainly in the triage of ASC-US and LSIL cytology. The EEMAPS trial, which 
included 776 ASC-US/LSIL cases, has found great sensitivity in p16/Ki-67 dual staining 
for detecting ≥CIN2 (92–94%), comparable with the rates of hrHPV testing or single 
p16 staining. However, the specificity of the morphology-independent test for the 
detection of ≥CIN2 was substantially better than that of hrHPV testing and single p16 
testing.116 The study by Petry et al. confirms this.117 A large pan-European screening 
study (the PALMS trial) evaluated the performance of p16/Ki-67 dual staining in a 
screening setting. The sensitivity for the detection of ≥CIN2 in this study (86.7%) was 
significantly greater than that of Pap cytology (68.5%) with identical specificities 
(95.2 vs 95.4%). The HPV testing in this trial was more sensitive (93.3%), but less 
specific (93.3%).118 A combination of this dual staining test and automated detection 
is a promising future development.119 Perhaps, p16/Ki-67 dual testing can be used to 
reduce colposcopy referrals; it has a promising role as a triage marker in HPV-based 
screening strategies.
MCM2/TOP2A dual staining 
The minichromosome maintenance protein 2 (MCM-2) and topoisomerase II-α 
(TOP2A) are biomarkers for aberrant S-phase induction, which is the premature and 
prolonged entry in the S-phase of the cell cycle. Deregulation and activation of the HPV 
oncoproteins E6 and E7 trigger this condition and cause malfunction at the G1/S cell-
cycle checkpoint. The MCM-2 functions as a replicative helicase in an early stage of 
DNA replication. The nuclear enzyme TOP2A is responsible for enzymatic unlinking 
of DNA strands during replication. Both MCM-2 and TOP2A have been shown to 
accumulate in HPV-transformed cells and are overexpressed in high-grade CIN and 
cancer. A commercially available immunocytochemical assay has been designed as a 
reflex test for women with borderline and low-grade cytology for identifying ≥CIN2. 
Several studies have examined the performance of this immunocytochemical 
assay in triaging borderline and low-grade cytology. Two studies have found more 
sensitivity and specificity for the detection of ≥CIN2,120-122 and another one has found 
less sensitivity, but more specificity for triage MCM2/TOP2A dual staining than 
for hrHPV testing.123 Depuydt et al.124 investigated the efficacy of eight screening 
strategies. Cytology with ASC-US triage with MCM2/TOP2A dual staining showed 
slightly less sensitivity for the detection of ≥CIN2 (relative sensitivity 0.96 [0.95–
0.97]) and more specificity [relative specificity 1.90 (1.84–1.92)] than cytology only. 
Primary hrHPV screening with MCM2/TOP2A dual staining triage, however, showed 
more sensitivity (relative sensitivity 1.30 [1.20 - 1.41]) and more specificity (relative 
specificity 2.89 [2.58-3.15]) than cytology only.124 
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A major drawback of the MCM2/TOP2A dual staining assay is the morphology-
dependent interpretation that faces the same problems as p16INK4a assays do. 
Standardized interpretation and scoring methods are therefore needed.125 More 
studies are required to determine the utility of MCM2/TOP2A dual staining in clinical 
practice. 
E6/E7 protein markers
Overexpression of E6 and E7 oncoproteins are better predictors of cervical precancer 
and cancer than the mere presence of HPV DNA. Most E6/E7 assays are based on 
mRNA testing, which is prone to degradation. Therefore, diagnostic tests based on 
the direct detection of E6 or E7 oncoprotein have potential advantages over mRNA 
or HPV DNA testing. However, purified recombinant HPV E6 and E7 in their native 
form are difficult to generate. Peptides or denatured proteins are mainly used for 
antibody production. These antibodies, however, are not sensitivity enough for 
clinical use.126 Recently purified recombinant HPV E6 and E7 proteins in their native 
form have been produced for the generation of monoclonal antibodies recognizing 
E6 and E7 from many hrHPV types. The first study using a whole-cell ELISA, based 
on a pan-HPV E6 monoclonal antibody, has shown equal sensitivities of the assay and 
HPV DNA testing for the detection of ≥CIN3, but the assay is more specific.126 A recent 
study of Zhao et al. confirmed this higher specificity for ≥CIN3.127 Further prospective 
studies are needed to validate and determine the clinical utility of the assay.
3q26 (TERC) biomarker 
The 3q26 region contains sequences for the RNA component of the human telomerase 
gene, which serves as a template for telomere addition, which is a potential basis 
for telomerase-based cell immortalization.128 The frequency of 3q26 gain has been 
shown to increase with the severity of the dysplasia.129 Furthermore, there is 
evidence that 3q26 testing in ASCUS and LSIL results is applicable to stratify patients’ 
risk who are less likely to progress to CIN2/3 or cancer and hence can be followed 
more conservatively.128-132 
A recent study of Heitmann et al. evaluated an automated and manually method 
of detecting 3q26. The highest sensitivity and NPV, 80 and 98% respectively, was 
measured when only the automated method of detecting 3q26 gain was used.130 
Several small studies with LSIL cases confirmed NPV’s between 97 and 100% in 
predicting ≥CIN2.130-132 
These high NPVs indicate that 3q26 gain may have the potential to triage women 
with LSIL who are negative for 3q26 gain to a conservative treatment, while sending 
those who are positive for 3q26 gain for colposcopy. 
However, most of the studies on 3q26 are retrospective and are relatively small 
with a short follow-up interval. Larger prospective studies are necessary to validate 
and determine the use of 3q26 testing. Prospective studies are ongoing to establish 
the sensitivity, specificity, PPV and NPV of 3q26 gain over time.
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Protein biomarkers for productive hrHPV infections
The major capsid protein of HPV, L1 is produced within the cytoplasm and translocated 
into the nucleus during the productive phase of the viral life cycle. Expression of 
L1 is progressively lost during cervical carcinogenesis. This loss is related to the 
progressive behavior of cervical lesions because the expression escapes immune 
system recognition. The L1 capsid protein is produced in about 80% of CIN1 and 
CIN2, but only in 25% of higher-grade lesions.133 Most studies used the L1 assay in 
combination with p16INK4a staining to confirm the association of the lesion with an 
HPV infection. Although L1-positive/p16-negative as well as L1-negative/p16-negative 
expression patterns in CIN1/CIN2 lesions are associated with high rates of regression 
(100 and 72%, respectively), this was only 16% for L1-negative/p16-positive cases.134 A 
prospective study that investigated L1 as a stand-alone marker in mild and moderate 
dysplastic cytology has found a low malignant potential for L1-positive cases (61% 
remission and 25% progression) while L1-negative cases progressed to CIN3 or more 
in 72.4% of the cases and showed remission in only 5.2%.135 Despite L1’s potential 
as a progression risk marker, a substantial portion of high-grade lesions retain the 
ability to differentiate to some extent, to replicate the virus, and thus to still express 
L1. A positive L1 assay therefore does not fully exclude high-grade CIN, which limits 
its clinical use.
Methylation markers
Epigenetic changes in both host and viral DNA have been linked to the carcinogenesis 
of cervical cancer and its precursor lesions. Various studies have found that 
methylation of CpG islands within the promoter regions of tumor suppressor 
genes can lead to silencing of gene expression. The CpG islands are DNA regions 
that contain a high frequency of CpG dyads. CpG dyads are pairs of cytosine (C) and 
guanine (G) linked by a phosphodiester bond (p) next to each other. The CpG islands 
that are located near a gene promoter probably have a role in the control of gene 
expression and silencing. Methylation of DNA is a normal epigenetic event in human 
development. However, abnormal DNA methylation of normally unmethylated CpG 
islands in promoter regions is associated with inactivation of tumor suppressor 
genes. This affects cell-cycle genes, DNA repair, cell-to-cell interactions, apoptosis and 
angiogenesis, all of which are involved in malignant transformation. Methylation 
of tumor-specific genes occurs in many malignancies but also in premalignant 
lesions. Since DNA methylation is a stable epigenetic modification, it facilitates the 
development of specific tests. 
Methylation of host genes
In the last years, many studies have addressed epigenetic alterations in the HPV host 
cell that could serve as molecular markers of cervical premalignant or malignant 
disease.110 A systematic literature review has summarized the most promising 
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methylation markers that are potentially involved in cervical cancer.136 A high 
degree of heterogeneity between the studies was observed, and no highly consistent 
results for most genes were found. Only three methylation markers (DAPK1, CADM1 
and RARB) showed consistently high methylation levels in cervical cancer across the 
studies. 
Unfortunately, stand-alone testing for methylation markers lacks sensitivity.137 
Therefore, most studies exploring the clinical use of these markers use a panel of 
various methylation markers. Sensitivities over 80% for CIN3+ were obtained with 
the marker panels SOX1/PAX1, SOX1/LMX1A, SOX1/NKX6-1, PAX1/LMX1A, PAX1/
NKX6-1, LMX1A/NKX6-1,138 JAM3/EPB41L3/TERT/C13ORF18,139 and CADM1/MAL140 for 
cervical smears of referral populations. 
Methylation marker panels may hold great promise as a new triage test strategy 
after hrHPV testing within a population-based screening setting. However, none of 
the marker panels, except CADM1/MAL, have yet been validated in large population-
based screening studies.141 The results warrant further investigation with studies 
that identify and validate the best panels of markers and prove their clinical value in 
large longitudinal studies. 
Methylation of viral genes
Methylation of HPV genes varies with the viral life cycle, probably between viral 
subtypes, but also with the presence of cervical dysplastic lesions. Methylation of 
HPV genes with concurrent silencing of HPV oncogenes could be a host defense to 
foreign DNA, but also a strategy of the virus itself to maintain a long-term infection 
by evading immune recognition.110,142 Nonetheless, it has also been suggested that 
HPV gene methylation may be the result of integration of the viral DNA into the host 
genome. In so, the methylation status of HPV genes may indicate whether the HPV 
infection will persist or clear and thus have prognostic and diagnostic value. 
The main HPV methylation gene studies focus on HPV16 and have found that 
hypermethylated L1, L2, E2 and E4 regions are associated with high-grade cervical 
disease.143,144 Methylation of HPV18, HPV31 and HPV45 has been studied too, and 
elevated methylation levels at multiple CpG sites in the E2, L2 and L1 regions in 
women with CIN3 were greater than those of women with transient infections.145 By 
contrast, elevated DNA methylation in the HPV16 E6 regions was associated with less 
likelihood of CIN.146 The HPV DNA methylation of HPV16, 18, 31 and 45 may be useful 
as a triage test for distinguishing hrHPV-positive women with a high risk of high-
grade CIN or cancer from those with transient infections. However, studies should 
first be extended to methylation patterns in other important hrHPV types and should 
be validated in cohorts of women in different settings.
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HPV self-sampling & triage of self-sampled material 
As already discussed, participation is the most important factor determining the 
success of a screening program. Studies have already shown that self-sampling 
increases the participation of non-responders in current screening programs up to 
39%.47-49,51,147-149 Additionally, self-sampling has facilitated access to cervical screening 
for women in developing countries.150-152
Meta-analyses and systematic reviews have shown that self-collected 
cervicovaginal samples are suitable for HPV testing with a high level of concordance 
in HPV detection rates of physician-collected samples.153-157 Further, self-sampling 
for hrHPV testing has proven feasible and effective for detecting ≥CIN2.153,154,158 As 
a result, this is a way to further improve population coverage, and it might further 
reduce the incidence of cervical cancer as well as the related mortality rate.
Self-sampling is an inexpensive HPV detection method that women find very 
acceptable.159 There is no need for a physician to perform a speculum examination; 
the woman can take the sample herself at home, or if preferred, in a clinic. Several 
studies have reported that women prefer self-sampling over physician sampling.160-162 
Participation in screening by using a self-sampling device is mainly related to issues 
of self-control and time efficiency.159,163
There are various designs of self-sampling devices (e.g., brushes, swabs, tampons 
and lavage devices). The main concern of self-sampling is that, in some studies, 
women report a lack of confidence in doing the test correctly.164-166 Some types may 
be easier to use and give women a better indication that they have done the test 
correctly.159,164 
Triage for women testing HPV-positive in self-collected cervicovaginal material is 
required since hrHPV testing is not specific enough for the detection of ≥CIN2 to 
directly refer all positive-testing women for colposcopy.167,168 It has been proven that 
testing cytology directly on self-sampled material does not yield reliable results.169,170 
Therefore, the currently accepted triage method is to ask HPV-positive women to have 
the physician take a smear for further triage.171 For countries with a poorly developed 
cytology-based screening program, VIA may be an appropriate triage strategy.152,172,173 
It has the advantage of providing immediate results, which makes it possible to triage 
and treat without delay during the same visit.174 Zhao et al. explored both triage 
systems, and they calculated that self-sampling coupled with cytology reduced the 
referral rate to 4.8% and self-sampling with VIA reduced referrals to 4.5%.175
It is critical that the follow-up and further management are acceptable to the 
participants, especially when participants are reluctant. Therefore, several triage 
strategies applied directly to the self-sampled specimen have been described. 
However, which triage strategy is the most optimal one remains uncertain.
A study of DNA methylation marker testing on self-sampled cervicovaginal 
specimens  has shown that methylation marker analysis is feasible as an alternative 
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triage marker for detecting ≥CIN3 in self-collected cervicovaginal material from HPV-
positive women.176 The delay or loss to follow-up of HPV-positive women, who need 
their physician to take a smear could be circumvented with a direct triage test on 
self-collected cervicovaginal material.
Furthermore, it is possible to genotype HPV on self-collected cervicovaginal 
specimens.177-179 This facilitates direct triage of specific types of HPV, especially HPV16 
and/or 18. Women who test positive can be referred to colposcopy directly without 
the need for follow-up cytology, which reduces the risk of losing patients to follow-up. 
Expert commentary
Cytology screening in the last decades was extremely important in decreasing the 
incidence of cervical cancer worldwide. Now, there is a firm basis for primary HPV 
testing in cervical screening that may further reduce the incidence of cervical cancer. 
However, HPV testing leads to more false-positive screening results than cytology, 
which may result in high referral rates, high costs and possible overtreatment. 
Proper evaluation of potential screening and triage strategies, including evaluation 
of benefits and harms, is imperative before implementation can be considered. All 
of these approaches are still in development, so that their mode of application and 
potential joint use, either concurrently or sequentially, must still be defined. Large 
well-powered epidemiologic studies need to be designed to test these approaches 
for their utility in the early detection of cervical cancer and their cost-effectiveness 
needs to be further evaluated.
Participation is the most important factor for the efficacy of cervical screening 
programs. Self-sampling for HPV testing is promising in increasing participation. 
HPV self-sampling can be used as an additional tool in a screening program for 
non-participants or as an alternative for office-based sampling, especially in under-
resourced areas lacking medical services. Topics of further research include ways to 
improve triage testing following a hrHPV-positive self-sample. Since cytology testing 
on self-sampled material is not feasible, most current protocols advocate advising 
women who test hrHPV-positive on their self-sample to visit a physician for a cervical 
smear. Direct triage testing, such as molecular testing, on the same sample provides 
an opportunity to realize a more woman-friendly cervical screening and less loss to 
follow-up.
Five-year view
In several countries, especially European countries, such as Italy, Sweden, the UK 
and the Netherlands, trials on primary hrHPV screening are being conducted. These 
countries may convert from cytology screening to primary hrHPV screening as the 
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standard cervical cancer screening method within the next 5 years, due to its higher 
sensitivity for high-grade CIN. The discussion on triage strategies will continue 
with the release of new evidence and research into additional markers to reduce 
overtreatment through a better selection. The developing countries will still need 
simple, single-visit, affordable, cost-effective screening approaches for cervical 
cancer prevention. Instant HPV DNA testing, followed by ‘screen and treat’ VIA for 
positive hrHPV tests may prove to be beneficial.
Strategies, such as self-sampling, to increase participation rates will be 
implemented, probably initially for non-responders, but later optionally for all 
women. Direct molecular triage on self-sample material will facilitate woman-
friendly cervical screening via more objective, molecular methods that are all 
applicable to the same self-sample. 
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Key issues 
 - An infection with high-risk human papillomavirus (hrHPV) is the necessary cause 
in the development of precancerous or cancerous cervical lesions. Vaccination 
against HPV types 16 and 18 has become available, but cervical screening will 
remain necessary for many years, even for vaccinated women. 
 - Participation is the most important factor determining the success of a screening 
program. Several ways of improving screening participation have been successful 
in organized screening. Examples are fixed appointment with date and time, and 
sending non-responders more reminder invitations sooner. Self-sampling for 
HPV testing is most promising: it makes cervical screening more women-friendly 
and it makes direct molecular triage of self-sample material possible. 
 - Organized cytology screening (the Pap test) has helped reduce the incidence and 
mortality rate to a low level in developed countries with a screening program. 
However, cytology is not sensitive enough for detecting high-grade cervical 
intraepithelial neoplasia (CIN) and cervical cancer.   
 - Because hrHPV testing is more sensitive in detecting CIN and cervical cancer than 
cytology, hrHPV may replace cytology in cervical screening. The great advantages 
are that HPV detection assays are automated and objective: they therefore have 
greater reproducibility than cytology.
 - Since hrHPV testing is associated with more positive tests without underlying 
high-grade CIN or cervical cancer (lower specificity) than cytology testing, a 
positive hrHPV test needs a more specific triage test before referral for colposcopy 
can be considered.
 - Different triage strategies may help reduce the number of unnecessary 
colposcopies and treatment. These strategies include cytology and/or other 
promising triage tests: hrHPV genotyping, mRNA HPV testing, P16 staining, p16/
Ki-67 dual staining, MSM2/TOP2A dual staining, E6/E7 protein markers, 3q26 
(TERC) and DNA methylation markers.
 - At present, there is still insufficient evidence to justify integrating these strategies 
into the standard of care for cervical cancer screening. Therefore, proper 
evaluation of potential screening strategies, including evaluation of benefits and 
harms, is imperative before implementation can be considered.
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Abstract 
OBJECTIVES: High attendance rates in cervical screening are essential for effective can-
cer prevention. Offering HPV-self-sampling to non-responders increases participation 
rates. The objectives of this study were to determine why non-responders do not attend 
regular screening, and why they do or do not participate when offered a self-sampling 
device.
METHODS: A questionnaire study was conducted in the Netherlands from October 
2011 to December 2012. A total of 35,477 non-responders were invited to participate 
in an HPV-self-sampling study; 5347 women did opt-out. Finally, 30,130 women 
received a questionnaire and self-sampling device.
RESULTS: The analysis was based on 9484 returned questionnaires (31.5%) with a 
self-sample specimen, and 682 (2.3%) without. Among women who returned both, 
the main reason for non-attendance to cervical screening was that they forgot to 
schedule an appointment (3068; 32.3%). The most important reason to use the self-
sampling device was the opportunity to take a sample in their own time-setting 
(4763; 50.2%). A total of 30.9% of the women who did not use the self-sampling device 
preferred after all to have a cervical smear taken instead.
CONCLUSIONS: Organisational barriers are the main reason for non-attendance 
in regular cervical screening. Important reasons for non-responders to the regular 
screening to use a self-sampling device are convenience and self-control.
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Introduction 
Screening programmes are only effective if a substantial part of the target population is 
screened.1 The coverage of all European cervical screening programmes is below 80%, 
ranging from 10% to 79%. In only five regions (France, England, Finland, the Netherlands 
and Sweden) the coverage was 70% or more.2 Women not participating in the cervical 
screening programme, called ‘non-responders’, are at increased risk of cervical cancer.3,4
It is commonly assumed that high-risk human papillomavirus (hrHPV) testing on 
clinician-collected cervical samples provides better protection against cervical cancer 
than cytology,5,6 given its higher sensitivity for detecting cervical intraepithelial neoplasia 
grade 2 or worse.7-9 Therefore, many developed countries will probably convert from 
cytology to primary HPV testing. Furthermore, hrHPV DNA testing on self-sampled 
cervicovaginal material (HPV-self-sampling) has similar sensitivity for detecting 
high-grade CIN as hrHPV DNA testing on clinician-collected material, provided that a 
combination of a clinically validated self-sampling device and ditto HPV test is used.10-12 
Offering self-sampling for hrHPV DNA testing has proven to be an effective screening 
method for women who do not attend regular cervical screening programmes; one third 
return the self-sampling device, thereby increasing the attendance rate of the screening 
programme significantly.6,13-16 
The aims of the study were to determine non-responders’ reasons not to attend 
regular cervical screening, and why these non-responding women do or do not 
participate when offered a self-sampling device. This study is the first to report on 
women’s reasons to participate neither in the regular screening programme, nor in a 
self-sampling programme. This information may provide opportunities to increase 
screening coverage.
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Methods
In the Netherlands, cervical cancer screening started in the early 1970s. Since the 
subsequent restructuring of the Dutch screening programme in 1988 and 1996, 
there has been a nationwide programme targeting women aged 30–60 years. Those 
women are invited at 5-year intervals for cervical smears, often taken by their 
general practitioner or practice assistants.17-18 The Dutch screening programme has 
contributed to a reduction in morbidity and mortality of cervical cancer.19
This study is a part of a large randomised controlled trial (PRotection by Offering 
HPV TEsting on Cervicovaginal specimens Trial, PROHTECT 3B) in the setting of the 
Dutch population-based cervical screening programme. The PROHTECT 3B study 
assesses the feasibility and efficacy of offering either a cervicovaginal lavage self-
sampling device or a brush self-sampling device for hrHPV testing to non-responders 
of the regular screening programme (1:1 randomisation). Details of this study design 
are reported elsewhere (Dutch Trial Register, NTR3350). 
A total of 35,477 non-responders were selected who lived in the provinces of 
Noord-Holland, Flevoland, Utrecht or Gelderland and who had received a screening 
invitation in 2008. The selected non-responders were registered in the databases 
of the screening organisations. A ‘non-responder’ was defined as a woman who 
responded neither to the regular invitation to the national screening programme nor 
to a standard reminder after 6 months. All the selected non-responders received a 
pre-invitation letter by regular post. Non-responders who did not want to participate 
could opt out by returning a form by regular post, sending an e-mail, calling a service 
desk, or opting out via the study website (http://www.thuistesthpv.nl). All women who 
did not opt out within 3 weeks received a self-sampling device with a questionnaire. 
A total of 5347 women did opt out and 30,130 women received both a self-sampling 
device and a questionnaire (Figure 1). 
For the data collection process Cardiff Teleform Software (version 10.1, 2010; 
Cambridge, UK) was used. This programme enabled the data manager to scan, verify, 
and store large quantities of information in an integrated SPSS (Statistical Package 
for the Social Sciences, version 20.0.1 for Windows) database. 
Women could either or not return a self-sampling device, and either or not 
return a questionnaire. The four outcome-groups are shown in Figure 1. For this 
questionnaire study, we could calculate only the data for the two groups who returned 
the questionnaire; non-responding women from the cervical screening programme 
who participated in the self-sampling study and returned a questionnaire (i.e. group 
1, n = 9484) and non-responding women from the cervical screening programme 
who did not participate in the self-sampling study but did return a questionnaire (i.e. 
group 3, n = 682). 
Each question in the questionnaire contained multiple answer options as well 
as an open answer option. Women were allowed to fill in multiple answers. All 
different answer combinations were analysed and it was calculated whether these 
Reasons for non-attendance and preferences for HPV self-sampling | 
C
H
A
P
T
E
R
.3
63
combinations changed the results. Open answers were analysed and grouped 
into categories. Percentages were calculated for each answer option. Categories 
constituting less than 5% were collected in a rest group.  
Figure 1. Study design 
Results
A total of 10,027 out of 30,130 women (33.3%) returned a self-sampling device, of 
whom 9484 women also returned a questionnaire (group 1), and 543 only returned a 
self-sample specimen without a questionnaire (group 2). A total of 20,130 women did 
not return a self-sampling device, of whom 682 women did return a questionnaire 
(group 3). These groups are shown in Figure 1. Overall, 10,166 questionnaires were 
returned. Response rates per age group (groups 1 and 3) are shown in Table 1.
Reasons for non-attendance in the last regular screening round 
The main reason for non-attendance in the last regular screening round in both 
groups was that women forgot to make an appointment for a physician-taken cervical 
smear. This answer was given by 32.3% of group 1, and 14.2% of group 3 (Table 2). 
10,027 women 
(33.3%) returned
a self-sampling
device
20,103 women 
(67.7%) returned
no self-sampling 
device
5,347 women 
opted out (15,1%)
9,484 women (31.5%)
returned a selfsample
specimen with a
questionnaire
Group 1 Group 2 Group 3 Group 4
543 women (1.8%) 
returned a self-sample 
specimen without a 
questionnaire
682 women (2.3%)
returned a question-
naire without a
self-sample specimen
19,421 women (64.4%)
returned no question-
naire and no self-
sample specimen
35,477 non-responders
of the cervical scree-
ning programme
(30-60 years old)
30,130 self-sampling 
devices with a 
questionnaire 
were sent
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Table 1. Total amount of women who returned a questionnaire, categorised by age. 
Age category in 
years
Total amount 
of women 
offered an HPV 
self-sampling 
device with 
questionnaire
Questionnaires returned
Participants  
to self-sampling 
who returned a 
questionnaire 
(%)
(group 1)
Non-
participants 
to self-sampling 
who returned a 
questionnaire 
(%)
(group 3)
Total amount 
of women who 
returned a 
questionnaire 
(%)
29–33 6526 1916 (29.3) 136 (2.1) 2052 (31.4)
34–38 6698 2118 (31.6) 115 (1.7) 2233 (33.3)
39–43 4482 1470 (32.8) 55 (1.2) 1525 (34.0)
44–48 3832 1216 (31.7) 88 (2.3) 1304 (34.0)
49–53 3232 1083 (33.5) 98 (3.0) 1181 (36.5)
54–58 2825 892 (31.6) 71 (2.5) 963 (34.1)
59–63 2635 789 (29.9) 119 (4.5) 908 (34.4)
Total 30,130 9484 (31.5) 682 (2.3) 10,166 (33.7)
In the open answer section, 18.2% of the women in group 3, and 11.9% of the women 
in group 1 answered that they had already had a smear taken in the past 3 years. 
The second most mentioned open answer in group 1 was that they were pregnant, 
breastfeeding or in a fertility treatment during the last screening round (8.5%).
Furthermore, some women in group 1 felt too embarrassed to have a cervical 
smear taken by the physician (1576; 16.6%); this number decreased with age. 
Also anxiety for having a smear taken decreased with age; 12.2% in women aged 
29–33 years, to 6.1% in women aged 59–63 years. By contrast, previous unpleasant 
experiences with having a smear taken increased with age (3.1% in women aged 29–
33 years to 9.3% in women aged 59–63 years). Among women in group 3, the second 
most given reason (46; 6.7%) for not participating in the population-based screening 
was that they were too afraid to have a smear taken. Feelings of embarrassment 
were scored less often. 
A single answer was scored in 77.9% of the cases in group 1 and in 90.5% of 
the cases in group 3. Analysis for multiple answers did not change the results 
compared to single answers (data not shown).
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Participating or not participating in the self-sampling study
A total of 9397 out of 9484 (99.1%) women who returned the self-sampling device 
and questionnaire (group 1) answered the question about why they used the self-
sampling device (Table 3). The most common reason was that it could be done in 
their own time setting at home (4763; 50.2%). “Performing the self-sampling test 
takes less effort than having a cervical smear taken” (3982, 42.0%), and “women 
can perform the self-sampling test themselves” were other important reasons (3478, 
36.7%). Younger women more often indicate 1) a reduction in embarrassment, 2) less 
effort and time investment, and 3) the do-it-yourself aspect as a reason to use the self-
sampling device than older women. (Table 3)
The women who did not return a self-sampling device were asked why they 
had not used the self-sampling device (Table 4). Most women who returned a 
questionnaire (211 out of 682; 30.9%) indicated that they preferred an invitation to 
have a regular cervical smear taken, whereas 123 women (18.0%) gave no specific 
reason for their non-attendance in the self-sampling study. 
Almost half of the women in group 1 (48.9%) selected one answer, whereas, of 
the women in group 3, 76.4% selected one answer.  Analysis for multiple answers in 
both groups did not change the results compared to single answers (data not shown).
Table 4. Results from the question ‘What was/were the reason(s) not to use the 
self-sampling device?’ (n = 682)a.
I prefer a smear and would like an invitation for the regular screening 211 (30.9)
I do not want to participate (no special reason) 123 (18.0)
I am pregnant 62 (9.1)
I had a hysterectomy 38 (5.6)
Filled in an open answer 271 (39.7)
I already had a cervical smear taken in the past 3 years 142 (20.8)
Otherb 129 (18.9)
a Women were allowed to indicate multiple answers.
b Open answers were categorised. Categories constituting less than 5% percent were collected in a 
rest group.
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Discussion
The main reason for non-attendance in the Dutch regular cervical screening 
programme, for women who returned the questionnaires, was that women forgot 
to schedule an appointment to have a cervical smear taken. This was the most 
given answer for both women who did (group 1) and did not (group 3) return a self-
sampling device along with the questionnaire. Furthermore, the women in group 
1 felt too embarrassed to have a cervical smear taken by the physician. Among the 
women in group 3, the second most given reason not to participate in the population-
based screening was that they were too afraid to have a smear taken.
In a study from the UK with 580 women of whom 86 non-responders for screening 
showed similar results for non-attendance. Practical barriers, such as difficulty in 
making an appointment and difficulty to get an appointment to fit in with work and 
childcare commitments, were found to be more predictive than emotional factors.20 
Emotional barriers, a previous negative experience, and dissatisfaction with their 
general practitioner were identified as other important reasons for women not 
to attend cervical screening.20,21 In our data these reasons were only reported in a 
minority of cases. Explanations for the different reasons to non-attendance might 
be another study design (interviews by phone), smaller number of participants, 
cultural differences, and age ranges other than the Dutch screening (30–60 years). 
Additionally, emotional barriers may be found more in women who participated 
neither in screening nor in self-sampling, and who did not return a questionnaire 
either (n = 19,421; group 4).
Recently, to increase the participation rate, the Dutch Minister of Health recently 
decided to reshape the screening programme.22 Starting from 2016, instead of 
the regional screening organisations, the general practitioner will be the one to 
send an invitation for screening together with a date and time based on previous 
reports from literature.23-25 For women it is an extra barrier if they have to make an 
appointment themselves for an unpleasant test.21,25,26 It is known that an invitation by 
the general practitioner leads to a slightly higher participation rate compared to an 
invitation sent by a national or regional organisation.25,27,28 Organising more flexible 
general practitioner office hours may further lower the threshold for participation;26 
however, the effect of this type of intervention has not been studied yet. Finally, 
sending a reminder invitation sooner after the regular invitation, sending reminder 
letters more frequently or phoning the non-responders might also increase 
participation.14,29-31 
Another approach to lower the threshold for participation that will be introduced 
in the Dutch screening programme in 2016, is to offer HPV-self-sampling to non-
participants of regular screening. Several studies compared two methods for 
improving attendance rates and concluded that offering self-sampling significantly 
increases the attendance to the cervical screening programme compared to sending 
another reminder invitation.13-15,32-34 
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Indeed, the main reason to perform HPV-self-sampling for the self-sampling 
responders in the current study was that they could do it in their own time and it was 
less time consuming than having a cervical smear taken. In an Italian study by Giorgi 
Rossi et al. the main reason was the do-it-yourself opportunity, whereas in the current 
study this was the third most common answer.32 Altogether, these results show that 
self-control and time efficiency are the most important reasons for Dutch non-
responders to use a self-sampling device. This seems to apply mostly to the younger 
women, as they mention those reasons more often, as well as embarrassment and 
anxiety for having a smear taken. Thus, younger women might benefit more from 
the introduction of HPV self-sampling in a national screening programme, especially 
since non-participation is more common in younger women.5 
The strength of this study is the large cohort of 30,130 women, which is broadly 
representative of the general Dutch population. To our knowledge, this is the largest 
survey carried out in a population based screening cohort of non-responding women 
described in literature so far. From previous research it goes that non-responders to 
the regular screening program respond in about 30% when offered a self-sampling 
device.13-15,32-34 The return rate of self-sampling devices in our study was indeed 33,3% 
(10,027 out of 30,130). Out of  the 10,027 women who returned the self-sampling 
device, 9484 women also returned a questionnaire. This representative part (94.6%) 
is a solid basis to pronounce upon this group of self-sampling responders as a whole.
Additionally, this study is the first to report on women’s reasons to participate 
neither in the regular screening programme, nor in a self-sampling programme. 
Because of their reluctance to participate in any programme or study, reasons for non-
participation in this specific subgroup are hard to study. We reported a low response 
rate for this subgroup in our study (682 out of 30,130, 2.3%). Therefore, the results 
in this subgroup have to be interpreted with caution, and cannot be generalised for 
all 20,103 women who did not respond at all. However, since this is the first time 
this information is reported, the report of these results does provide first insights in 
women’s motives and gives an impetus to further research on this subject.
Remarkably, one third of the women who did not participate in the self-sampling 
study, but did return a questionnaire  indicates their preference to a cervical smear 
and would like to receive another invitation for regular screening. One third of 
these women who prefer an invitation for regular screening were pregnant or 
breastfeeding or already had a smear taken in 2008. Another explanation why these 
women prefer a cervical smear might be that women lack confidence to perform 
the test correctly, as described before in the literature,35,36 or lack confidence in the 
self-sampling device itself. Furthermore, the wording of the invitation to the self-
sampling study might have made them more aware of the importance of screening. 
The results of this study most of all pronounce on the women who responded to 
the self-sampling study by returning a self-sample and/or questionnaire. They may 
not be generalised offhand to all non-responders to cervical screening (n = 35,477); 
especially since we have no information on the women who opted out (n = 5347), and 
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the majority of invited women did not respond at all (n = 19,421, group 4). Another 
weakness of this study is the poor registration of opportunistic screening in the 
database of the regional screening organisations. For this study we selected non-
responders of the screening programme in 2008. At least 12.8% ((1130+124) / 10,166) 
of the women who returned a questionnaire already had a smear taken in the last 3 
years (Table 2). This percentage might be an underestimation, because this answer 
was only given as an open answer.
In conclusion, this study shows that among women who returned the 
questionnaire, organisational barriers are the main reasons for non-attendance 
in the cervical screening programme; emotional arguments appeared to be less 
important. Important reasons for women who did use a self-sampling device are 
convenience and self-control. To further improve cervical screening efficacy, special 
attention should be paid to the group of women who forgot to get a cervical smear 
taken. Small interventions in the regular screening programme as well as offering 
self-collection devices to non-responders might partly resolve the organisational 
barriers and therefore might increase attendance rates in cervical screening.
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 Appendix: Questionnaire
1. Did you perform the HPV-self-sampling?
o Yes, proceed to question 2 and 3
o No, proceed to question 3 and 4
2. What was/were the most important reason(s) to use the self-sampling device? 
(multiple answers allowed) 
o I feel less embarrassed of taking a self-sample than having a cervical smear taken 
  at my general practitioner
o It takes less effort and time than having a cervical smear. 
o I can do it alone and by myself instead of the general practitioner or assistant
o I can do it in my own time
o I am now more aware of the risk of getting cervical cancer
o I am less afraid for pain with the self-sample device
o Open answer
3. What was/were the reason(s) for not participating in the last regular 
screening round for cervical cancer? (multiple answers allowed) 
o I feel too embarrassed to have a smear taken by my general practitioner
o I am afraid to have a smear taken
o I do not want a cervical smear taken by my own general practitioner
o I could not make a suitable appointment
o I forgot to schedule an appointment
o I had a previous unpleasant experience with having a smear taken
o I do not participate because of principle reasons
o Open answer
4. What was/were the reason(s) not to use the self-sampling device? (multiple 
answers allowed)
o I had a hysterectomy
o I am pregnant
o I do not want to participate (no special reason)
o I prefer a smear and would like an invitation for the regular cervical screening
o Open answer
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Chapter 4
Dry storage and transport 
of a cervicovaginal self-sample by 
use of the Evalyn Brush, providing 
reliable human papillomavirus 
detection combined with comfort 
for women
R. van Baars, R.P. Bosgraaf, B.W.A. ter Harmsel,  
W.J.G. Melchers, W.G.V. Quint, R.L.M. Bekkers
Journal of clinical microbiology. 2012;50:3937-3943 
Abstract
Primary screening using high-risk human papillomavirus (hrHPV) detection has 
been suggested as a way of improving cervical cancer prevention. Women currently 
not attending screening (non-responders) are more likely to participate when 
given the opportunity of self-sampling for hrHPV testing. The Evalyn Brush is a 
new cervicovaginal self-sampling device, developed specifically to meet women’s 
demands, which is user-friendly and easy to use. The aims of this study were to 
investigate agreement of hrHPV detection by two PCR methods between the Evalyn 
Brush and physician-obtained samples and to study women’s acceptance of this 
self-sampling device. Each of 134 women visiting the gynecology outpatient clinic 
collected a self-obtained sample (self-sample) and completed a questionnaire. The 
brush was stored dry. After self-sampling, a trained physician obtained a conventional 
cervical cytology specimen in ThinPrep medium. HrHPV detection was performed 
using the SPF10-DEIA-LiPA25 and GP5+/6+-LQ-test. The overall agreement for hrHPV 
detection using SPF10-DEIA-LiPA25 between the self-sample and the physician-taken 
sample was 85.8% (kappa value, 0.715; 95% confidence interval [CI], 0.597 to 0.843; P 
= 1.000). The overall agreement for hrHPV detection using GP5+/6+-LQ between the 
self-sample and the physician-taken sample was 86.6% (kappa value, 0.725; 95% CI, 
0.607 to 0.843; P = 0.815). Ninety-eight percent of the women rated their experience 
as good to excellent. Moreover, 95% of women preferred self-sampling to physician 
sampling. Self-sampling using the dry Evalyn Brush system is as good as a physician-
taken sample for hrHPV detection and is highly acceptable to women. To validate 
this self-sampling device for clinical use, a large screening cohort should be studied.
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Background
Cervical cytology screening programs have significantly decreased the incidence 
and mortality of cervical cancer. Primary screening using high-risk human 
papillomavirus (hrHPV) detection has been found to be more sensitive than 
conventional cervical cytology for detecting cervical precancer.11,34,41-42 All data 
argue for the implementation of hrHPV testing as a primary test in cervical cancer 
screening, and the Health Council in the Netherlands has advised the Minister of 
Health to implement primary screening with hrHPV detection as a way of improving 
cervical cancer prevention.24 
Cervical cancer incidence is higher among women who do not respond (non-
responders) or have no access to cervical screening programs than in screened 
women. A substantial number of non-responders participate in screening when 
given the opportunity of self-sampling for hrHPV testing.1,19 Self-sampling for hrHPV 
therefore has the potential to reduce cervical cancer incidence, especially among 
non-responders.5
Cervicovaginal self-collected samples (self-samples) have proved to be as reliable 
as physician-obtained cervical samples for the detection of hrHPV.9,22,37-39,44-45,50 Studies 
on HPV self-sampling have used a great variety of collection devices, such as tampons, 
swabs, cervicovaginal brushes, and cervicovaginal lavage. Women are more familiar 
and comfortable with tampons than with other self-sampling methods, and the use of 
tampons is an attractive self-sampling method for women.15,22-23 However, tampons 
need more extensive processing than swabs and brushes for performance of HPV 
analysis.21 Furthermore, studies that used a brush or lavage7-9,43 for self-collection 
have demonstrated a higher sensitivity for cervical intraepithelial neoplasia grade 
two or worse (CIN2+) than studies that used a Dacron or cotton swab.2,6,48,51
Although cervicovaginal lavage is the most studied self-sampling technique,1,3,9,20,31,37 
the main disadvantage is that liquid specimens are not convenient to send by mail. 
This might be an obstacle in national screening programs.32 Brushes, on the other 
hand, may be used for dry transport and storage.47 Richman et al.40 showed that the 
majority of women who were offered the choice between the Qiagen cervical brush, 
the Fournier cervical self-sampling device, and the Pantarhei cervicovaginal lavage 
preferred the brush. Brushes are flexible and easy to use, can be processed in the 
same way as physician-obtained smears, and are suitable for sending by mail.32,44-45 
Although self-sampling for HPV testing is very acceptable to women, they are still 
concerned about performing the self-sampling procedure properly.4,14,16,22,37,49
To improve women’s confidence and the convenience of performing self-
sampling, a new cervicovaginal self-sampling device, the Evalyn Brush, was 
developed. This device is more understandable and user-friendly to women, as it 
indicates a standard depth of insertion and the number of rotations (Figure 1). The 
depth of insertion is controlled by the wings. The brush needs to be rotated five times, 
and at each rotation, there is an audible click indicating the number of rotations. 
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After self-sampling, the cap can be clicked onto the case and the brush can be sent 
by mail as is. The FTA cartridge, another previously reported dry storage system,13,32 
has the disadvantage that the DNA from the brush can be only partly transferred to 
the cartridge.
Figure 1. The Evalyn Brush
The Evalyn Brush is about 20 cm in length and consists of a transparent case with wings. Within the 
casing is a pink stick with a pink plunger at one end and a white brush at the other. You can push 
the white brush out of the case by pushing the pink plunger toward the transparent casing. After 
self-sampling, you can pull the brush back in, and a cap can be clicked onto the case before transport. 
We conducted the present study to investigate clinical applicability of the Evalyn Brush 
as a dry transport system compared to concurrently physician-obtained samples for 
the detection of hrHPV. We also investigated the acceptability of self-sampling using 
this device and women’s preferences for self-sampling or physician sampling.
The pink cap
The wingsThe white brush
The pink plunger
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Materials and methods
Clinical specimen collection
Clinical specimens were collected between September 2010 and May 2011 from 134 
women aged 18 years and above visiting the gynecological outpatient clinics of the 
Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, and of the 
Reinier de Graaf Hospital, Voorburg, Netherlands, for colposcopic evaluation due to 
an abnormal Pap smear or for a follow-up visit after an abnormal Pap smear. Women 
self-collected a cervicovaginal sample with the Evalyn Brush (Rovers Medical Devices 
B.V., Oss, Netherlands) after they had received verbal and written instructions with 
illustrations and consented to the study. After the specimen was obtained, a cap was 
clicked onto the case, and it was stored dry in the original state. After self-sampling, 
a trained physician obtained a liquid-based cytology sample using a Rovers Cervex-
Brush (Rovers Medical Devices B.V., Oss, Netherlands). The Cervex-Brush was rinsed 
in ThinPrep medium (Hologic, Marlborough, MA) at Radboud University Nijmegen 
Medical Centre and in SurePath medium (Klinipath BV, Duiven, Netherlands) at 
Reinier de Graaf Hospital. Cytological examination and classification were performed 
at the local laboratory according to the CISOE-A (composition, inflammation, 
squamous epithelium, other and endometrium, endocervical columnar epithelium, 
and adequacy of the smear) classification, which can easily be translated into the 
Bethesda 2001 classification.10 All samples were stored and transported at room 
temperature to DDL Diagnostic Laboratory, Voorburg, Netherlands, for molecular 
testing. All samples were assigned an anonymous, unique patient code.
Questionnaires
To investigate the acceptability of using the Evalyn Brush, all women were asked 
to fill out a short questionnaire using a 5-point ordinal scale to record their 
general experience, their response to the instructions, and their assessment of the 
convenience of using the Evalyn Brush. Participants were also asked whether they 
preferred self-sampling or physician sampling.
Specimen preparation 
The dry Evalyn Brush was resuspended in 1 ml of ThinPrep. The vials were vortexed 
for 3 × 15 s, stored overnight at 4°C, and again vortexed for 2 × 15 s. From each 
resuspended dry Evalyn brush specimen and from each cervical cytological specimen 
in liquid-based medium, 250 μl was used to obtain 100 μl of eluate with the QIAamp 
MinElute Virus Spin kit (Qiagen Inc., Valencia, CA) as described by the manufacturer. 
The mean interval between obtaining the specimen and HPV DNA isolation was 
2 months, with a range of 2 weeks to 6 months. Each DNA isolation and PCR test 
run contained HPV-positive and -negative controls. All self-collected and physician-
obtained samples were tested for HPV with both the analytically sensitive SPF10-PCR 
system29,30 and the clinically validated GP5+/6+-PCR-based test 25, 35.
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HPV detection and genotyping: SPF10 PCR-DEIA-LiPA25 system 
Broad-spectrum HPV DNA amplification was performed using a short-PCR-fragment 
assay (HPV SPF10-LiPA25, version 1; Labo Bio-medical Products B.V., Rijswijk, 
Netherlands). This assay amplifies a 65-bp fragment of the L1 open reading frame of 
HPV genotypes, as described by Kleter et al.29,30 HPV detection of at least 54 anogenital 
HPV genotypes was performed using a cocktail of 9 conservative probes in a microtiter 
hybridization assay, the DNA enzyme immunoassay (DEIA).30,36 The samples positive 
for HPV by DEIA were then analyzed with the line probe assay (LiPA25) by reverse 
hybridization with type-specific probes for HPV 6, 11, 16, 18, 31, 33, 34, 35, 39, 40, 42, 
43, 44, 45, 51, 52, 53, 54, 56, 58, 59, 66, 68/73, 70, and 74.29 The LiPA strips were visually 
inspected and interpreted following the standardized reference guide.
HPV detection and genotyping: GP5+/6+-EIA-LQ HPV amplification and detection 
The samples were also tested with the clinically validated hrHPV GP5+/6+ primer-
mediated PCR assay (Diassay, Rijswijk, Netherlands). With this, detection of DNA 
from 14 hrHPV genotypes, i.e., HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 
and 68, can be determined.46 Briefly, 10 μl of DNA was amplified with the biotin-
labeled GP5+/6+ primer set. The GP5+/6+ amplimers were subsequently genotyped 
by the digene HPV Genotyping LQ test using xMAP technology for high-throughput 
screening (Qiagen, Hilden, Germany) according to the manufacturer’s instructions.18
For the comparison of the two collection systems, only the 14 hrHPV types 16, 18, 31, 
33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68 were evaluated. Comparing the presence 
of hrHPV between the samples, results were classified as identical, concordant, or 
discordant. If all genotypes were the same in both samples, the results were called 
identical. If analyses showed at least one identical genotype in both samples, the 
results were called concordant. Genotype results were called discordant when the 
genotypes were different.
Statistical analysis
The level of agreement was determined using Cohen’s kappa statistics. The two-
tailed McNemar’s test was used for mutual comparison of positivity rates. The level 
of statistical significance was set at 0.05. All analyses were performed using SPSS 
version 17.0 for Windows (Chicago, IL). Cytology and histology data were used to 
investigate clinically relevant differences in hrHPV detection. 
This study was approved by the local medical ethical committees of both hospitals.
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Results
A self-collected sample and a subsequent conventional physician-taken cervical 
smear were obtained from 134 women (mean age, 40 years [standard deviation 
{SD}, 9.5 years]; range, 21 to 66 years). For 44 of the 134 women, histology results 
were available. Of the 44 biopsy specimens, 8 contained normal tissue, 9 had a CIN1 
lesion, 13 a CIN2 lesion, and 14 a CIN3 lesion. Cytology results were available for 
all women. If a histology diagnosis was available, this was used in the analyses of 
hrHPV detection in relation to cytohistological diagnosis. Five of the cytology results 
were not obtained during the same visit as that in which the sample for HPV analysis 
was obtained. Of these five women, three had an earlier smear with borderline 
dyskaryosis and two had an earlier negative result. These earlier results were used 
as the diagnoses in the analyses of hrHPV detection for women without concurrent 
cytohistological diagnoses.
SPF10 PCR-DEIA-LiPA25 system 
Table 1 shows the SPF10 PCR-DEIA-LiPA25 results in relation to the cytohistological 
diagnoses. The hrHPV positivity rate in physician-taken samples was 72/134 (54%) 
using the SPF10-DEIA-LiPA25 system. By comparison, 71 (53%) of the self-samples were 
hrHPV positive with SPF10-PCR. Ten women were SPF10 positive in the physician-taken 
samples but negative in self-samples, and 9 women tested positive in self-samples 
only but negative on the physician-taken sample. Fifty-three women were hrHPV 
negative in both samples. These differences in hrHPV results were observed in all 
diagnostic categories. There was no difference in the percentage of HPV positivity 
and the number of discordant cases between the specimens that were tested after 
2 weeks to 1 month and the specimens that were tested after 2 to 6 months (data 
not shown). There was good agreement for hrHPV detection using SPF10-DEIA-LiPA25 
between the self-sample and the physician-taken sample (kappa value [κ] = 0.715; 95% 
confidence interval [CI], 0.597 to 0.843; P = 1.000) with 85.8% concordance. Of the 62 
samples that were SPF10 positive in the physician-taken sample and the self-sample, 
41 (66%) showed identical hrHPV genotypes, 18 (29%) showed concordant hrHPV 
genotypes, and 3 (5%) showed discordant genotypes. In the concordant cases, in 7/18 
(39%) cases the self-sample detected an additional hrHPV genotype and in 5/18 (28%) 
cases an additional hrHPV type was detected in the physician-taken sample. In the 6 
other cases, one or two genotypes were replaced by one or two other genotypes in the 
other sample. In 3 discordant cases, the physician-taken samples showed HPV types 
52, 56, 31, and 39/68/73 (LiPA25 cannot distinguish between these types), whereas the 
self-samples showed HPV types 16, 31, and 16, respectively.
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Table 1. Agreement in hrHPV positivity (14 hrHPV genotypes) in self-sampled 
dry Evalyn Brush samples compared to physician-obtained samples with SPF10-
DEIA-LiPA25 in relation to the diagnoses
Diagnoses n
hrHPV positivitya detected by SPF10 in:   
Dry Brush 
and 
physician-
obtained 
samples 
Physician-
obtained 
samples 
only
Dry 
Brush 
samples 
only
Neither 
of the 
two 
systems
κ value (95% CI)
P 
value
Negativeb 70 21 7 3 39 0.695 (0.522-0.868) 0.344
BMDc 28 15 0 5 8 0.632 (0.360-0.904) 0.063
CIN 1 9 4 1 1 3 0.550 (0.001-1.000) 1.500
CIN 2 13 11 0 0 2 1.000 (1.000-1.000) 2.000
CIN 3 14 11 2 0 1 0.440 (0-1.000) 0.500
TOTAL 134 62 10 9 53 0.715 (0.597-0.834) 1.000
a Values indicate the number of samples. 
b Two of these results were not obtained at the same time as the sample for HPV analysis was 
obtained. 
c Three of these results were not obtained at the same time as the sample for HPV analysis was
obtained; one of these samples was a vagina top smear. 
BMD, borderline or mild dyskaryosis.
The 72 physician-taken samples and 71 self-samples that were SPF10-DEIA positive 
were genotyped by LiPA25. Only the 14 hrHPV types were considered. Table 2 shows 
that the overall agreement for hrHPV genotyping between physician-taken samples 
and self-samples was good (κ = 0.691; 95% CI, 0.617 to 0.766; P = 1.000). No statistically 
significant differences were found. From the 72 hrHPV-positive physician-taken 
samples, 25 (35%) contained a multiple infection with two or more hrHPV types, 
compared to 20/71 (28%) in the self-samples.
GP5+/6+-LQ
Table 3 shows the GP5+/6+-LQ test results in relation to the cytohistological diagnoses. 
With GP5+/6+-PCR, hrHPV was detected in 58 (43%) of 134 physician-taken samples. 
A similar number of self-samples tested hrHPV positive (56/134 [42%]; P = 0.815). Ten 
samples were found GP5+/6+ positive in physician-taken samples but negative in self-
samples. Only two of these physician-taken samples were also SPF10 positive. Both 
were negative by SPF10 in self-samples. With GP5+/6+-PCR, hrHPV was detected in 
eight self-samples that were negative in the physician-taken sample. For 68 women 
both samples were hrHPV negative, and for 48 women both samples were hrHPV 
positive. None of the diagnostic categories showed a significant difference in hrHPV 
detection. The concordance for hrHPV detection using GP5+/6+-LQ between self-
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samples and physician-taken samples was 86.6%, with good agreement (κ = 0.725; 
95% CI, 0.607 to 0.843; P = 0.815).
All GP5+/6+-positive samples were genotyped by LQ. Only the 14 hrHPV types 
were considered. The results are shown in Table 4. The 48 samples that were 
GP5+/6+-LQ positive in both the physician-taken sample and the self-sample did not 
show discordant genotypes, 37/48 samples (77%) had identical hrHPV genotypes, and 
11/48 (23%) had concordant hrHPV genotypes. We found good agreement for hrHPV 
genotyping between physician-taken samples and self-samples (κ = 0.768; 95% CI, 
0.691 to 0.846; P = 0.110). A multiple infection with two or more genotypes was found 
in 24% (14/58) of the physician-taken samples and 25% (14/56) of the self-samples.
Table 2. Comparison of hrHPV genotyping by SPF10-DEIA-LiPA25 in physician-
obtained and dry Evalyn Brush samples
Genotype
hrHPV positivitya detected by SPF10-LiPA25 in:  
Dry Brush 
and 
physician-
obtained 
samples 
Physician-
obtained 
samples 
only
Dry 
Brush 
samples 
only
Neither 
of the 
two 
systems
κ value (95% CI) P value
HPV16 13 1 3 117 0.850 (0.706-0.994) 0.625
HPV18 8 2 0 124 0.881 (0.719-1.000) 0.500
HPV31 8 3 6 117 0.604 (0.369-0.839) 0.508
HPV33 5 1 0 128 0.905 (0.721-1.000) 1.000
HPV35 2 1 0 131 0.796 (0.407-1.000) 1.000
HPV39 2 4 2 126 0.378 (0-0.770) 0.687
HPV45 2 0 0 132 1.000 (1.000-1.000) 2.000
HPV51 7 0 4 123 0.763 (0.540-0.985) 0.125
HPV52 5 5 5 119 0.460 (0.177-0.743) 1.000
HPV56 4 3 3 124 0.548 (0.226-0.870) 1.000
HPV58 1 1 0 132 0.663 (0.044-1.000) 1.000
HPV59 4 4 0 126 0.653 (0.339-0.967) 0.125
HPV66 9 1 4 120 0.763 (0.563-0.962) 0.375
HPV68/73 1 2 2 129 0.318 (0-0.812) 1.000
HPV39/68/73 0 2 0 132 NCb 0.500
Any type 71 30 29 1,880 0.691 (0.617-0.766) 1.000
a Values indicate the number of samples. 
b NC, this quantity cannot be calculated.
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Table 3. Agreement in hrHPV positivity (14 hrHPV genotypes) in self-sampled 
dry Evalyn Brush samples compared to physician-obtained samples with 
GP5+/6+-LQ in relation to the diagnoses.
Diagnoses n
hrHPV positivitya detected by GP5+/6+ in:   
Dry Brush 
and 
physician-
obtained 
samples
Physician-
obtained 
samples 
only
Dry 
Brush 
samples 
only
Neither 
of the 
two 
systems
κ value (95% CI) P value
Negativeb 70 13 4 4 49 0.689 (0.490-0.889) 1.273
BMDc 28 12 1 3 12 0.716 (0.460-0.971) 0.625
CIN 1 9 4 2 0 3 0.571 (0.098-1.000) 0.500
CIN 2 13 9 1 1 2 0.567 (0.032-1.000) 1.500
CIN 3 14 10 2 0 2 0.588 (0.107-1.000) 0.500
TOTAL 134 48 10 8 68 0.725 (0.607-0.843) 0.815
a Values indicate the number of samples.
b Two of these results were not obtained at the same time as the sample for HPV analysis was 
obtained.
c Three of these results were not obtained at the same moment as the sample for HPV analysis was 
obtained; one of these samples was a vagina top smear. 
BMD, borderline or mild dyskaryosis.
Detection rate of CIN2+
CIN2+ was present in 27 women (20.1%). The sensitivities for the detection of CIN2+ 
in physician-obtained samples with the SPF10 and the GP5+/6+-PCR were 88.9% and 
81.5%, respectively, and in the self-samples 81.5% and 74.1%, respectively  (Table 5). 
The specificities for the detection of CIN2+ samples in physician-taken samples with 
the SPF10 and the GP5+/6+-PCR were 55.1% and 66.4%, respectively, and in the self-
samples 54.2% and 66.4%, respectively. No significant difference in the sensitivity 
for the detection of CIN2+ could be found between the physician-taken samples and 
the self-samples with both detection methods (for SPF10, P = 0.500; and for GP5+/6+, 
P = 0.625).
Questionnaires
Of the 134 questionnaires, 127 (95%) were returned for analysis. The results from 
the questionnaires are shown in Table 6. From this group, 124 (98%) women rated 
their experience with the brush as good to excellent. The instructions for using the 
Evalyn Brush were considered good to excellent by 124 (98%) of the 127 women, and 
125 (98%) women rated the convenience of using this self-sampling device as good to 
excellent. Most women (n = 120 [95%]) preferred self-sampling to physician sampling 
Dry storage and transport of a cervicovaginal self-sample by use of the Evalyn Brush | 
C
H
A
P
T
E
R
.4
87
because it was simple, easy, and less painful than a physician-collected smear. Also 
women that never used tampons judged their experience with the brush as very 
good. Women also liked the option of self-sampling because it was time saving, as no 
visit to the clinician was needed. The most frequent reason (6/7 [86%]) for preferring 
the physician-taken smear was that the women considered it more reliable. 
Among the women who preferred self-sampling to physician sampling, 2/120 (2%) 
nevertheless considered the physician-taken sample more reliable and 3/120 (3%) 
questioned whether they had performed the test correctly. Women commented on 
the appearance of the Evalyn Brush and said that they liked the color.
Table 4. Comparison of hrHPV genotyping by GP5+/6+-LQ in physician-obtained 
and dry Evalyn Brush samples
Genotype
hrHPV positivitya detected by GP5+/6+-LQ in:   
Dry Brush 
and 
physician-
obtained 
samples
Physician-
obtained 
samples 
only
Dry 
Brush 
samples 
only
Neither 
of the 
two 
systems
κ value (95% CI) P value
HPV16 11 4 3 116 0.729 (0.539-0.920) 1.000
HPV18 7 1 1 125 0.867 (0.686-1.000) 1.000
HPV31 6 3 2 123 0.686 (0.427-0.945) 1.000
HPV33 5 1 0 128 0.905 (0.721-1.000) 1.000
HPV35 2 0 0 132 1.000 (1.000-1.000) 2.000
HPV39 2 0 1 131 0.796 (0.407-1.000) 1.000
HPV45 2 0 0 132 1.000 (1.000-1.000) 1.000
HPV51 4 3 1 126 0.651 (0.334-0.969) 0.625
HPV52 1 1 1 131 0.492 (0-1.000) 1.000
HPV56 4 4 0 126 0.653 (0.339-0.967) 0.125
HPV58 2 1 0 131 0.796 (0.407-1.000) 1.000
HPV59 3 0 1 130 0.853 (0.570-1.000) 1.000
HPV66 8 2 1 123 0.830 (0.642-1.000) 1.000
HPV68 0 1 0 133 NCb 1.000
Any type 56 21 11 1658 0.768 (0.691-0.846) 0.110
a Values indicate the number of samples. 
b NC, this quantity cannot be calculated.
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Table 5. Sensitivity and specificity for the two collection devices with the SPF10 
and the GP5+/6+-system for the detection of CIN2+
Physician-obtained samplesa Dry Brush samplesa
 SPF10 GP5+/6+ SPF10 GP5+/6+
Sensitivity 88.9% (24/27) 81.5% (22/27) 81.5% (22/27) 74.1% (20/27)
Specificity 55.1% (59/107) 66.4% (71/107) 54.2% (58/107) 66.4% (71/107)
a Values in parentheses are number of samples in which CIN2+ was detected/total number.
 
Table 6. Questionnaire results
Question topic Excellent Very Good Good Moderate Poor
n % n % n % n % n %
Experience 43 34 39 31 42 33 3 2 0 0
Instructions 46 36 35 28 43 34 3 2 0 0
Convenience 45 35 45 35 35 28 1 1 1 1
Convenience compared  
to physician-taken smear 56 44 30 24 34 27 5 4 2 1
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Discussion
The dry self-samples showed good agreement with the physician-taken samples in 
hrHPV detection with both the analytically sensitive SPF10-PCR and the clinically 
validated GP5+/6+-PCR. Our results indicate that self-sampling using the dry 
Evalyn Brush system is as good as a physician-taken smear for hrHPV detection. 
Our results are in line with previous studies showing repeatedly that self-collected 
cervicovaginal samples are as reliable as clinician-collected specimens for hrHPV 
detection.9,12,19,26,28,37-39,44 
Previous HPV self-sampling studies have used a variety of collection devices 
and HPV DNA tests. The concordance between the dry brush system and physician 
sampling in this study was 85.8% with SPF10 and 86.6% with GP5+/6+. This is 
comparable with the mean concordance calculated in the meta-analysis of Petignat 
et al. (87%)39 and with the more recent review of Schmeink et al. (85.2%).44 The kappa 
statistic showed good agreement between self-sampling and physician sampling for 
hrHPV in this study (κ = 0.715 and κ = 0.725). This agreement was higher than the mean 
κ obtained by Schmeink et al. (κ = 0.60)44 and by Petignat et al. (κ = 0.66)39. In our study, 
the sensitivities for CIN2+ did not differ significantly between the self-samples and 
the physician-taken samples. Some previous publications reported that self-sampling 
has a lower sensitivity than clinician sampling for HPV detection,2,8,17,33,37,45,51-52 but 
these results have not been consistently found.9,22,26 The difference in sensitivity 
between studies might be due to differences in collection devices (brush, swab, 
tampon, or lavage), populations (screening population or women with an abnormal 
Pap smear), and the HPV DNA tests used. Schmeink et al. concluded that PCR-based 
HPV testing shows better results than studies performed with HC2. From our results, 
it appears that the use of an analytically sensitive test, like the SPF10, results in a 
lower specificity than that obtained with the less sensitive GP5+/6+. Further studies 
are needed to determine the most suitable test in different populations.
The Evalyn Brush is a well-accepted self-sampling method for HPV detection 
according to 98% of women who used this device because it is easy to use, time saving, 
and more comfortable than collection by a physician. This self-sampling device was 
specifically designed to improve women’s confidence in, and the convenience of, 
self-sampling. Indeed, 95% of women preferred self-sampling to physician sampling. 
The few women in our study who preferred clinician sampling specified their main 
reason as fear of inadequate self-sampling. This is in line with findings of previous 
studies.14,23,28,40,49 Acceptability of the self-sampling device may be important for 
women who ignore the invitation to attend the national cervical cancer screening 
program or in settings without organized cervical screening programs.27 Use of 
the Evalyn Brush may help increase the participation rate for cervical screening 
programs.
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A limitation of this study is that it was performed in a hospital setting. Self-sampling 
is shown to be accepted well by women with a history of an abnormal Pap smear, 
but this study population is not representative of the broader population of women 
not participating in screening. Therefore, this study cannot be generalized to such 
a population. Another theoretical limitation is that the self-sample was always 
obtained before the physician-taken smear. This was done to avoid interference with 
HPV detection by the lubricating gel used on the speculum. The order of sampling 
could influence the amount of HPV DNA sampled, but Harper et al.21 showed in a 
randomized controlled trial that the order of sampling did not influence the result. 
Third, the number of patients included in this study is small. The response rate and 
performance of the Evalyn Brush are currently being investigated in non-responders 
to the Netherlands national screening program.
In conclusion, although the number of women included in this study was limited, 
the dry-stored Evalyn Brush showed good agreement for hrHPV detection with 
the physician-taken smears and is a well-accepted self-sampling device. Clinical 
validation and evaluation of the acceptability of this self-sampling device in screening 
populations should be the next step.
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What’s new?
If people won’t come into the clinic to get tested for HPV, send the test to them: that’s 
the public health strategy the Netherlands will employ beginning in 2016. This study 
compared two methods of self-sampling for HPV, one brush based and one lavage 
based. The authors measured participation rates, user comfort, how often each 
method detected the virus, and how often neoplasias were detected. They found 
non-inferiority in the participation rates, and in all other measures the two methods 
performed equally well.
Abstract
We determined whether the participation rate for a brush-based cervicovaginal 
self-sampling device is non-inferior to the participation rate for a lavage-based one 
for testing for hrHPV (high-risk human papillomavirus). Additionally, positivity 
rates for hrHPV, the detection rates for cervical intraepithelial neoplasia grades 2 
and 3 or worse (CIN2+/3+), and user comfort were compared. A total of 35,477 non-
responders of the regular cervical screening programme aged 33-63 years were 
invited to participate. Eligible women (n=30,130) were randomly assigned to receive 
either a brush-based or a lavage-based device, and a questionnaire for reporting 
user convenience. Self-sampling responders testing hrHPV-positive were invited 
for a physician-taken sample for cytology; triage-positive women were referred 
for colposcopy. A total of 5218 women participated in the brush-based sampling 
group (34.6%) and 4809 women in the lavage-based group (31.9%), i.e. an absolute 
difference of 2.7% (95%CI 1.8–4.2). The hrHPV-positivity rates in the two groups were 
identical (8.3%, relative risk (RR) 0.99, 95%CI 0.87–1.13). The detection of CIN2+ and 
CIN3+ in the brush group (2.0% for CIN2+; 1.3% for CIN3+) was similar to that in the 
lavage group (1.9% for CIN2+; 1.0% for CIN3+) with a cumulative RR of 1.01, 95%CI 
0.83–1.24 for CIN2+ and 1.25, 95%CI 0.92–1.70 for CIN3+. The two self-sampling 
devices performed similarly in user comfort. In conclusion, offering a brush-based 
device to non-responders is non-inferior to offering a lavage-based device in terms 
of participation. The two self-sampling methods are equally effective in detecting 
hrHPV, CIN2+/CIN3+ and are both well accepted.
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Introduction
The introduction of organised programmes for cervical cancer screening in developed 
countries has contributed to a significant decrease in the incidence and mortality 
rate of cervical cancer.1-5 A major issue concerning the effectiveness of the screening 
programmes is that many women do not attend the cervical screening (i.e., non-
responders). Non-participation women are at increased risk of developing cervical 
cancer; therefore, it is important to reach these women.5-8 Offering self-sampling 
for testing for high-risk human papillomavirus (hrHPV) is a suitable screening 
method for previously unscreened or under-screened women. Large-scale cohort 
studies have demonstrated that about one-third of a non-responder population will 
participate in the screening programme when offered a self-sampling device.9-17 This 
improves population coverage and might further reduce both the incidence and 
mortality rate of cervical cancer.18,19 Recent studies have shown a high concordance 
of hrHPV test results between most vaginal self-samples and physician-taken 
cervical scrapes. Even more, vaginal self-samples and physician-taken samples show 
similar test accuracy in detecting cervical intraepithelial neoplasia grade 2 or worse 
(CIN2+), provided that the test and the self-sampling device have been validated both 
individually and in a combined method.20-22 
Although various self-sampling devices have been investigated in research 
settings, no large-scale population-based studies have compared different self-
sampling devices in a randomised setting and considered the participation 
rates, prevalence of hrHPV, and detection of CIN. Most prospective studies have 
compared a self-sampling approach with a re-invitation to the regular screening 
programme.9,10,12-14,16 Before self-sampling devices are used in population-based 
screening,23 it is important to explore their acceptability and user-friendliness. No 
large population-based studies have evaluated this aspect yet.24-28 
Here, we present the results of a randomised controlled trial that took place 
within the setting of a national screening programme in the Netherlands. We have 
compared the performance of brush-based and lavage-based self-sampling devices 
(in the PROHTECT-3B trial). The primary outcome was the participation rate, and the 
secondary outcomes were detection of hrHPV and the yields of CIN2+ and CIN3+. We 
used a questionnaire to investigate the acceptability and user-friendliness of both 
self-sampling devices and the participants’ preference for either self-sampling or a 
physician-taken smear for cytological testing in the next screening round. The results 
of this study can be used in developing future screening programmes in which self-
sampling may play an important role.
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Methods
Study population
Cervical screening in the Netherlands is organised in a nationwide programme in 
which the screening organisations invite women aged 30–60 years for a cervical 
smear at 5-year intervals. Women who do not attend regular screening are registered 
as ‘non-responders’ in the databases of the screening organisations. In the current 
study, 35,477 who did not respond in 2008 and who were living in regions of North 
Holland, Flevoland, Utrecht, and Gelderland were invited to participate in the 
PROHTECT-3B (Protection by Offering HPV Testing on self-sampled Cervicovaginal 
specimens Trial-3B) study between October 2011 and February 2012. All the eligible 
women received a pre-invitation letter and could ‘opt out’ of this trial. The exclusion 
criteria were previous hysterectomy, being followed up by a gynaecologist because 
of a previous abnormal cytological test result less than 2 years before inclusion, and 
a current pregnancy. Those wishing to opt out could do so by returning a form by 
regular post, sending an e-mail, calling a service desk, or opting out via the study 
website (http:// www.thuistesthpv.nl). Figure 1 shows the study design. 
Randomisation
We randomised the invited women who did not opt out within 3 weeks in a 1:1 ratio. 
We used a computer number generator to determine who would receive a self-
sampling brush device (Evalyn Brush, Rovers Medical Devices, Oss, The Netherlands, 
Figure 2A) and who would receive a self-sampling lavage device (second generation 
Delphi Screener, Delphi Bioscience, Scherpenzeel, The Netherlands, Figure 2B). 
The randomisation was stratified for age (seven age cohorts) and degree of 
urbanisation. Population areas with fewer than 100,000 inhabitants were considered 
low-level urban areas and those with more than 100,000 inhabitants, high-level urban 
areas. Researchers and health professionals were blinded to the randomisation, 
which was performed by an independent statistician. All patient data were entered 
and managed within a password-protected web-based database approved for ‘good 
clinical practice’ (Infermed MACRO, London, UK). The national ethics committee 
(Ministry of Public Health No 2010/04WBO) approved this study, the trial was 
registered in the trial register (Trialregister.nl, NTR3350) and all participants gave 
written informed consent.
Self-sampling procedures
The self-sampling kit consisted of either a brush device or a lavage device. The brush 
device (Figure 2A) is about 20 cm long and consists of a transparent case with wings 
that control the depth of insertion into the vagina. After the device has been inserted 
up to its wings, pushing the plunger toward the casing will push the brush out into 
the vagina. The brush needs to be rotated five times; at each rotation there is an 
audible click. After rotation, the brush can be pulled back into the case and removed 
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Figure 1. Study design
BMD = borderline or mildly dyskaryotic; hrHPV = high-risk human papillomavirus
Non-participants of the regular 
screening programme (30-60 years)
Offering a brush device Offering a lavage device
Opting out
Offering an HPV self-sampling device to 
the eligible women. Randomisation (1:1)
Participation brush device group
hrHPV-negative
Normal cytology
Cytology and 
hrHPV test 
at 6 months
Normal cytology 
and hrHPV-negative
Back to regular 
screening 
programme
Back to regular 
screening 
programme
Colposcopy 
and biopsy
Colposcopy 
and biopsy
Normal cytology 
and hrHPV-negative
Abnormal cytology 
(≥BMD) and/or 
hrHPV-positive
Abnormal cytology 
(≥BMD) and/or 
hrHPV-positive
Cytology and 
hrHPV test 
at 6 months
Normal cytologyAbnormal 
cytology (≥BMD)
Colposcopy 
and biopsy
Colposcopy 
and biopsy
Abnormal 
cytology (≥BMD)
Back to regular 
screening 
programme
Back to regular 
screening 
programme
hrHPV-negative
Participation lavage device group
hrHPV-positive hrHPV-positive
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from the vagina. A cap is to be clicked onto the case and the brush can be directly 
sent by regular mail. The lavage device (Figure 2B) is 22.5 cm long and is pre-filled 
with 3 ml of sterile saline. After the participant removes the seal covering the top, she 
inserts the device into the vagina until she feels resistance. Pressing the white button 
at the back releases the sterile saline, which will spread around the cervical area. 
When the button is released, the fluid from the cervix and vagina will flow back into 
the device. The device is then removed from the vagina and the fluid is transferred 
to a test tube for sending by regular mail.
The self-sampling kit also included an explanatory letter, an informed consent 
form, user instructions (written and drawn), a questionnaire, and a return envelope 
with the address of the laboratory. The women were asked to return the used brush 
device or the lavage device’s collection vial, the signed informed consent form, and 
the questionnaire. For both groups, the self-sampling kits contained similar content 
except for the type of device and the accompanying user instructions. 
Figure 2. Self-sampling devices 
A) Brush-based device (Evalyn Brush) B) Lavage-based device (Delphi Screener) 
Testing of the self-sampled material
Upon arrival of the dry brush devices at the laboratory, they were resuspended in 
1.5 ml of Preservcyt medium (Hologic, Marlborough, Mass.). The vials were vortexed 
for 3 × 15 s, stored overnight at 4°C, and again vortexed for 2 × 15 s. The vials were 
visually inspected and scored on a small pellet or no pellet. 
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When the lavage-based specimens arrived at the laboratory, they were visually 
inspected the same way as the brush specimens were. The lavage specimens were 
centrifuged to concentrate the cell material. Then the supernatant was removed 
before the pellet was resuspended in 1.5 ml of Preservcyt medium. 
The brush and lavage specimens were tested for hrHPV by means of the 
clinically validated hrHPV GP 5+/6+ PCR (EIA HPV GP HR kit, Diassay, Voorburg, The 
Netherlands) according to the manufacturer’s instructions. A PCR for the β-globin 
gene was used to check for the presence of amplifiable DNA in all samples with 
a small or no pellet on arrival at the lab and in an additional random 5% of the 
samples.29 Samples were considered invalid if the β-globin PCR test was negative. In 
such cases, the participants were requested to send a new sample. If no new sample 
was received, their results were classified as inadequate for evaluation.
All participants were notified of the test result. Those who tested negative for 
hrHPV were advised to participate in the next regular screening round, and women 
who tested positive were advised to have an additional cervical cytological smear 
taken by the general practitioner for colposcopy triage.
Follow-up algorithm
All liquid-based cytological specimens were taken with the Cervex brush (Rovers 
Medical Devices, Oss, The Netherlands), stored in PreservCyt and sent to the 
Department of Pathology at the Radboud University Medical Center. The monolayer 
slides were then prepared and classified according to the Dutch CISOE-A classification 
system, which can easily be translated into the Bethesda nomenclature.30 The 
cytological test results were grouped as normal, borderline or mildly dyskaryotic 
(BMD; corresponding to Bethesda ASCUS/LSIL), or moderately dyskaryotic or worse 
(>BMD; corresponding to Bethesda ASC-H/HSIL or worse). 
Participants with abnormal cytological test results (threshold BMD) were referred 
to a gynaecologist for colposcopy, and participants with cytologically normal smears 
were invited for cytology testing and hrHPV retesting after 6 months. If either of 
these tests was abnormal (threshold BMD and/or hrHPV-positive), the participants 
were referred to a gynaecologist for colposcopy. Those with both a normal cytological 
test result and a hrHPV-negative result at 6 months were advised to participate in 
the next regular screening round. Three months later, a reminder letter was sent to 
all women and their general practitioners who did not comply with the follow-up 
protocol.
At colposcopy, cervical lesions were biopsied and/or treated according to 
the standard procedure in the Netherlands.31,32 If no abnormalities were seen at 
colposcopy, the gynaecologist was advised to take two random biopsies. Firstly, 
we decided for two biopsies in this subgroup to ensure the same study end point 
for all participants and secondly, because of the fact that colposcopy has only a 60-
80% positive predictive value. That means, 20-40% of all cases are false negative. 
In addition, the positive predictive rate of the colposcopic impression in cases with 
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minor grades of CIN is lower than in cases with severe dysplasia.33 
Histopathological analysis took place according to the current guidelines. The 
results were recorded in the nationwide network and registry of histopathology and 
cytopathology in the Netherlands (PALGA, Utrecht, The Netherlands). 
Questionnaire
The self-sampling kit contained a questionnaire about the self-sample device. The 
participants were asked about the overall convenience, user comfort, and their 
perceptions during self-sampling about shame, feeling at ease, usability, stress, 
comfort, pain, and trust in completing the test correctly. They were asked which test – 
self-sampled or physician-sampled – they would prefer for the next screening round. 
The participants sent the questionnaires and their self-samples to the laboratory. 
All questionnaires were collected and analysed centrally. Cardiff Teleform Software 
(version 10.1, 2010; Cambridge, UK) was used to design the questionnaire and to 
record the data. 
Outcome measures
The primary outcome measure of PROHTECT-3B was the participation rate, i.e. the 
percentage of randomised women who returned a self-sample. All women who 
submitted self-samples between October 2011 and December 2012 were counted as 
self-sampling responders. The secondary outcome measures were hrHPV positivity, 
the number of histologically confirmed CIN2+ and CIN3+ lesions, and user comfort 
as the questionnaire reported. 
The participants reached a study end point if (i) their self-samples tested HPV-
negative, (ii) they were hrHPV-negative and had normal cytology at the 6-month 
follow-up, or (iii) if there was a positive or negative histopathological result. Women 
with a negative colposcopy without biopsy did not meet the study end point and this 
was considered as incomplete follow-up.
The most severe diagnosis was registered when more histological diagnoses were 
available in the follow-up period. All cytological and histological findings recorded 
before June 2013 were included in our analysis. At this point, the database was 
complete after a mean follow-up of 15 months for both devices (range 6–18 months). 
Follow-up outcomes of all participants were retrieved from the nationwide network 
and registry of histology and cytology database (PALGA) was used, and if necessary, 
obtained from general practitioner or gynaecologists. 
Statistical analysis 
The primary objective of the study was to compare the participation rates of women 
who received the brush device and those who received the lavage device. A difference 
in participation of at most 1.4% was defined as the non-inferiority margin: if the 
lower limit of the 95% CI for the difference (brush group vs. lavage group) was above 
-1.4%, the participation rate of the brush group could be considered non-inferior to 
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the participation rate of the lavage group. We selected the non-inferiority margin 
on the basis of clinically important differences, costs, and feasibility of the national 
cervical cancer screening. To achieve a power of 80% while assuming a participation 
rate of 27%,9, 34 we had to invite at least 16,500 women for each arm. 
We analysed the data with SPSS (Statistical Package for the Social Sciences, version 
20.0.1 for Windows). Wald confidence intervals for proportions were presented. The 
association between the self-sampling group and categorical outcomes was tested 
with the Pearson chi-square test, except for the association between age and the 
proportion of hrHPV-positive women, which was tested with the chi-square test 
for linear trend. We used risk ratios (RRs) to compare detection ratios. We fitted 
them by means of a log-binomial model, and adjusted for age group and degree of 
urbanisation. Differences with a two-sided p<0.05 were considered significant. The 
CONSORT (CONsolidated Standards Of Reporting Trials) Statement on the reporting 
of non-inferiority trials was followed.35
Results
Patient characteristics and participation rate
A total of 35,477 non-responding women were approached to participate in the 
current study; 5347 (15.1%) opted out. A total of 3149 out of 5347 women who opted 
out met the inclusion criteria, but decided not to participate. The remaining 30,130 
women were randomly assigned to receive either the self-sampling brush device or 
the self-sampling lavage device in a ratio of 1:1. A total of 5218 women (34.6%, 95% 
CI 33.9–35.4) in the brush group (mean age 44.5 years, range 33–63 years) and 4809 
women (31.9%, 95% CI 31.2–32.7) in the lavage group (mean age 44.8 years, range 
33–63 years) returned self-sampled material and a signed informed consent form 
(absolute difference 2.7%, 95% CI 1.8–4.2). As a result, the participation rate in the 
brush group was non-inferior to, and higher than the participation in the lavage 
group. The self-sampling participation rates in the different age strata ranged from 
31.3% to 37.8% in the brush group and from 30.1% to 34.7% in the lavage group 
(Table 1). The overall participation rate of all non-responders who met the inclusion 
criteria in this study was 30.1% (10,027 participants out of 33,279 women who met 
the inclusion criteria). Figure 3 shows the trial flowchart.
HPV test positivity rate
While 433 (8.3%) brush samples were hrHPV-positive, 4762 (91.3%) were hrHPV-
negative and 23 (0.4%) were inadequate for evaluation. Of the lavage samples, 401 
(8.3%) were hrHPV-positive, 4384 (91.2%) were hrHPV-negative, and 24 (0.5%) were 
inadequate for evaluation (Figure 3). The hrHPV positivity rate did not differ between 
the brush group and the lavage group; RR 0.99 (95% CI 0.87–1.13). The proportion of 
hrHPV-positive women decreased with age from 12.2% at age 33 years to 5.3% at age 
63 years (Pearson chi-square for linear trend = 79.81; p<0.01) and was similar for the 
two devices (Table 1).
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Figure 3. Trial profile
hrHPV = high-risk human papillomavirus; 
CIN = cervical intraepithelial neoplasia
35,477 non-responders were invited (30-60 years)
30,130 self-sampling devices were sent 
Randomly assigned (1:1)
15,077 women received a brush device
5,218 brush device participants (34.6%)
4,762 hrHPV-negative 
(91.3%)
231 cytology negative
(55.8%)
174 hrHPV and cytology 
triage at 6 months
90 normal smear 
and HPV-negative
34 no CIN 
14 CIN 1 
4 CIN 2 
6 CIN 3 
0 cancer
Brush device group: overall study endpoint
90 normal smear and HPV-negative
69 no CIN
39 CIN 1
34 CIN 2
61 CIN 3
9 cancer
35 no CIN 
25 CIN 1 
30 CIN 2 
55 CIN 3 
9 cancer
Back to regular 
screening programme
433 hrHPV-positive 
(8.3%)
178 cytology positive 
(43.0%)
431 eligible for 
cytology triage
414 cytology triage
26 no histology
2 excluded; not eligible
17 no cytology
24 no histology57 no exit test
23 inadequate 
for evaluation (0.4%)
5 inadequate 
for evaluation (1.2%)
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hrHPV = high-risk human papillomavirus; 
CIN = cervical intraepithelial neoplasia
5,347 women opted out (15.1%)
4,384 hrHPV-negative 
(91.2%)
221 cytology negative 
(56.8%)
167 hrHPV and cytology
triage at 6 months
78 normal smear 
and HPV-negative
30 no CIN
17 CIN 1
4 CIN 2
3 CIN 3
0 cancer
Lavage device group: overall study endpoint
82 normal smear and HPV-negative
63 no CIN
41 CIN 1
41 CIN 2
40 CIN 3
8 cancer
4 normal smear 
and HPV negative
33 no CIN
24 CIN 1
37 CIN 2
37 CIN 3
8 cancer
Back to regular 
screening programme
22 no histology54 no exit test
35 no histology
1 excluded; not eligible
11 no cytology
401 hrHPV-positive 
(8.3%)
165 cytology positive 
(42.4%)
400 eligible for 
cytology triage
389 cytology triage
24 inadequate 
for evaluation (0.5%)
3 inadequate
for evaluation (0.8%)
15,053 women received a lavage device
4,809 lavage device participants (31.9%
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Cytology triage testing
No cervical sample was taken for cytological testing from 17 of the 431 eligible 
women (3.9%) who were hrHPV-positive in the brush group. Of the remaining 
414, 178 women (43.0%) had abnormal smears; 231 (55.8%), a normal smear; and 
5 (1.2%), an invalid result. No cervical sample was taken for cytological testing from 
11 of 400 eligible women (2.8%) who were hrHPV-positive in the lavage group. Of 
the remaining 389 women, 165 (42.4%) had abnormal smears; 221 (56.8%), normal 
smears; and 3 (0.8%), an invalid results. The overall compliance for cytological triage 
after a hrHPV-positive result was 97% (803 of 831); 96% in the brush group and 97% 
in the lavage group (Figure 3). 
CIN2+ and CIN3+ detection rates
Baseline
Of the 178 women in the brush group with abnormal results in the cytological triage 
test, 94 (52.8%) were diagnosed with CIN2+, of whom 55 with CIN3, 6 with squamous 
cell carcinoma, and 3 with adenocarcinoma (64 CIN3+), while 60 women (33.7%) had 
CIN1 or less (35 no CIN and 25 CIN1). Of the 165 women in the lavage group with 
abnormal cytology triage results, 82 (49.7%) were diagnosed with CIN2+, of whom 37 
with CIN3, 7 with squamous cell carcinoma, and 1 with adenocarcinoma (45 CIN3+); 
further, 57 women (34.5%) had CIN1 or less (33 no CIN and 24 CIN1; Figure 3). 
Follow-up
Follow-up of 231 women with hrHPV-positive results and normal cytology at 
baseline in the brush group yielded 10 women (4.3%) with CIN2+ (4 CIN2, 6 CIN3), 
14 (6.1%) with CIN1, 34 (14.7%) with no CIN, 90 (39.0%) with normal cytology and 
hrHPV-negative results, and 83 (35.9%) did not return for follow-up testing or had 
no histopathological end point. Follow-up of 221 women with hrHPV-positive results 
and normal cytology at baseline in the lavage group yielded 7 women (3.2%) with 
CIN2+ (4 CIN2 and 3 CIN3), 17 (7.7%) with CIN1, 30 (13.6%) with no CIN, 78 (35.3%) 
who had normal cytology and were hrHPV-negative, and 89 (40.3%) did not return 
for follow-up or had histopathological end point (Figure 3).
Overall, 17 cancers (0.2%), 118 (1.2%) CIN3+, and 193 (1.9%) CIN2+ were detected in 
this study. In the brush group, 104 CIN2+ (2.0%, 95% CI 1.7–2.4), of which 70 CIN3+ 
(1.3%, 95% CI 1.1–1.7) were detected. In the lavage group, 89 CIN2+ (1.9%, 95% CI 
1.5–2.3), of which 48 CIN3+ (1.0%, 95% CI 0.8 – 1.3) were detected. The detection of 
CIN2+ and CIN3+ in the brush group was similar to that in the lavage group. The RR 
of the cumulative CIN2+ and CIN3+ detection in the brush group compared to the 
lavage group was 1.01 (95% CI 0.83–1.24; p=0.87) and 1.25 (95% CI 0.92–1.70; p=0.16), 
respectively (Table 1 and Figure 3). 
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Questionnaires
A total of 9484 questionnaires (94.6%) were returned for analysis; 4855 (93.0%) in the 
brush group and 4629 (96.3%) in the lavage group. Overall, 9302 women rated their 
self-sample device; 97% (4619 of 4769) of the brush users and 98% (4445 of 4533) of 
the lavage users rated their devices as good to very good (p>0.05). 
The participants felt no shame at all in most cases; 93% (3764 of 4060) in the brush 
group and 87% (3465 of 3994) in the lavage group. Feeling at ease and usability were 
rated as moderate to very good in 75% of the brush group and 84% of the lavage 
group. More than 70% of the women experienced no discomfort, and more than 80% 
experienced no pain during the use of the self-sampling device. In each group, 20% 
of the participants were concerned about taking the self-sample correctly. No notable 
differences were observed between the groups in any of the categories (Table 2).
Overall, most women (80.5%, 7533 of 9360) preferred the self-sampling over a 
physician-taken smear for a next screening round, while 13% (1216 of 9360) had 
no preference. No statistically significant differences were found between the brush 
group and the lavage group.
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Discussion
This study shows that the participation rate in the brush based self-sampling device 
group was higher than in the lavage based group. While 34.6% of the non-responders 
to invitations to organised cervical screening participated when offered a vaginal 
self-sampling brush device, 31.9% participated when offered a lavage device. The 
prevalences of hrHPV and the cumulative CIN2+ and CIN3+ yields were similar in the 
two groups, and the devices provided equally well-accepted self-sampling methods.
The participation rates associated with the devices in this study are similar to 
those reported in most other European studies of self-sampling for hrHPV testing 
among non-responders to organised cervical screening.9-12,36 One of the devices used 
in this study was a new brush-based self-sampling device (the Evalyn Brush), and 
was specifically developed for cervicovaginal self-sampling. Our study used it in 
a screening population for the first time. Two previous, large, self-sample studies 
with a brush device developed for vaginal, ectocervical and endocervical sampling 
(VibaBrush) have shown participation rates between 30.8% and 34.2%.10,36 Studies 
with lavage devices (Delphi Screener) have shown participation rates between 27.5% 
and 31.5%.9,11,12 Population-based studies in other European countries and with 
other self-sampling device types have reported participation rates in a wider range 
(8.7–39.1%).13-17,21 In general, and across studies, HPV self-sampling results in better 
participation than a recall for regular cytological testing.9-12,36
Increasing the participation rate is considered the simplest and best way 
to improve the effectiveness of organised screening programmes.19 We have 
shown that self-sampling can reach those who do not respond to invitations to a 
regular screening programme.37 Our study also shows that self-sampling improves 
participation rates in all age categories to almost the same extent. The participation 
rates varied marginally with age in the brush group (31.3%–37.8%) and the lavage 
group (30.1%–34.7%). In contrast, participation rates in the current regular Dutch 
screening programme depend greatly on age: participation in the category of 50–55 
years is about 20% greater than in the category of 30–35 years.38 
The compliance to triage after an hrHPV-positive test is high in the current study 
(97%). This is higher than in previous PROHTECT-1 and 2 studies with a comparable 
triage strategy (89-90%).9,10 Also the compliance to follow-up after a negative triage 
test is higher in the current study (75%), than in PROHTECT 1 and 2 (57-58%). There 
are some minor differences in study methodology, which may explain these different 
compliance rates. Firstly, in the above-mentioned studies reminders were sent only 
to the participants. In our study, to motivate women to comply with the study, we sent 
reminders to both the participating women and their physicians. This is in line with 
the recently published PROHTECT-3 study.39 In this study, also a high triage follow-
up rate was achieved; 99% of the hrHPV-positive women had a cytological triage 
test taken. Secondly, in our study protocol we used a 6 months follow-up algorithm 
instead of a 1-year follow-up algorithm in PROHTECT 1 and 2. The rationale of these 6 
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months is that with a period of 1 year, the sense of urgency might decrease and more 
women might be lost to follow up. This time period of 6 months is also determined 
in the new protocol for primary HPV screening, which will be introduced in the 
Netherlands in 2016.23
A self-sampling device must be user friendly if we wish to benefit optimally 
from self-sampling and achieve high participation rates. Only small studies have 
yet explored the acceptability of different self-sampling devices, and the outcomes 
are conflicting.26,27 We explored the acceptability of two self-sampling methods for 
HPV detection that were both designed with consideration of qualitative feedback 
from women who used the methods. In our population-based study, the participants 
found both devices very acceptable. The overall rating was good to very good in more 
than 95% of the cases. However, in each group, 20% of the women were concerned 
about doing the self-sampling properly. This is in line with findings of previous 
studies.28,40-45 This issue will need to be addressed if self-sampling is to be integrated 
with the primary invitation to cervical cancer screening.
This is the first study that directly compares the accuracy of different devices in 
a population-based setting of non-responders in a randomised controlled manner. 
Because different devices could have diverse effects with respect to attendance and 
disease detection, direct comparative studies are important. Our study compares a 
brush device and a lavage device, with similar results. The cumulative incidence of 
CIN2+ was 2.0% (95% CI 1.7–2.4) in the brush group, and 1.9% (95% CI 1.5–2.3) in the 
lavage group.
The CIN2+ yield was slightly greater than in previous PROHTECT studies with a 
comparable triage strategy (PROHTECT-1: 99 of 7384 (1.3%) and PROHTECT-2: 119 of 
7844 (1.5%) for CIN2+)9,10 and much greater than in the regular cytological screening 
programme (0.9%).34 This likely reflects the increased risk of non-responders because 
they form an under-screened population. Their high CIN2+ yield also parallels a 
relatively high HPV-positivity rate in the non-responder population (8.3%). This is 
almost twice that of the normal Dutch screening population (4%–5%).46,47 Moreover, 
cytological testing is the primary screening tool in the Dutch screening programme, 
and cytological testing is considerably less sensitive in detecting CIN2+ than HPV 
testing.48 However, Gök et al.’s study showed similarly increased RRs for CIN2+ after 
their analysis was restricted to women with abnormal cytological test results at 
baseline.34 Therefore, the increased RR of self-sampling responders cannot be solely 
attributed to a more sensitive screening test.
The main strengths of our study are its large size and its setting in the regular 
screening programme in the Netherlands. Therefore, the outcome provides a reliable 
and representative image of self-sampling among non-responders to organised 
screening. Another strength is the use of an opt-out approach in the study invitation. 
This approach modestly reduced the waste and costs of unused devices compared 
to those of other studies.9,10 Furthermore, a better selection of the eligible non-
responders was possible because ineligible women could opt out.
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In the Dutch colposcopy standards, it is defined that if the colposcopy is 
satisfactory and normal, no biopsies are advised, but follow-up is needed. In our 
study, colposcopies were performed by a large number of gynaecologists in different 
clinics, therefore, we advised to take two biopsies if no abnormalities were seen at 
colposcopy. This ensured a histological study end point in all participants and could 
equalize differences in quality of colposcopic assessment between clinics as much as 
possible.
A limitation of our study is the number of women (38.1%, 172 of 452) without 
a study end point, i.e. they had no exit test or no histopathological result after they 
tested positive for hrHPV and received normal baseline cytological test results. The 
overall CIN2+ and CIN3+ yield detected in this study may be an underestimation 
because histological abnormalities may also occur among women lost to follow-up, 
and they remain undetected in this study. The relatively low follow-up rates are 
possibly due to relief because of a normal cytological test result at baseline after a 
positive hrHPV test, or perhaps these rates can be explained by the presumption that 
these former non-responders may be more prone to abandon follow-up. It is vitally 
important that the follow-up be acceptable to the participants, especially reluctant 
ones. More efficient triage techniques could reduce this loss to follow-up. Promising 
triage strategies performed directly on the self-sampled specimens have already 
been described; they include DNA methylation and HPV genotyping.49-52 The delay 
or loss to follow-up of women who need to have one or more cervical smears taken 
by their general practitioner may be circumvented with a direct triage test on self-
collected cervicovaginal material.
In conclusion, offering a brush-based device to non-responders of the cervical 
screening programme is non-inferior to offering a lavage-based device in terms of 
participation. In clinical performance, the two self-sampling methods are equally 
effective in detecting hrHPV, CIN2+, and CIN3+, and they are equally well accepted. 
On the basis of these results, self-sampling can now be used in the development of 
future HPV-based screening programmes. Given the outcome of our study, aspects 
other than participation, clinical performance, and user friendliness may be 
important in choosing the device to be used in a future screening programme. For 
example, whether new and more efficient triage strategies are equally applicable to 
these devices is being investigated. Such an aspect, or the costs of the device, may 
prove to be the deciding factor in choosing which device is to be used in a screening 
programme.
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Abstract
BACKGROUND: The low specificity of hrHPV testing makes triage necessary to 
prevent high referral rates and overtreatment of hrHPV-positive women. Baseline 
cytology testing is a widely accepted triage method for cervical cancer screening 
of hrHPV-positive self-sampled material. The aim of this study was to compare the 
clinical value of hrHPV genotyping with cytology testing  as a triage test for hrHPV-
positive women. 
METHODS:  520 hrHPV-positive women were include from a randomized controlled 
self-sampling trial (PROHTECT-3B; 33-63 years). Eighteen baseline triage strategies 
were evaluated for cytology and HPV genotyping (Roche Cobas 4800 system) on 
physician-sampled triage material. Cytology with an atypical squamous cells of 
undetermined significance (ASC-US) threshold was used as reference strategy. The 
sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), 
referral rate, and number of referrals needed to diagnose (NRND) were calculated for 
CIN2+ and CIN3+ as outcome measure. A triage strategy was considered as feasible, 
as it met the NPV criterion of at least 98%, had similar sensitivity, and significantly 
better specificity and PPV for CIN3+ than the reference triage strategy.
RESULTS: Three triage strategies met the criteria: HPV16+ or low-grade squamous 
intraepithelial lesions or worse (≥LSIL); HPV16+ or high-grade squamous 
intraepithelial lesion  or worse (≥HSIL); (HPV16+ and/or HPV18+) or ≥HSIL. 
Combining HPV16+ and ≥HSIL cytology testing gave the highest specificity (74.9%, 
95% CI 70.5–78.9) with a sensitivity (94.4%, 95% CI 89.0–97.7) similar to that of the 
reference strategy (93.5%, 95% CI 87.7–97.1). Of these strategies, HPV16+ with ≥HSIL 
cytology testing had the lowest colposcopy referral rate (39.5%) compared with that 
of the reference strategy (52.2%).
CONCLUSION: Triage by cytology testing can be improved by combining it with HPV 
genotyping. The addition of HPV16 and/or 18 genotyping and raising the threshold 
of cervical cytology testing from ASC-US or worse to ≥LSIL or ≥HSIL improves the 
referral rate and the specificity for detecting CIN3+ lesions while maintaining 
adequate sensitivity.
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Introduction
Almost half the cases of invasive cervical cancer are found in women who do not 
attend cervical screening (non-responders).1-4 Offering a self-collection device for 
high-risk human papillomavirus (hrHPV) testing has been shown to be effective in 
recruiting non-responders. Recent European literature has reported that response 
rates to HPV self-sampling among non-responders are up to 39%; therefore, self-
sampling increases the compliance to screening programs significantly.5,6
The main concern about hrHPV testing has been its relatively low specificity, 
which is due to the fact that the assay cannot distinguish transient from persistent, 
clinically relevant  hrHPV infections. Therefore, additional triage is required to 
identify the women with the highest risk of cervical precancer or cancer in need of 
treatment.7,8 A triage procedure may prevent overdiagnosis and overtreatment, and 
thus reduce potential harm.9 In the Netherlands, the proposed triage tool for hrHPV-
positive women is cytology testing.10,11 However, the clinical value of this triage test 
can be improved. A suitable supplemental or alternative triage method may further 
reduce needless colposcopies, invasive diagnostics such as biopsies, overtreatment, 
patient anxiety, and unnecessary costs.9,12-15 
HrHPV genotyping, supplemental or alternative to cytology, may be a potential 
solution to this clinical dilemma in the management of hrHPV positive women. 
Of all cervical malignancies, 55% are caused by HPV16, 15% by HPV18, and the 
remaining 30% by 12 other hrHPV types.16-18 The risk of developing cervical cancer 
increases when an hrHPV infection persists. HPV16 tends to persist longer than 
other hrHPV types and is consequently more oncogenic. HPV18 causes lesions that 
tend to be located high in the endocervical canal, and for that reason they are more 
difficult to detect by cytology.19,20 The ATHENA (Addressing THE Need for Advanced 
HPV diagnostics) study has investigated different screening strategies, including 
hrHPV genotyping, on the basis of the increased absolute and relative risks of CIN2+ 
lesions for women with HPV16 and/or 18.21 The results of this study were promising, 
showing maintained or increased sensitivity and increased PPV and/or specificity for 
genotyping compared with cytologic triage alone.22,23 
Whereas the ATHENA trial assessed hrHPV genotyping in an opportunistic 
screening population, we conducted a post-hoc analysis of 520 physician-taken triage 
samples of non-responders to the regular screening program whose self-samples 
tested hrHPV positive in the PROHTECT-3B study (PRotection by Offering HPV 
TEsting on self-sampled Cervicovaginal specimens Trial-3B; N = 35,477; 33–63 years). 
The aim of our current study was to assess the clinical value of hrHPV genotyping 
as a supplemental or alternative triage strategy in hrHPV positive women compared 
with liquid-based cytology testing with an ASC-US threshold.
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Methods
Study population and study design
The PROHTECT-3B study is a randomized controlled trial designed to determine 
whether the participation rate for a brush-based cervicovaginal self-sampling device 
is non-inferior to the participation rate for a lavage-based one for testing for hrHPV.48 
The Ministry of Health gave ethical approval for this study (No. 2010/WBO04). In 
short, non-responders to the regular cervical screening program, aged 33–63 years, 
were invited to participate. Women participated by returning self-sampled material 
to the laboratory for hrHPV testing (GP5+/6+ PCR; EIA HPV GP HR kit; Diassay, 
Voorburg, The Netherlands). All women who tested hrHPV negative were advised to 
participate in the next screening round. All hrHPV-positive women were advised to 
have an additional cervical smear taken by a physician for cytology testing. 
All cervix cytology samples were tested in the laboratory of the Department 
of Pathology, Radboud University Medical Center, Nijmegen, The Netherlands. 
The Dutch CISOE-A classification system was used to report the test results for the 
cervical smears, which can easily be translated into the Bethesda nomenclature.24 
Cytologic results were reported as normal, atypical squamous cells of undetermined 
significance (ASC-US, including AGC), low-grade squamous intraepithelial lesions 
(LSIL), or high-grade squamous intraepithelial lesions (HSIL).
Women with abnormal cytologic results (determined by the ASC-US threshold) 
were referred for a colposcopy-directed biopsy, while women with normal cytologic 
results were re-invited for an exit test (cytology and hrHPV co-testing) 6 months 
later. Women with a positive exit test (positive cytologic and/or hrHPV test results) 
were referred for a colposcopy-directed biopsy. Women with an abnormal biopsy 
result (CIN2+) were treated according to the Dutch national guidelines.15,25 If no 
abnormalities were seen at colposcopy, the gynecologist was advised to take two 
random biopsies according to the study protocol. Data concerning histology were 
obtained from the physicians and gynecologists. The final histologic data were 
retrieved from the Dutch nationwide computerized registry of histopathology and 
cytopathology (PALGA).26 The outcomes were classified as CIN2+ and/or CIN3+, CIN1, 
or no CIN on the basis of the histologic test results. If several different histologic 
diagnoses were available in the follow-up period, the most severe diagnosis was 
registered. Women with a double-negative exit test (normal cytologic and negative 
hrHPV results) after 6 months had a minimal risk of CIN2 lesions and were not 
referred for colposcopy. In the analyses, these women were classified as having 
<CIN2. We included all results recorded before June 2013. At this point, the database 
was closed after a mean follow-up of 15 months (range 6–18 months). The regional 
institutional review board approved the protocol for this post-hoc analysis, and all 
the women provided written informed consent.
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HPV genotyping
The physician-taken triage samples left over after cytologic analysis were analyzed 
for the presence of specific HPV genotypes. For this purpose, we used the clinically 
validated Roche Cobas 4800 test according to the manufacturer’s recommendations 
in the laboratory of the Department of Medical Microbiology, Radboud University 
Medical Center. This test provides separate results for HPV16, 18, and a pool of 12 
other hrHPV types (i.e.,31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68).27 
The HPV genotyping results were categorized as follows: HPV positive (positive for 
any of 14 hrHPV types); HPV negative (negative for all 14 hrHPV types); HPV16 and/
or 18 positive (positive for HPV16 and/or 18, regardless of the presence or absence of 
12 other HPV types); positive for 12 other HPV types (positive for one or more of the 
12 other HPV types and negative for HPV16 and 18).
Triage strategies
Eighteen different triage strategies were evaluated: genotyping for HPV16, HPV16 
and/or HPV18, and different thresholds for cytologic interpretations (ASC-US or 
worse, LSIL or worse, or HSIL or worse). Further, combinations of cytologic testing 
and HPV genotyping were investigated. These strategies were assessed to identify 
potentially better algorithms for triage to immediate colposcopy (Table 2). 
Statistical analysis
The performance of each strategy in detecting CIN3 or worse (CIN3+), or CIN2 or worse 
(CIN2+), was explored. The sensitivity, specificity, positive predictive value (PPV), 
negative predictive value (NPV), and referral rate were estimated for each screening 
strategy. To analyze the extent of overdiagnosis, we estimated the number of referrals 
needed to diagnose (NRND) one lesion with end point CIN2+ or CIN3+. In evaluating 
the strategies, we considered an NPV for CIN3+ of at least 98% (corresponding with a 
2- to 3-year CIN3+ risk of maximally 2%) to be a minimal requirement. This is based 
on Castle and colleagues’ currently widely accepted risk thresholds for the risk of 
CIN3+.28 These risk thresholds are based on examples in currently used management 
strategies. Women with a less than 2% risk of cancer or precancer in the subsequent 
2–3 years might have an acceptably low risk for remaining in regular interval 
screening. Rescreening within 1 year might be warranted for women with a risk of 
2% to less than 10%, whereas immediate colposcopic evaluation may be warranted 
for women with a 10% or greater risk.28 Two other criteria for the performance of 
the strategies were maintenance or improvement of sensitivity and an increase in 
specificity compared to the reference strategy (ASC-US).
Confidence intervals (95%) were calculated for sensitivity, specificity, PPV, and 
NPV. Differences between the reference strategy and the other strategies in sensitivity 
and specificity were evaluated with McNemar’s chi square test; and differences in 
PPV and NPV, with Kosinski and colleagues’ method.29 
We used SPSS (Statistical Package for the Social Sciences), version 20.0.1 for 
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Windows, (Chicago, Illinois) to analyze the data. Differences in PPV and NPV were 
estimated with R, version 3.0.1, package DTComPair (Vienna, Austria).30,31
Results
Patient characteristics
In the PROHTECT-3B study, 35,477 women who did not respond to an invitation for 
regular screening were invited to submit a self-sample for HPV testing and 10,027 
women participated. Of the 834 HPV self-sample positive women, we included all 
women (n=520) whose self-samples tested hrHPV positive, who had an additional 
cervical smear taken for cytology triage, whose physician taken triage sample was 
available for genotyping and who reached a study end point (Figure 1). A total of 
314 women were excluded due to inadequate follow-up (no histology or no exit 
evaluation) or no sample available for genotyping. The mean age of the studygroup 
was 42 years (range 33–63). Of 520 women included in this study, 275 women tested 
hrHPV positive on a self-sampling brush device (Evalyn Brush, Rovers Medical 
Devices, Oss, The Netherlands) and 245 women tested hrHPV positive on a self-
sampling lavage device (second generation Delphi Screener, Delphi Bioscience, 
Scherpenzeel, The Netherlands). 
A total of 271 (52.1%) had a ≥ASC-US result, and the remaining 249 women had a 
cytologic test result within normal limits (WNL). In the group of 249 women with an 
initial WNL result, 36 women (14.5%) had a ≥ASC-US result at repeat cytologic testing 
at 6 months. 
A histologic diagnosis was available for 373 of the 520 women (122 had no CIN, 
and the other diagnoses were 71 CIN1, 73 CIN2, 92 CIN3, and 15 carcinomas). The 
remaining 147 women were considered to have <CIN2, based on both a HPV-negative 
and WNL cytologic result at 6 months. Fifteen CIN2+ lesions, of which 7 were CIN3+ 
lesions, were diagnosed during follow-up for women with an initial WNL cytologic 
result. 
HPV genotyping
Three samples were invalid for genotype testing and were excluded. A total of 517 
physician-taken triage samples were used for analysis. All 107 CIN3+ lesions were 
hrHPV positive, and samples were frequently positive for more than one type of HPV: 
HPV16 was positive in 62.6% (67 of 107) of the CIN3+ lesions, HPV18 was positive in 
16.8% (18 of 107) of the CIN3+ lesions, and the other 12 types were positive in 58.9% 
(63 of 107). 
While HPV16 was positive with genotyping in 55.0% (99 of 180) of the CIN2+ 
lesions, HPV18 was positive in 16.7% (30 of 180) of the CIN2+ lesions. The other 12 
types were positive in 67.2% (121 of 180) of the CIN2+ lesions. A total of 2.2% (4 of 
180) CIN2+ lesions were HPV negative.
The clinical value of HPV genotyping as a triage test in hrHPV positive women | 
C
H
A
P
T
E
R
.6
129
Table 1 shows the distribution of 1) the hrHPV-negative results; 2) the hrHPV16-
positive and/or HPV18-positive results, regardless of the presence or absence of 12 
other HPV types; 3) 12 other hrHPV-positive types and negative for HPV16 and 18; 
and 4) positive for any of the 14 hrHPV types in relation to histology.
Screening strategies
Triage at baseline with cytology testing only, i.e., with an ASC-US threshold (strategy 
2), was used as the reference strategy in our study population, and it yielded a 
sensitivity of 93.5% (95% CI 87.7–97.1), a specificity of 58.5% (95% CI 53.7–63.2), a 
PPV of 37.0% (95% CI 31.4–42.9), an NPV of 97.2% (95% CI 94.6–98.8) for CIN3+, a 
referral rate of 52.2%, and an NRND of 2.70. The test characteristics of the reference 
strategy and the other 17 strategies for detecting CIN3+ lesions are described in detail 
in Table 2. 
Six triage strategies met the test criterion of an NPV of at least 98% for CIN3+. All 
of these strategies were a combination of cytologic testing with HPV16 and/or HPV18 
genotyping. The PPVs of these strategies ranged from 33.1% to 49.5%.
Three triage strategies with a combination of cytologic testing and genotyping 
increased the specificity for CIN3+ compared with the reference strategy, without 
decreasing the sensitivity. Of these three strategies, strategy 11 achieved the highest 
specificity (74.9%, 95% CI 70.5–78.9; p<0.001) with HPV16 positive or a ≥HSIL 
threshold with an NRND of 2.02. The sensitivity in this strategy was similar to that 
of the reference strategy. A specificity 70.0% (95% CI 65.4–74.3) was achieved with 
HPV16 and/or 18 positive or a ≥HSIL threshold (strategy 17), with a sensitivity of 
97.2% (95% CI 92.9–99.3). Strategy 17 resulted in a referral rate of 43.9% and NRND 
of 2.18.
The sensitivity of strategy 9 (HPV16 positive or a ≥LSIL threshold) was also similar 
to those of the reference strategy. However, the specificity of this strategy increased 
to 65.6% (95% CI 60.9–70.1; p=0.003). Genotyping alone was not better than cytologic 
triage since the sensitivity was lower for HPV16 positive and/or HPV18 positive 
(74.8%, 95% CI 66.0–82.3) and for HPV16 positive (62.6%, 95% CI 53.2–71.4) compared 
with the reference strategy.
The test characteristics of all 18 strategies for detecting CIN2+ lesions are described 
in detail in Table 3. Only strategy 9 (HPV16 positive or a ≥LSIL threshold) showed an 
improvement in specificity to 75.1% (95% CI 70.3–79.5) compared to the reference 
strategy (68.8% (95% CI 63.8–73.6; p=0.024) with a similar sensitivity. None of the 
other strategies showed improvement in specificity without a decreased sensitivity 
for the detection of CIN2+ lesions as compared to baseline cytology. 
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Figure 1. Trial profile
*An exit evaluation consists of initial cytology test result within normal limits (WNL), then, after 6 
months, a WNL result and a hrHPV-negative test
25,450 excluded:
No participation
9193 excluded:
9146 hrHPV negative
47 invalid results
314 excluded:
Inadequate follow-up 
(no histology/no exit evaluation) 
or no sample available 
for genotyping
517 cases with valid genotyping results 
and study endpoints:
370 cases with histologic endpoints:
 180 CIN2+
  107 CIN3+
147 cases with exit-evaluations*: 
147 considered less than CIN2
3 excluded:
Invalid hrHPV
genotyping result
35,477 women were offered self-sampling 
for hrHPV testing
10,027 women participated by returing self-
sampled material
834 women tested hrHPV-positive on self-
sampled material
520 hrHPV-positive cases for genotyping
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Table 2. Strategies for triage of HPV-positive women for immediately identifying women 
with CIN3 or worse 
No.
Sensitivity (n=107) Specificity (n=410) PPV NPV
Referral rate 
(N=517)
NRND 
% (95% CI) p-value % (95% CI) p-value % (95% CI) p-value % (95% CI) p-value % Ratio
1 None* 100.0 ... 0.0 ... 20.7 (17.4–24.3) ... - ... 100.0 4.83
2 ≥ASC-US 93.5 (87.7–97.1) REF 58.5 (53.7–63.2) REF 37.0 (31.4–42.9) REF 97.2 (94.6–98.8) REF 52.2 2.70
3 ≥LSIL 86.9 (79.7–92.4) 0.016 78.0 (73.9–81.9) <0.0001 50.8 (43.6–58.0)  <0.001 95.8 (93.3–97.6) 0.129 35.4 1.97
4 ≥HSIL 82.2 (74.3–88.7) <0.001 90.2 (87.1–92.9) <0.0001 68.8 (60.4–76.4)  <0.001 95.1 (92.7–97.0) 0.058 24.8 1.45
5 HPV16+ 62.6 (53.2–71.4) <0.001 81.7 (77.8–85.2) <0.0001 47.2 (39.1–55.4) 0.002 89.3 (85.9–92.2) <0.001 27.5 2.12
6 HPV16+ and/or 18+ 74.8 (66.0–82.3) <0.001 75.6 (71.3–79.6) <0.0001 44.4 (37.3–51.7) 0.008 92.0 (88.8–94.6) 0.007 34.8 2.25
7 HPV16+ or ≥ASC-US 99.1 (95.9–99.9) 0.031 50.7 (45.9–55.6) <0.0001 34.4 (29.3–39.8) 0.003 99.5 (97.9–100.0) 0.026 59.6 2.91
8 HPV16+ and ≥ASC-US 57.0 (47.5–66.1) <0.001 89.5 (86.3–92.2) <0.0001 58.7 (49.1–67.8) <0.001 88.9 (85.6–91.7) <0.001 20.1 1.70
9 HPV16+ or ≥LSIL 96.3 (91.5–98.8) 0.508 65.6 (60.9–70.1) 0.003 42.2 (36.1–48.5) 0.002 98.5 (96.6–99.5) 0.227 47.2 2.37
10 HPV16+ and ≥LSIL 53.3 (43.8–62.6) <0.001 94.1 (91.6–96.1) <0.0001 70.4 (59.9–79.6) <0.001 88.5 (85.3–91.3) <0.001 15.7 1.42
11 HPV16+ or ≥HSIL 94.4 (89.0–97.7) 1.000 74.9 (70.5–78.9) <0.0001 49.5 (42.7–56.3) <0.001 98.1 (96.2–99.2) 0.433 39.5 2.02
12 HPV16+ and ≥HSIL 50.5 (41.1–59.8) <0.001 97.1 (95.1–98.4) <0.0001 81.8 (71.4–89.8) <0.001 88.2 (85.1–91.0) <0.001 12.8 1.22
13 (HPV16+ and/or 18+) or ≥ASC-US 100.0 (96.6–100.0) 0.014 47.3 (42.5–52.2) <0.0001 33.1 (28.1–38.4) <0.001 100.0 (96.6–100.0) 0.017 62.5 3.02
14 (HPV16+ and/or 18+) and ≥ASC-US 68.2 (59.0–76.5) <0.001 86.8 (83.3–89.9) <0.0001 57.5 (48.8–65.9) <0.001 91.3 (88.2–93.8) <0.001 24.6 1.74
15 (HPV16+ and/or 18+) or ≥LSIL 98.1 (94.3–99.7) 0.180 61.5 (56.7–66.1) 0.281 39.9 (34.1–45.9) 0.076 99.2 (97.6–99.9) 0.082 50.9 2.50
16 (HPV16+ and/or 18+) and ≥LSIL 63.6 (54.2–72.3) <0.001 92.2 (89.3–94.5) <0.0001 68.0 (58.5–76.6) <0.001 90.6 (87.6–93.2) <0.001 19.3 1.47
17 (HPV16+ and/or 18+) or ≥HSIL 97.2 (92.9–99.3) 0.344 70.0 (65.4–74.3) <0.0001 45.8 (39.4–53.3) <0.001 99.0 (97.3–99.7) 0.122 43.9 2.18
18 (HPV16+ and/or 18+) and ≥HSIL 59.8 (50.4–68.8) <0.001 95.9 (93.6–97.5) <0.0001 79.0 (69.3–86.9) <0.001 90.1 (87.1–97.2) <0.001 15.7 1.27
≥ASC-US = atypical squamous cells of undetermined significance or worse; ≥HSIL = high-grade squamous 
intraepithelial lesions or worse; ≥LSIL = low-grade squamous intraepithelial lesions or worse; CIN3 = 
cervical intraepithelial neoplasia, grade 3; HPV = human papillomavirus; NPV = negative predictive value; 
NRND = number of referrals needed to diagnose one CIN3+ lesion; PPV = positive predictive value; REF = 
reference standard. *All women with HPV-positive self-samples were referred for colposcopy
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Table 2. Strategies for triage of HPV-positive women for immediately identifying women 
with CIN3 or worse 
No.
Sensitivity (n=107) Specificity (n=410) PPV NPV
Referral rate 
(N=517)
NRND 
% (95% CI) p-value % (95% CI) p-value % (95% CI) p-value % (95% CI) p-value % Ratio
1 None* 100.0 ... 0.0 ... 20.7 (17.4–24.3) ... - ... 100.0 4.83
2 ≥ASC-US 93.5 (87.7–97.1) REF 58.5 (53.7–63.2) REF 37.0 (31.4–42.9) REF 97.2 (94.6–98.8) REF 52.2 2.70
3 ≥LSIL 86.9 (79.7–92.4) 0.016 78.0 (73.9–81.9) <0.0001 50.8 (43.6–58.0)  <0.001 95.8 (93.3–97.6) 0.129 35.4 1.97
4 ≥HSIL 82.2 (74.3–88.7) <0.001 90.2 (87.1–92.9) <0.0001 68.8 (60.4–76.4)  <0.001 95.1 (92.7–97.0) 0.058 24.8 1.45
5 HPV16+ 62.6 (53.2–71.4) <0.001 81.7 (77.8–85.2) <0.0001 47.2 (39.1–55.4) 0.002 89.3 (85.9–92.2) <0.001 27.5 2.12
6 HPV16+ and/or 18+ 74.8 (66.0–82.3) <0.001 75.6 (71.3–79.6) <0.0001 44.4 (37.3–51.7) 0.008 92.0 (88.8–94.6) 0.007 34.8 2.25
7 HPV16+ or ≥ASC-US 99.1 (95.9–99.9) 0.031 50.7 (45.9–55.6) <0.0001 34.4 (29.3–39.8) 0.003 99.5 (97.9–100.0) 0.026 59.6 2.91
8 HPV16+ and ≥ASC-US 57.0 (47.5–66.1) <0.001 89.5 (86.3–92.2) <0.0001 58.7 (49.1–67.8) <0.001 88.9 (85.6–91.7) <0.001 20.1 1.70
9 HPV16+ or ≥LSIL 96.3 (91.5–98.8) 0.508 65.6 (60.9–70.1) 0.003 42.2 (36.1–48.5) 0.002 98.5 (96.6–99.5) 0.227 47.2 2.37
10 HPV16+ and ≥LSIL 53.3 (43.8–62.6) <0.001 94.1 (91.6–96.1) <0.0001 70.4 (59.9–79.6) <0.001 88.5 (85.3–91.3) <0.001 15.7 1.42
11 HPV16+ or ≥HSIL 94.4 (89.0–97.7) 1.000 74.9 (70.5–78.9) <0.0001 49.5 (42.7–56.3) <0.001 98.1 (96.2–99.2) 0.433 39.5 2.02
12 HPV16+ and ≥HSIL 50.5 (41.1–59.8) <0.001 97.1 (95.1–98.4) <0.0001 81.8 (71.4–89.8) <0.001 88.2 (85.1–91.0) <0.001 12.8 1.22
13 (HPV16+ and/or 18+) or ≥ASC-US 100.0 (96.6–100.0) 0.014 47.3 (42.5–52.2) <0.0001 33.1 (28.1–38.4) <0.001 100.0 (96.6–100.0) 0.017 62.5 3.02
14 (HPV16+ and/or 18+) and ≥ASC-US 68.2 (59.0–76.5) <0.001 86.8 (83.3–89.9) <0.0001 57.5 (48.8–65.9) <0.001 91.3 (88.2–93.8) <0.001 24.6 1.74
15 (HPV16+ and/or 18+) or ≥LSIL 98.1 (94.3–99.7) 0.180 61.5 (56.7–66.1) 0.281 39.9 (34.1–45.9) 0.076 99.2 (97.6–99.9) 0.082 50.9 2.50
16 (HPV16+ and/or 18+) and ≥LSIL 63.6 (54.2–72.3) <0.001 92.2 (89.3–94.5) <0.0001 68.0 (58.5–76.6) <0.001 90.6 (87.6–93.2) <0.001 19.3 1.47
17 (HPV16+ and/or 18+) or ≥HSIL 97.2 (92.9–99.3) 0.344 70.0 (65.4–74.3) <0.0001 45.8 (39.4–53.3) <0.001 99.0 (97.3–99.7) 0.122 43.9 2.18
18 (HPV16+ and/or 18+) and ≥HSIL 59.8 (50.4–68.8) <0.001 95.9 (93.6–97.5) <0.0001 79.0 (69.3–86.9) <0.001 90.1 (87.1–97.2) <0.001 15.7 1.27
All data are crude estimates. The p-values represent comparisons of various triage strategies to ASC-US 
or worse. Differences in sensitivity and specificity between the reference strategy and the other strategies 
were evaluated with McNemar’s chi square test, and differences in PPV and NPV were evaluated with 
Kosinski and colleagues’ method.29 ASC-US or worse includes cytologic interpretations of ASC-US, AGC, 
LSIL, and HSIL. 
The strategies meeting the criterion for an NPV of at least 98%, had similar sensitivity, and significantly 
better specificity and PPV for CIN3+ than the reference triage strategy at a CIN3+ threshold are 
marked in white
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Table 3. Strategies for triage of HPV-positive women for immediately identifying 
women with CIN2 or worse 
No.
Sensitivity (n=180) Specificity (n=337) PPV NPV
Referral rate 
(N=517)
NRND 
% (95% CI) p-value % (95% CI) p-value % (95% CI) p-value % (95% CI) p-value % Ratio
1 None* 100.0 ... 0 ... 34.8 (30.8–39.0) ... - ... 100.0 2.87
2 ≥ASC-US 91.7 (87.0–95.1) REF 68.8 (63.8–73.6) REF 61.1 (55.2–66.8) REF 93.9 (90.5–96.5) REF 52.2 1.64
3 ≥LSIL 77.8 (71.3–83.4) <0.001 87.2 (83.4–90.5) <0.0001 76.5 (70.0–82.3) <0.001 88.0 (84.3–91.2) <0.001 35.4 1.31
4 ≥HSIL 62.2 (55.0–69.1) <0.001 95.3 (92.6–97.2) <0.0001 87.5 (81.0–92.5) <0.001 82.5 (78.5–86.1) <0.001 24.8 1.14
5 HPV16+ 49.4 (42.2–56.7) <0.001 84.3 (80.1–87.9) <0.0001 62.7 (54.5–70.4) 0.681 75.7 (71.2–79.9) <0.001 27.5 1.60
6 HPV16+ and/or 18+ 60.6 (53.3–67.5) <0.001 78.9 (74.4–83.1) <0.0001 60.6 (53.3–67.5) 0.870 78.9 (74.4–83.1) <0.001 34.8 1.65
7 HPV16+ or ≥ASC-US 96.7 (93.4–98.7) 0.004 60.2 (54.9–65.4) <0.0001 56.5 (50.9–62.0) <0.001 97.1 (94.3–98.8) 0.011 59.6 1.77
8 HPV16+ and ≥ASC-US 44.4 (37.3–51.7) <0.001 92.9 (89.8–95.3) <0.0001 76.9 (68.2–84.3) <0.001 75.8 (71.5–79.8) <0.001 20.1 1.30
9 HPV16+ or ≥LSIL 88.9 (83.8–92.9) 0.405 75.1 (70.3–79.5) 0.024 65.6 (59.5–71.4) 0.052 92.7 (89.2–95.4) 0.471 47.2 1.53
10 HPV16+ and ≥LSIL 38.3 (31.4–45.6) <0.001 96.4 (94.1–98.1) <0.0001 85.2 (76.4–91.8) <0.001 74.5 (70.3–78.5) <0.001 15.7 1.17
11 HPV16+ or ≥HSIL 78.3 (71.9–83.9) <0.001 81.3 (76.9–85.2) <0.0001 69.1 (62.6–75.2) 0.006 87.5 (83.6–90.9) 0.003 39.5 1.45
12 HPV16+ and ≥HSIL 33.3 (26.7–40.4) <0.001 98.2 (96.4–99.3) <0.0001 90.9 (82.4–96.3) <0.001 73.4 (69.2–77.3) <0.001 12.8 1.00
13 (HPV16+ and/or 18+) or ≥ASC-US 97.2 (94.1–99.0) 0.002 56.1 (50.8–61.3) <0.0001 54.2 (48.7–59.6) <0.001 97.4 (94.5–99.1) 0.012 62.5 1.85
14 (HPV16+ and/or 18+) and ≥ASC-US 55.0 (47.7–62.2) <0.001 91.7 (88.4–94.3) <0.0001 78.0 (70.2–84.6) <0.001 79.2 (75.0–83.1) <0.001 24.6 1.28
15 (HPV16+ and/or 18+) or ≥LSIL 90.6 (85.7–94.3) 0.832 70.3 (65.3–75.0) 0.675 62.0 (56.0–67.7) 0.707 93.3 (89.8–96.0) 0.726 50.9 1.61
16 (HPV16+ and/or 18+) and ≥LSIL 47.8 (40.6–55.1) <0.001 95.8 (93.4–97.6) <0.0001 86.0 (78.3–91.9) <0.001 77.5 (73.3–81.3) <0.001 19.3 1.16
17 (HPV16+ and/or 18+) or ≥HSIL 81.1 (75.0–86.4) 0.003 76.0 (71.2–80.3) 0.028 64.3 (57.9–70.4) 0.255 88.3 (84.2–91.6) 0.009 43.9 1.55
18 (HPV16+ and/or 18+) and ≥HSIL 41.7 (34.6–48.9) <0.001 98.2 (96.4–99.3) <0.0001 92.6 (85.6–97.0) <0.001 75.9 (71.8–79.8) <0.001 15.7 1.08
≥ASC-US = atypical squamous cells of undetermined significance or worse; ≥HSIL = high-grade squamous 
intraepithelial lesions or worse; ≥LSIL = low-grade squamous intraepithelial lesions or worse; CIN3 = 
cervical intraepithelial neoplasia, grade 3; HPV = human papillomavirus; NPV = negative predictive value; 
NRND = number of referrals needed to diagnose one CIN2+ lesion; PPV = positive predictive value; REF = 
reference standard. *All women with HPV-positive self-samples were referred for colposcopy 
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Table 3. Strategies for triage of HPV-positive women for immediately identifying 
women with CIN2 or worse 
No.
Sensitivity (n=180) Specificity (n=337) PPV NPV
Referral rate 
(N=517)
NRND 
% (95% CI) p-value % (95% CI) p-value % (95% CI) p-value % (95% CI) p-value % Ratio
1 None* 100.0 ... 0 ... 34.8 (30.8–39.0) ... - ... 100.0 2.87
2 ≥ASC-US 91.7 (87.0–95.1) REF 68.8 (63.8–73.6) REF 61.1 (55.2–66.8) REF 93.9 (90.5–96.5) REF 52.2 1.64
3 ≥LSIL 77.8 (71.3–83.4) <0.001 87.2 (83.4–90.5) <0.0001 76.5 (70.0–82.3) <0.001 88.0 (84.3–91.2) <0.001 35.4 1.31
4 ≥HSIL 62.2 (55.0–69.1) <0.001 95.3 (92.6–97.2) <0.0001 87.5 (81.0–92.5) <0.001 82.5 (78.5–86.1) <0.001 24.8 1.14
5 HPV16+ 49.4 (42.2–56.7) <0.001 84.3 (80.1–87.9) <0.0001 62.7 (54.5–70.4) 0.681 75.7 (71.2–79.9) <0.001 27.5 1.60
6 HPV16+ and/or 18+ 60.6 (53.3–67.5) <0.001 78.9 (74.4–83.1) <0.0001 60.6 (53.3–67.5) 0.870 78.9 (74.4–83.1) <0.001 34.8 1.65
7 HPV16+ or ≥ASC-US 96.7 (93.4–98.7) 0.004 60.2 (54.9–65.4) <0.0001 56.5 (50.9–62.0) <0.001 97.1 (94.3–98.8) 0.011 59.6 1.77
8 HPV16+ and ≥ASC-US 44.4 (37.3–51.7) <0.001 92.9 (89.8–95.3) <0.0001 76.9 (68.2–84.3) <0.001 75.8 (71.5–79.8) <0.001 20.1 1.30
9 HPV16+ or ≥LSIL 88.9 (83.8–92.9) 0.405 75.1 (70.3–79.5) 0.024 65.6 (59.5–71.4) 0.052 92.7 (89.2–95.4) 0.471 47.2 1.53
10 HPV16+ and ≥LSIL 38.3 (31.4–45.6) <0.001 96.4 (94.1–98.1) <0.0001 85.2 (76.4–91.8) <0.001 74.5 (70.3–78.5) <0.001 15.7 1.17
11 HPV16+ or ≥HSIL 78.3 (71.9–83.9) <0.001 81.3 (76.9–85.2) <0.0001 69.1 (62.6–75.2) 0.006 87.5 (83.6–90.9) 0.003 39.5 1.45
12 HPV16+ and ≥HSIL 33.3 (26.7–40.4) <0.001 98.2 (96.4–99.3) <0.0001 90.9 (82.4–96.3) <0.001 73.4 (69.2–77.3) <0.001 12.8 1.00
13 (HPV16+ and/or 18+) or ≥ASC-US 97.2 (94.1–99.0) 0.002 56.1 (50.8–61.3) <0.0001 54.2 (48.7–59.6) <0.001 97.4 (94.5–99.1) 0.012 62.5 1.85
14 (HPV16+ and/or 18+) and ≥ASC-US 55.0 (47.7–62.2) <0.001 91.7 (88.4–94.3) <0.0001 78.0 (70.2–84.6) <0.001 79.2 (75.0–83.1) <0.001 24.6 1.28
15 (HPV16+ and/or 18+) or ≥LSIL 90.6 (85.7–94.3) 0.832 70.3 (65.3–75.0) 0.675 62.0 (56.0–67.7) 0.707 93.3 (89.8–96.0) 0.726 50.9 1.61
16 (HPV16+ and/or 18+) and ≥LSIL 47.8 (40.6–55.1) <0.001 95.8 (93.4–97.6) <0.0001 86.0 (78.3–91.9) <0.001 77.5 (73.3–81.3) <0.001 19.3 1.16
17 (HPV16+ and/or 18+) or ≥HSIL 81.1 (75.0–86.4) 0.003 76.0 (71.2–80.3) 0.028 64.3 (57.9–70.4) 0.255 88.3 (84.2–91.6) 0.009 43.9 1.55
18 (HPV16+ and/or 18+) and ≥HSIL 41.7 (34.6–48.9) <0.001 98.2 (96.4–99.3) <0.0001 92.6 (85.6–97.0) <0.001 75.9 (71.8–79.8) <0.001 15.7 1.08
All data are crude estimates. The p-values represent comparisons of various triage strategies to 
ASC-US or worse. Differences between the reference strategy and the other strategies in sensitivity 
and specificity were evaluated with McNemar’s chi square test. Differences in PPV and NPV were 
evaluated with Kosinski and colleagues’ method.29 ASC-US or worse includes cytologic interpretations 
of ASC-US, AGC, LSIL, and HSIL. 
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Discussion
We have evaluated 18 triage strategies on physician taken cervical smears of women 
tested HPV positive of self-sampled material with different thresholds for cytologic 
testing, HPV genotyping, and a combination of both. Three of the evaluated strategies 
for the triage of HPV-positive women met the NPV criterion of at least 98% for CIN3+. 
This means that the risk of precancer or cancer in the next 2–3 years is less than 2% 
for women testing triage-negative, which is an acceptably low risk for remaining in 
regular interval screening. These three strategies were 1) HPV16 positive or ≥LSIL, 
2) HPV16 positive or ≥HSIL, and 3) HPV16 positive and/or HPV18 positive or ≥HSIL. 
These strategies might be attractive for implementation because there is only a small 
risk of developing a high-risk lesion and no follow-up is needed. The three strategies 
meeting the NPV criterion for CIN3+, all had similar sensitivities, and a significantly 
better specificity and PPV for CIN3+ compared with the reference triage strategy 
(which used baseline cytologic testing with an ASC-US threshold). In addition, the 
referral rates decreased by 1.2–12.7%, thereby preventing unnecessary colposcopies, 
overtreatment, costs, and anxiety for the women involved. 
Our findings are in line with previous findings in the ATHENA study, which is 
a large clinical trial that assessed HPV DNA tests and liquid-based cytology testing 
for cervical cancer screening.22 We assessed these strategies in the physician-taken 
triage material of hrHPV-positive non-responders, whereas the ATHENA trial tested 
hrHPV genotyping in an opportunistic screening population. Our findings confirm 
the improvement of diagnostic accuracy when the cytologic threshold is raised by 
adding HSIL and HPV genotyping to cytologic triage. 
The choice for one of the three favorable strategies will depend on the clinical 
needs. When the proposed cytologic triage is used in clinical practice, there may be a 
need to reduce the colposcopy rate because of, for example, costs or overdiagnosing. 
In such a case, referring women with HPV16 or ≥HSIL cytologic test results (strategy 
11) may be a good alternative since the specificity is significantly improved, and the 
sensitivity is similar to that of the reference strategy. As a result, the referral rate 
decreases from 52.2% to 39.5%, and instead of 4.83 women, only 2.02 women need to 
be referred to diagnose one CIN3+. 
When there is a clinical need to use a test with the highest possible sensitivity, 
strategy 13 (HPV16 and/or HPV18 positive or ≥ASC-US cytologic testing) with 100% 
sensitivity for CIN3+ (95% CI 96.6–100%) may be an alternative. The referral rate 
increased to 62.5%, and the NRND to 3.02, while the specificity decreased to 47.3%. 
Although these increases in colposcopy referrals and NRND are probably undesirable, 
an advantage of this highly sensitive method is that a negative test result provides 
enough certainty to refer negative women back to the regular screening program. 
However, the length of follow-up in this study is too short for determining the actual 
consequences of their returning to the regular program. Furthermore, this strategy 
did not yield such high sensitivity in previous clinical trials.10,22 This might have been 
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due to inter-laboratory differences in the rather subjective diagnosis of an ASC-US 
cytologic result.32 
In the use of either of these triage methods, there is still a group of hrHPV-
positive women who would not be referred. These women are diagnosed with or 
without cytologic abnormalities and/or an hrHPV-positive, HPV16/18-negative result. 
These women may feel uncomfortable about their mixed test results even if their 
CIN3+ risk is low enough for them to return to the next screening round. To prevent 
anxiety among women who are directed back to screening, it is essential that the last 
screening test be negative. A repeat visit for cytologic testing only, at 6 to 12 months, 
meets this requirement.10 This is easy to communicate to both the physician and the 
woman.
Providing a repeat test will entail loss to follow-up while existing CIN3+ lesions 
may be missed.33 Previous studies have shown a 10-year cumulative incidence rate 
of CIN3+ lesions of about 17–20% among HPV16-positive women, 13–17% among 
HPV18-positive women and only 3% among hrHPV-positive, HPV16/18-negative 
women.28,34 An advantage of hrHPV genotyping is that it may make it possible to 
objectively select women who have either an increased risk (e.g., HPV16 positive) 
or a relatively low risk (e.g., positive for types other than hrHPV16/18) of developing 
CIN3+ lesions. Adequate follow-up based on an individual risk stratification can be 
provided.34,35 Unfortunately, the follow-up in this study has been too short to confirm 
or disaffirm this. Future studies may further assess this technique, which holds 
promise for tailored personalized screening.
A limitation of our study is the lack of histology in the group of women who 
had a cytologic triage result within normal limits and, after 6 months of follow-up, 
an HPV-negative result and a cytologic result within normal limits. The medical 
ethics committee did not allow to take cervical biopsies in this group of women. 
Furthermore, women with inadequate follow-up were excluded from this study. 
In that group, women with normal cytology at baseline might be over-represented. 
These factors may lead to an under- or overestimation of the screening results.
Various other biomarkers being expressed during transforming infections could 
also fulfill the role in the triage of hrHPV-positive women. As knowledge about the 
molecular oncogenesis of cervical precancer and cancer is expanding, the clinical 
utility of a wide variety of novel biomarkers in supplementary or stand-alone triage 
tests is being studied extensively. Different triage strategies, other than cytologic 
testing and HPV genotyping, may help to reduce the number of unnecessary 
colposcopies and treatment such as mRNA HPV testing, P16 staining, p16/Ki-67 dual 
staining, MSM2/TOP2A dual staining, E6/E7 protein markers, and DNA methylation 
markers.36-38 For identifying hrHPV-positive women with cervical precancer or 
cancer who need treatment, the optimal triage strategy remains unclear; at the same 
time, unnecessary referrals of women with transient infections must be limited.39 
Therefore, the clinical performance of the various triage strategies should be further 
assessed in regular screening programs.
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In regular European screening programs, hrHPV testing is expected to replace 
cytology testing as a primary screening tool in the coming years. Dutch primary HPV 
screening will start in 2016, and non-responders will be able to opt for HPV self-
sampling. For the time being, if an HPV self-sampling result is positive, triage will 
consist of cytologically testing a physician-taken smear. In such a screening program, 
HPV can be genotyped on the same cervical smear, which offers opportunities for 
personalized risk management.
In the future, screening might fully convert to self-sampling, and triage strategies 
might be adjusted in order to obviate the need to visit a physician. Triage strategies 
performed directly on the self-sampled specimens, such as DNA methylation and 
HPV genotyping, have already been described.37,40-43 Both DNA methylation and HPV 
genotyping of self-collected cervicovaginal samples show promising results.36,37,41,44,45 
However, the combination of genotyping and cytologic testing which shows such 
good results will not be possible on self-sampled material; it has been shown that 
direct cytologic testing of self-sampled material does not yield reliable results. 
Cytologic testing still requires a supplemental physician-taken smear.46,47
We conclude that HPV16 and/or 18 genotyping combined with raising the threshold 
of cervical cytologic testing from ≥ASC-US to ≥LSIL or ≥HSIL clearly improves the 
referral rate and the specificity for detecting CIN3+ lesions while maintaining 
adequate sensitivity. 
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Abstract 
BACKGROUND: Primary high-risk human papillomavirus (hrHPV) testing in 
cervical cancer screening shows relatively low specificity, which makes triage testing 
necessary. In this study, DNA methylation analysis was compared with cytology for 
triage testing in hrHPV-positive women. Moreover, feasibility of DNA methylation 
analysis directly on brush-based self-sampled specimens was assessed.
METHODS: Non-responding women from population-based screening were invited 
to self-collect a cervico-vaginal specimen for hrHPV testing; hrHPV-positive women 
were referred to a physician for triage liquid-based cytology. DNA methylation 
analysis was performed on 128 hrHPV-positive physician-collected triage samples 
and 50 matched brush self-samples with QMSP for C13ORF18, EPB41L3, JAM3 and 
TERT.
RESULTS: In physician-taken triage material, DNA methylation analysis of JAM3 
showed the highest combined specificity (88%) and sensitivity (82%) for detection of 
CIN3+, whereas cytology showed a specificity of 48% and a sensitivity of 91%. Out of 
39 women with abnormal cytology and normal histology (false-positive by cytology), 
87% were negative for JAM3 and 90% for C13ORF18 methylation. Agreement 
between DNA methylation analysis performed directly on the matched self-sampled 
material and physician-taken samples was 88% for JAM3 (κ=0.75, P<0.001) and 90% 
for C13ORF18 (κ=0.77; P<0.001).
CONCLUSIONS: DNA methylation analysis as a triage test in hrHPV-positive women 
is an attractive alternative to cytology. Furthermore, DNA methylation is feasible 
directly on brush-based self-samplers and showed good correlation with matched 
physician-taken samples. Direct molecular triage on self-collected specimens could 
optimise the screening program, especially for non-responders, as this would 
eliminate the need for an additional physician-taken scraping for triage testing.
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Introduction
Cytomorphological assessment of cervical scrapings is still the most common method 
used in population-based cervical cancer screening. Several randomised trials 
have demonstrated that high-risk human papillomavirus (hrHPV) testing shows 
higher sensitivity for detecting (pre)malignant cervical lesions and consequently 
improves screening for cervical cancer.1-4 However, hrHPV testing has a lower 
specificity compared with cytology, especially in younger women.5 To prevent 
unnecessary referrals to the gynaecologist, a triage test for hrHPV-positive women 
is necessary. Currently, cytological triage is the approach that is mostly advocated.6-8 
DNA methylation analysis of cancer-specific genes with quantitative methylation-
specific PCR (QMSP) might be an alternative triage tool for early detection of cervical 
neoplasia.9-11 DNA promoter methylation of tumour suppressor genes is an early event 
in cervical carcinogenesis.11,12 Several studies indeed reported that DNA methylation 
analysis could be a valuable objective triage tool for hrHPV-positive women.13-15 
Scenario analysis comparing triage testing either by cytological examination or DNA 
methylation analysis after primary HPV screening showed that DNA methylation 
analysis as triage test will detect more CIN3 lesions, less carcinoma will be missed 
and more patients will be correctly referred to the gynaecologist.13 The recently 
published randomised controlled trial by Verhoef et al.16 showed that detection of 
CIN2+ with methylation triage on self-samples directly in hrHPV-positive women 
was non-inferior to cytology triage on physician-taken smears, leading to a shorter 
time to CIN2+ diagnosis, although referral was higher in the methylation triage group 
given the positive predictive value of this test being lower compared with cytology.
Apart from the efficacy of the screening test, the low participation rate is another 
aspect in population-based screening programs for cervical neoplasia that could 
be improved.17 About 35% of the women in the Netherlands do not respond to the 
screening invitation (referred to as non-responders). These women are at increased 
risk of developing cervical cancer, as more than 50% of the women diagnosed with 
cervical cancer had no history of participating in the population-based screening 
program.18,19 Introduction of self-sampling methods for hrHPV testing has shown 
an increase in participation up to 39% of these non-responders.20 Furthermore, 
the response rate of the non-responders is significantly higher when offered a self-
sampling device compared with a recall for regular cytology-based screening.21-24
Recent studies have shown a high concordance of hrHPV test results between 
most self-collected samples and physician-taken cervical scrapings. Even more, 
vaginal self-samples and physician-taken samples showed similar test accuracy 
in detecting CIN2+ lesions, especially when PCR-based HPV tests were used.20,23,25,26 
However, it is critical that follow-up and further management are acceptable to the 
participants, especially when participants are reluctant.27 Therefore, direct triage 
testing on self-sampled material is preferred over an extra visit to a physician, but 
the concordance between cytology on self-obtained specimens vs physician-taken 
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samples is poor.20,28-30 DNA methylation analysis directly performed on self-sampled 
material might solve this problem.14,16,31
The aim of the present study was (1) to compare the performance of DNA 
methylation analysis with cytology as triage test on physician-taken samples of women 
who previously tested hrHPV-positive on a self-sampled specimen; (2) to analyse the 
feasibility of direct triage testing with DNA methylation analysis on brush-based self-
sampled specimens and compare these results with DNA methylation results in the 
matched physician-taken samples.
Material and methods
Study population
Women with a hrHPV-positive brush-based self-sampling result (Evalyn Brush, 
Rovers Medical devices B.V., Oss, The Netherlands) were selected for this pilot 
study. These women had participated in the PROHTECT-3B (PRotection by Offering 
HPV TEsting on Cervico-vaginal specimens Trial-3B) among non-responders of the 
Dutch screening program in the year 2008. The PROHTECT-3B study is a randomised 
controlled trial designed to determine whether the participation rate for a brush-
based cervico-vaginal self-sampling device is non-inferior to the participation rate 
for a lavage-based self-sampling device.32 The study was ethically approved by the 
Ministry of Health (No 2010/WBO04). In short, a total of 35 477 non-responders of the 
regular cervical screening programme aged 33–63 years were invited to participate. 
The self-sampling kit was sent to the home address of all eligible women. In total, 
10 027 women participated by returning self-sampled material to the laboratory for 
hrHPV testing (GP5+/6+ PCR; EIA HPV GP HR kit; Diassay, Voorburg, The Netherlands). 
All women who tested hrHPV-negative were advised to participate in the next 
screening round. All hrHPV-positive women (8.3%) were advised to comply with an 
additional cervical smear taken for cytology. All participating women gave informed 
consent.
Primary hrHPV testing of self-samplers
Upon arrival the dry self-sampled brushes were resuspended in 1.5 ml of ThinPrep 
preservation medium (Hologic Inc., Marlborough, MA, USA). The vials were mixed 
for 3 × 15 s, stored overnight at 4 °C and again mixed for 2 × 15 s. For the primary 
hrHPV test, 1/10th of the self-sampled material was used. DNA was isolated with the 
Roche MagNA Pure MP 96 isolation station (Roche Diagnostics, Indianapolis, IN, USA) 
and hrHPV GP5+/6+-PCR testing was performed using the Diassay EIA HPV GP HR kit 
(Diassay), according to the instructions of the manufacturer.33
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Cytology triage testing
HrHPV-positive women underwent an additional cervical smear taken by a physician 
approximately 6 weeks later. These cervical smears were collected in 20 ml Thinprep 
Preservcyt medium (Hologic Inc.) and cytomorphologically assessed according to 
the Dutch CISOE-A classification system, which can easily be translated into the 
Bethesda nomenclature.34 Women with abnormal cytology results (threshold ASCUS) 
were referred to the gynaecologist where a biopsy specimen was taken; if the biopsy 
was abnormal (CIN2+) they were treated according to the national guidelines in 
the Netherlands.35 Women with normal cytology were re-invited after 6 months for 
a repeat cervical scraping for cytology and hrHPV co-testing. If one of these tests 
was abnormal, women were referred for colposcopy-directed biopsy; if there was a 
double-negative test result, they were advised to attend the next regular screening 
round.
Sample selection for the current DNA methylation study
The triage physician-taken samples of PROHTECT-3B study were used to compare 
the performance of DNA methylation analysis vs cytology as a triage test. Histology 
results were set as the gold standard. For this pilot study, a total of 128 women were 
selected based on different subgroups (Figure 1): women who were true-positive by 
cytology (abnormal cytology and abnormal histology, i.e., CIN2+); false-positive by 
cytology (abnormal cytology and normal histology, i.e., no CIN/CIN1); true-negative 
by cytology (twice normal cytology; at baseline and after 6 months) and false-
negative by cytology (baseline normal cytology and at 6 months abnormal histology, 
i.e., CIN2+).
Figure 1. Study design. 
hrHPV-positive with a brush-based
self-sampling device
Cytology triage with a
physician-taken sample (n=128)
Normal cytology (n=48) 
Abnormal 
repeat cytology
Histology: CIN2+
False negative
by cytology 
(n=8)
Normal 
repeat 
cytology
True negative
by cytology 
(n=40)
Histology: 
no CIN/CIN1
False positive
by cytology 
(n=39)
Histology: 
CIN2+
True positive
by cytology 
(n=41)
Abnormal cytology (n=80)
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To analyse the feasibility of direct triage testing with DNA methylation analysis 
on brush-based self-sampled material, a small group of 50 hrHPV-positive women 
were analysed for this study. These 50 hrHPV-positive women had subsequently 
undergone an additional cervical smear by a physician ~6 weeks later. About half 
of the group (n=24) had an abnormal histological outcome (CIN3+), and half of the 
group (n=26) had a normal histological outcome (≤CIN2).
DNA extraction, bisulfite treatment and QMSP
For quantitative methylation-specific PCR, a new DNA isolation was performed using 
5 ml of the 20 ml physician-taken specimen and the remaining material (9/10th) 
of the self-sampled specimen. Genomic DNA was isolated by standard overnight 
proteinase K treatment, salt-chloroform extraction, and isopropanol precipitation.13 
DNA quality was assessed according to the BIOMED-2 protocol.36 Sodium bisulfite 
treatment on isolated genomic DNA (1 μg per sample) was performed according to 
the manufacturer’s protocol of the EZ DNA methylation kit (Zymo Research Corp, 
Irvine, CA, USA).
Quantitative methylation-specific PCR was performed with bisulfite-treated DNA 
using an internal (FAM/TAMRA)-labelled hybridisation probe for quantitative 
analyses of four genes (C13ORF18, JAM3, EPB41L3 and TERT). Quantitative 
methylation-specific PCR conditions and primer and probe sequences are as 
described previously.13,31 To correct for DNA input, QMSP of the housekeeping gene 
β-actin was used. Quantitative methylation-specific PCR reactions were performed in 
a total volume of 20 μl, containing 10 μl of 2 × QuantiTect Probe Mastermix (Qiagen, 
Hilden, Germany), 600 nM of forward and reverse primers (Invitrogen, Carlsbad, CA, 
USA), 250 nM of hybridisation probe (IDT, Leuven, Belgium) and 50 ng bisulphite-
modified DNA. Each sample was analysed in triplicate in a 384-well plate using ABI 
PRISM 7900HT Sequence Detection System (Applied Biosystems, Life Technologies, 
Carlsbad, CA, USA). A pool of leukocyte DNA from healthy women was used as a 
negative control. As a positive control, in vitro methylated (by SssI enzyme) leukocyte 
DNA was used in each experiment. All amplification curves were visualised and 
scored without knowledge of clinical data. A DNA sample was considered methylated 
if at least 2 out of the 3 wells were methylation positive with a Ct-value below 50 and 
DNA input of at least 225 pg β-actin. Quantitative methylation-specific PCR values 
were adjusted for DNA input by expressing results as ratios between two absolute 
measurements ((average DNA quantity of methylated gene of interest/average DNA 
quantity for reference gene β-actin) × 10 000).37
Statistical analysis
Statistical analysis was performed using SPSS software package (SPSS 20, Chicago, 
IL, USA). Histology was set as the gold standard. Methylation levels per gene 
were compared with the severity of the underlying lesion by the Kruskall–Wallis 
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test. Sensitivity and specificity were calculated with CIN2+ and CIN3+ as cutoff. 
Methylation levels per gene with CIN3+ as cutoff were visualised in a receiver-
operating characteristic (ROC) curve. To compare sensitivity and specificity of triage 
testing by DNA methylation vs triage testing by cytology on the same group of patients, 
the extended McNemar test, described by Hawass38 was executed. Concordance 
between the DNA methylation analysis of the Evalyn Brush self-samples and paired 
physician-taken liquid-based samples was measured by Cohen’s Kappa. Correlation 
of DNA methylation ratio in the paired physician-taken liquid-based samples and 
Evalyn Brush self-samples was measured by the Spearman rank analysis; differences 
with a P-value <0.05 were considered statistically significant.
Results
Performance of DNA methylation analysis in physician-taken samples 
Liquid-based physician-taken samples of 128 hrHPV-positive women were used for 
QMSP of C13ORF18, JAM3, EPB41L3 and TERT. Methylation levels increased with the 
severity of the underlying lesion for all genes (P<0.001) (data not shown). Table 1 
shows the methylation positivity per subgroup. The patient group with abnormal 
cytology and CIN3+ lesions was methylation positive for C13ORF18 and JAM3 in 65% 
(20/31) and 84% (26/31) of the cases, respectively, whereas the group with abnormal 
cytology and normal histology showed DNA methylation positivity in only 8% (4/49) 
and 16% (8/49) of these cases, respectively.
Table 2 shows the accuracy of DNA methylation analysis and cytology for 
detection of CIN2+ and CIN3+. DNA methylation analysis of JAM3 showed the highest 
combined sensitivity (82%) and specificity (88%) for detection of CIN3+, whereas 
cytology showed a specificity of 48% and a sensitivity of 91%. Sensitivities for CIN3+ 
of JAM3 (82%), EPB41L3 (88%) and TERT (76%) were comparable to cytology (91%), 
whereas specificities for JAM3 (88%) and C13ORF18 (91%) were significantly better 
than for cytology (48%) (P<0.001). For each marker, ROC curves for CIN3+ were 
computed (Figure 2). The areas under the curve were 0.855 for JAM3, 0.881 for 
EPB41L3 and 0.795 for C13ORF18 and TERT.
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Figure 2. ROC curves for methylation ratio of C13ORF18, JAM3, EPB41L3 and 
TERT for CIN3+.
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Figure 3. Methylation ratio of C13ORF18, JAM3, EPB41L3 and TERT as determined 
in self-sampled material and in matched physician-taken triage material.
Table 3. Sensitivity and specificity of methylation markers on brush-based self-
sampled material for CIN3+ (n=49).
Test Sensitivity (95%CI) Specificity (95%CI)
C13ORF18 54% (35–72%) 96% (80–99%)
JAM3 71% (51–85%) 96% (80–99%)
EPB41L3 79% (60–91%) 88% (70–96%)
TERT 54% (35–72%) 80% (61–91%)
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DNA methylation analysis on self-sampled material and its correlation with 
physician-taken material
From 50 patients with a liquid-based physician-taken sample also the matched 
original Evalyn Brush self-samples were used to perform the DNA methylation 
analysis. High-quality DNA could be retrieved from 49 brush devices. Performance 
of DNA methylation analysis directly on original self-sampled material showed 
again high specificities for JAM3 and C13ORF18 (both 96%), with corresponding 
sensitivities of 71% and 54% for CIN3+, respectively, (Table 3). Also EPB41L3 showed 
high specificity (88%) with corresponding high sensitivity (79%). The agreement 
between the methylation outcome of the Evalyn Brush self-sampled specimen and 
the liquid-based samples taken by the physician was 90% for C13ORF18 (κ=0.77, 
P<0.001), 88% for JAM3 (κ=0.75, P<0.001), 80% for EPB41L3 (κ=0.59, P<0.001) and 71% 
for TERT (κ=0.41, P=0.003). Comparing the methylation ratios between the matched 
self- and physician-taken samples showed again a very high concordance (P<0.001), 
with the best results for C13ORF18 (r=0.82, P<0.001), EPB41L3 (r=0.84, P<0.001) and 
JAM3 (r=0.89, P<0.001) methylation (Figure 3). 
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Discussion
This study shows for the first time that DNA methylation analysis is feasible on 
brush-based self-sampled cervico-vaginal material. The concordance between DNA 
methylation analysis on self-sampled material and physician-taken samples in this 
study was high. Furthermore, the clinical performance of DNA methylation analysis 
as triage test on both hrHPV-positive physician-taken samples and self-collected 
samples was good, with high specificity, particularly for C13ORF18 and JAM3, and 
moderate to high sensitivity in the studied series.
The sensitivity of hrHPV assays evaluated in primary screening appeared consistently 
high for detection of CIN3+.1 In primary screening this higher clinical sensitivity may 
lead to earlier diagnosis of high-grade cervical lesions and prevent cervical cancer.4 
However, hrHPV screening is less specific, especially for young women, resulting in 
a relatively high false-positive rate.5 With a triage test, specificity can be improved 
and this results in fewer referrals for colposcopy, reduction of overtreatment and 
anxiety of false-positive women and also reduces the costs.39 Cytology as triage test, 
as suggested in the new Dutch HPV-screening program, will ensure that most women 
with underlying CIN2+ lesions are correctly referred for colposcopy.40 However, in 
this study we showed that specificity could be further improved by the use of DNA 
methylation.
The high-sensitivity and low-specificity results of cytology found in this study might 
be explained by the cytologist’s awareness of the HPV-positive results. Furthermore, 
the sample selection was based on different subgroups, and is therefore not 
representative for the whole group. Nonetheless, in these specified selected 
subgroups, our findings point to the methylation test as an attractive alternative 
to cytology as a triage test. The advantage of DNA methylation analysis as a triage 
test on cervical smear in comparison with cytology is that it is an objective, non-
morphological test. In this study, we showed a high specificity of C13ORF18 and JAM3 
methylation for CIN3+, and a moderate to high sensitivity for C13ORF18, JAM3 and 
EPB41L3. In addition, we showed in the group ‘false-positive by cytology’ (abnormal 
cytology and normal histology) that methylation positivity was very low, which in a 
screening context would result in a reduction of referrals of false-positive women to 
the gynaecologist. In addition, the methylation test detected out of 3 women with a 
CIN3 lesion who were missed with cytology triage testing.
DNA methylation analysis in self-sampled cervico-vaginal brush specimens 
showed high specificity and moderate to high sensitivity for detection of CIN3+ 
lesions. The concordance between DNA methylation analysis on the self-sampled 
material and the corresponding physician-taken sample taken ~6 weeks later from 
the same patient was high, which supports reliability of the methylation test in 
the self-sampled material. An advantage of DNA methylation analysis performed 
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directly on self-sampled material is that it eliminates the need for an additional 
cervical smear. As a result, loss to follow-up could decrease, especially in the non-
responder group. Large population-based studies in non-responders of the regular 
cervical cancer screening showed that about 10% of the HPV-positive women did not 
visit their physician for triage cytology.22,23
Previously, we evaluated the same four genes (C13ORF18, JAM3, EPB41L3 and TERT) 
by DNA methylation analysis on self-sampled material obtained by a lavage device.31 
In the current study, we showed representative methylation results for these four 
genes, and we also showed that DNA methylation analysis on self-samples by a dry 
cervical brush device can be used as well. The use of dry brush devices may have 
advantages over cervico-vaginal lavage devices, as brushes can be transported and 
stored dry, whereas liquid specimens are less convenient for sending by regular 
mail.41 But above all, both devices are not suitable for cytological examination.20 
Therefore, DNA methylation is more suitable for triage testing after hrHPV self-
sampling compared with cytology. In the current study, we analysed four genes, 
previously validated,13,31 of which some showed already better specificity compared 
with cytology without losing sensitivity to detect CIN3+. The advantage of using these 
particular genes is that setting a cutoff value is not needed. If the PCR product was 
negative (i.e., no amplification of specific product), the sample was called negative 
and any ratio above zero for two PCR products (analysed in triplicate) was called 
positive. This unique feature of the selected genes makes it an objective easy to 
interpret test. Furthermore, also other groups describe some of these genes (e.g., 
EPB41L3) as predictors for CIN2/3 lesions.42,43 Addition of other potential markers 
reported15,16,44-47 or identification of even better differentially methylated genes by 
genome-wide methods could even further improve the diagnostic accuracy of DNA 
methylation in the future.
Although the present study included a relatively small number of samples and 
comprised a selected series, it had several strengths. The primary HPV tests as well as 
DNA methylation analysis were both performed on the same self-sampled material. 
In addition, the matched physician-taken liquid-based cytology samples were 
available for DNA methylation analysis and this allowed direct comparison between 
DNA methylation analyses on self-samplers vs physician-taken samples. A limitation 
of our study is the lack of histology; the medical ethics committee did not allow to 
take cervical biopsies in women with normal triage cytology and normal follow-up 
cytology after 6 months, which may lead to an under- or overestimation of the exact 
performance of DNA methylation in the triage of these screening results.
In conclusion, DNA methylation analysis is feasible on brush-based self-sampled 
material, and its diagnostic performance as triage test for hrHPV-positive women 
showed similar results as DNA methylation analysis on physician-taken samples. 
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Direct methylation analysis on self-sampled material could be an important step 
forward in optimising the screening programme, as this would eliminate the need 
for an extra physician-taken cervical scraping for triage testing. In addition, owing 
to its high specificity it would reduce the number of false-positive women referred 
to the gynaecologist. Our data indicate that the detection of cervical neoplasia by 
DNA methylation analysis in cervico-vaginal brush specimens warrants further 
exploration of its use in large population-based prospective cohort studies.
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Chapter 8
Triage by methylation-marker 
testing versus cytology in women 
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Summary
BACKGROUND: Cytology is a widely used method of triaging women who test positive 
for human papillomavirus (HPV). However, self-sampled specimens, which can 
substantially increase participation in screening programmes, are not suitable for 
accurate cytological assessment. We investigated whether direct DNA methylation-
based molecular triage on self-sampled cervicovaginal specimens was non-inferior 
to cytology triage on additional physician-collected cervical samples in the detection 
of cervical intraepithelial neoplasia grade 2 (CIN2) or worse in women who did not 
attend cervical screening programmes.
METHODS: In this randomised controlled non-inferiority trial, we invited women 
(aged 33–63 years) registered as non-attendees of cervical screening in the Netherlands 
in 2007 to submit a self-collected cervicovaginal sample for HPV testing. Using a 
computer-generated sequence, we randomly allocated women who tested positive 
for high-risk hrHPV on a self-sample to either triage by cytology on an additional 
physician-taken smear or direct triage on the self-sample by methylation analysis 
of MAL and miR-124-2 genes (1:1; stratified by age and region, with block sizes by 
age group). Triage-positive women in either group were referred for colposcopy. The 
primary endpoint was detection of CIN2 or worse, analysed by intention to treat. The 
non-inferiority margin was 0.80. This study is registered in the Primary Trial Register 
of the Netherlands, number NTR6026.
FINDINGS: We invited 46,001 women to participate, 12,819 of whom returned 
self-sampled material; 1038 samples tested positive for high-risk HPV. Between 
November 1, 2010, and December 31, 2011, after exclusion of women who were 
ineligible, we enrolled and randomly allocated 515 women to methylation triage 
and 509 to cytology triage. The detection of CIN2 or worse with methylation triage 
was non-inferior to that with cytology triage (90 [17%] of 515 women vs 75 [15%] of 
509 women; relative risk 1.19, 95% CI 0.90–1.57). Referral for colposcopy was more 
common in the molecular group (284 [55%] women) than in the cytology group (149 
[29%] women; p<0.0001). Mean time to CIN2 or worse diagnosis was shorter in the 
molecular triage group (96 days, range 44–101) than in the cytology triage group (158 
days, 71–222; p=0.00084).
INTERPRETATION: DNA methylation analysis of MAL and miR-124-2 genes on HPV-
test-positive self-samples is non-inferior to cytology triage in the detection of CIN2 or 
worse, opening the way to full molecular screening.
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Introduction
In high-income countries, population-wide, cytology-based cervical cancer screening 
has decreased cervical cancer incidence and mortality.1 Almost half of the cases of 
invasive cervical cancer in high-income countries are in the 30% of women who 
do not attend cervical screening (ie, non-attendees).1-3 Offering self-collection of 
cervicovaginal material for high-risk HPV (hrHPV) testing in a laboratory (hereafter 
referred to as HPV self-sampling) has been shown to be effective in recruiting 
non-attendees into screening programmes,4-9 with responses varying from 8.7% 
to 39.0%.10 As such, HPV self-sampling can substantially increase compliance to 
screening programmes.
Women testing positive for hrHPV on self-sampled specimens require additional 
triage testing because specificity of hrHPV testing is too low to justify direct referral 
for colposcopy for all screen-positive women.11,12 Cytology is an accepted standard 
method of examination in triage for hrHPV-positive women.13,14 However, because 
cytology is not reliable on self-sampled material, triage by cytology requires an 
extra visit to a physician for a cervical smear.15,16 This visit is often unwelcome to 
the women, delays the diagnostic work-up, and leads to loss to follow-up.4,5 These 
drawbacks could be circumvented by direct molecular triage on HPV-positive 
cervicovaginal self-samples, provided that molecular testing is at least as sensitive 
as cytology for the detection of cervical intraepithelial neoplasia grade 2 (CIN2) or 
worse.
DNA methylation analysis of the promoter region of tumour-suppressor 
genes involved in cervical carcinogenesis can provide effective molecular triage 
of hrHPV-positive women.17-20 Methylation marker analysis is accurate on self-
sampled specimens.21,22 Combined methylation marker analysis of two genes—
MAL and miR-124-2—on HPV-positive self-collected cervicovaginal lavage material 
could distinguish CIN2 or worse and CIN3 or worse with minimum sensitivities of 
71.3% (for CIN2 or worse) and 77·0% (for CIN3 or worse), at specificity of 50%, thus 
exceeding the sensitivity of combined HPV16 and HPV18 genotyping.22 Application of 
this panel of markers would therefore allow direct triage for colposcopy of women 
with an HPV-positive self-sample.
We did the PRotection by Offering HPV TEsting on self-sampled Cervico-vaginal 
specimens Trial-3, (PROHTECT-3) to assess whether direct molecular triage with the 
bi-methylation marker panel MAL and miR-124-2 is non-inferior to indirect cytology 
triage on physician-collected cervical samples in the detection of CIN2 or worse in 
women with HPV-positive self-collected lavage specimens.
| Chapter 8
C
H
A
P
T
E
R
.8
168
Methods
Study design and participants
In the Dutch cervical screening programme, women aged 30–60 years are invited 
every 5 years by one of five regional screening organisations for a cervical smear 
at a general practitioner’s office. Non-compliant invitees are registered as non-
attendees in the databases of the screening organisations. For this randomised 
controlled trial, we invited 46 001 women (age 33–63 years) living in Noord-Holland, 
Flevoland, Utrecht, and Gelderland who were registered as non-attendees in 2007 
to participate. We enrolled women between November 1, 2010, and December 
31, 2011. Exclusion criteria were previous hysterectomy and a history of CIN2 or 
worse, or abnormal cytology in the preceding 2 years. We sent non-attendees a pre-
invitation letter allowing opt-out of this trial, and those who did not opt out within 3 
weeks subsequently received a self-sampling lavage device (Delphi screener; Delphi 
Bioscience, Scherpenzeel, Netherlands),16,23 an explanation letter, an informed 
consent form, a pictorial and written instruction form, collection tube, seal bag, 
and free return envelope as described elsewhere.4 Women were asked to return 
the collection tube, containing their self-sampled material, together with a signed 
informed consent form to the laboratory for hrHPV testing. During the study period, 
a website (http://www.hpvthuistest.nl), an email address, and telephone number 
were available for trial participants for additional information and questions about 
the study.
We did the trial at the VU University Medical Centre (VUmc), Radboud University 
Nijmegen Medical Centre (RUNMC), and the Screening Organisations Mid-West 
(Midden-West) and East (Oost). We report our study results according to the 2010 
CONSORT guidelines.24 This study was approved by a national review board (Ministry 
of Public Health No 2010/04WBO).
Randomisation and masking
LR randomly assigned women who tested hrHPV-positive on self-sampling to one of 
two triage groups in a 1:1 ratio using a computer-generated sequence: the molecular 
triage group, in which women received methylation-based triage testing directly 
on the self-sampled material, and the cytology triage group, in which women were 
advised to visit their physician for a cervical scrape. We stratified randomisation 
for age (seven categories: 30–34 years, 35–39 years, 40–44 years, 45–49 years, 50–
54 years, 55–59 years, and 60–64 years) and region (two categories: Midden-West 
and Oost). Cytotechnicians were not informed about the HPV status of the women, 
whereas physicians and gynaecologists were informed about the HPV and triage test 
results.
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Procedures
Participating women sent their self-collected cervicovaginal lavage material in 
their supplied 25 mL vial to the laboratory. We did hrHPV GP5+/6+-PCR testing 
using the Diassay EIA HPV GP HR kit (Diassay, Voorburg, Netherlands) as described 
previously.23 To find out whether sufficient material had been sampled we first did a 
visual inspection of the sample vial after centrifugation to check for the presence of 
a cell pellet.23,25 If no cell pellet was visible we regarded a sample as having possible 
poor material yield and subsequently did a β-globin PCR for assessing DNA presence. 
Of the remaining samples, every ninth sample was selected for β-globin PCR. In 
case of a negative β-globin PCR, samples were considered invalid and a new self-
sampling kit was sent. If women did not resubmit another sample, the overall result 
was classified as not determined. All women who submitted self-sampled material 
and their physicians (if known and consented by the women) received a letter with 
the laboratory test results and follow-up advice. We asked women who tested hrHPV-
negative to participate in the next round of regular screening.
Women with a positive triage test (ie, positive methylation test or abnormal 
cytology) were referred for a colposcopy-directed biopsy by the investigators of the 
VUmc, whereas women with a negative triage test (ie, negative methylation test or 
normal cytology) were re-invited after 6 months for an exit test. This exit test consisted 
of cytology and hrHPV co-testing, and if at least one of these tests was abnormal 
(ie, abnormal cytology or hrHPV-positive), women were referred for colposcopy-
directed biopsy. In case of a double-negative exit test (ie, normal cytology and hrHPV 
negative), women were referred back to regular screening. To motivate women to 
comply with the study, we sent reminders 16 weeks after HPV self-sampling and 
contacted their physicians.
Assessments
We did liquid-based cytology on cervical scrapes taken with a Cervex Brush (Rovers 
Medical Devices BV, Oss, Netherlands). The brush was collected in a vial with 
PreservCyt medium, which was sent to the Department of Pathology of the VUmc 
for making thin layer preparations. Cytology preparations were read according to 
the CISOE-A classification, which can be translated into the Bethesda system.26 We 
grouped cytological results as normal, borderline or mild dyskaryosis, or moderate 
dyskaryosis or worse, as described elsewhere.14
We did DNA methylation marker analysis for MAL17,20 and miR-124-227 genes. The 
clinical performance of this MAL/miR-124-2 panel has been described previously in 
a training set of 355 hrHPV-positive self-sampled cervicovaginal specimens.22 The 
investigators in that study noted that between three different methylation marker 
panels, the MAL/miR-124-2 panel was most robust in detecting CIN3 or worse. 
Here, we did the methylation assay with a preplanned protocol as a prospective 
component of the study, as previously described.22 Briefly, we treated extracted DNA 
from the self-sample with sodium bisulphite using the EZ DNA Methylation Kit (Zymo 
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Research, Orange, CA, USA).17,20 Bisulphite-treated DNA was subsequently used for 
real-time, quantitative methylation-specific PCR for the MAL gene, using the MAL-M1 
marker, and the miR-124-2 gene, using the miR-124-2 marker, on an ABI 7500 real-
time PCR system (Applied Biosystems, Carlsbad, CA, USA). Primers and probes for 
quantitative methylation-specific PCR are described elsewhere.17,27 As a reference, 
we did PCR for the bisulphite-converted housekeeping gene β-actin.17 Cycle threshold 
values were measured at a fixed fluorescence threshold (ie, 0.01). Cycle threshold 
ratios between cycle threshold values of the housekeeping gene and the target gene 
were calculated as previously described.17,22 When β-actin-negative samples were 
also negative for their target genes, we scored them as invalid. The thresholds used 
for scoring samples as methylation positive—the threshold for colposcopy referral—
were a cycle threshold ratio 0.33 for MAL-M1 marker and 0.064 for miR-124-2. 
Women were referred when either of these markers had a ratio value above the 
threshold. Findings from a previous study using these thresholds showed the highest 
sensitivity for CIN3 or worse at a predefined specificity of 50%.22
Outcomes
Women reached the study endpoint if they had a double negative exit test or a 
histological outcome. Histology was assessed in different pathology laboratories 
in the Netherlands according to recommended guidelines and recorded in the 
nationwide network and registry of histopathology and cytopathology in the 
Netherlands (PALGA, Houten, Netherlands).28 The primary outcome measure was 
detection of CIN2 or worse. Other predefined secondary outcome measures were 
detection of CIN3 or worse, colposcopy referral, and compliance to follow-up. We 
also did a post-hoc analysis of time to histological diagnosis of CIN2 or worse. We 
counted all women who submitted self-sampled specimens between November 1, 
2010, and December 31, 2011, as participants in this study. We retrieved follow-up 
outcomes for all participants from the PALGA database and, if necessary, from their 
physicians and gynaecologists. All cytological and histological findings were included 
in our analysis when recorded before January, 2013, to ensure a follow-up of at least 
12 months for each woman.
Statistical analysis
Analyses were done by intention to treat, unless otherwise specified. We calculated 
risk ratios for the detection of CIN2 or worse and CIN3 or worse in the molecular and 
cytology triage group with 95% Cornfield confidence intervals and sensitivity and 
positive predictive value (PPV) of both triage strategies with 95% Wald CIs, reporting 
both unadjusted and adjusted sensitivities. We corrected the adjusted sensitivities 
for the number of women who did not comply with the triage test or the exit test 
using formulae by Begg and Greenes.29
We analysed differences in time to diagnosis and in mean age with the unpaired 
t-test. We did a logistic regression analysis to estimate the effects of age on hrHPV 
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positivity. We tested the effect of age cohort on detection of CIN2 or worse and CIN3 
or worse with a Breslow-Day homogeneity test.
We assessed the sample size using calculations for non-inferiority trials. More 
precisely, a study of 45,000 women has 80% power to show non-inferiority for 
detection of CIN2 or worse at a non-inferiority threshold of 80% if the participation 
is set at 30%, the hrHPV positivity is set at 10%, and the significance level is set at 5% 
(appendix). We used SPSS (version 20) and STATA (version 11) for statistical analyses. 
This study is registered in the Primary Trial Register of the Netherlands, number 
NTR6026.
Role of the funding source
The sponsors had no role in data collection, data analysis, data interpretation, study 
design, or writing the paper. CJLMM and VMJV had full access to all data. CJLMM had 
the final responsibility for the decision to submit for publication.
Results
We invited 46,001 women to participate, 12,819 of whom returned their self-sampled 
material and a signed informed consent form. Self-samples from 1038 women tested 
hrHPV-positive—after exclusion of women who were ineligible for inclusion, we 
randomly allocated 515 women to methylation triage and 509 to cytology triage 
(Figure, Table 1). Women who opted out were, on average, older than those who 
did not (mean age 48.7 years vs 44.9 years; p<0.0001). Of those who did not opt out, 
women who responded were, on average, younger than those who did not (mean 
age 44.7 years vs 45.0 years; p=0.00043). The proportion of hrHPV-positive women 
decreased with age at a 5-year odds ratio of 0.87 (95% CI 0.83–0.90; p<0.0001).
Referral to colposcopy was 1.9 times higher in the methylation triage group than 
in the cytology triage group (p<0.0001; Figure). 465 (91%) of the 509 women in 
the cytology triage group attended triage testing within 16 weeks of self-sampling 
and 503 (99%) attended by the end of the study. The study endpoint (ie, a double-
negative exit test or a histological outcome) was reached in 408 women (79%) in the 
methylation group and 368 (72%) women in the cytology group (p=0.0097). For those 
who had a positive screening result, 253 (89%) of 284 women in the molecular triage 
group, and 137 (92%) of 149 women in the cytology triage group attended the follow-
up appointment.
Of 284 (55%) women who tested positive in the methylation triage group (Table 
2), five (2%) were diagnosed with squamous cell carcinoma, one (0.4%) with 
adenocarcinoma, 49 (17%) with CIN3, and 35 (12%) with CIN2. 50 (18%) women had 
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CIN1 lesions and 96 (34%) had no CIN—48 (17%) women did not comply with follow-
up advice, of whom 17 had both an hrHPV-negative test and normal smear in follow-
up and 31 were lost to follow-up (ie, had no study endpoint). Of 149 (29%) women 
in the cytology group with abnormal cytology (Table 2), five (3%) were diagnosed 
with squamous cell carcinoma, 48 (32%) with CIN3 lesions, and 22 (15%) with CIN2. 
Moreover, 27 (18%) women had a CIN1 lesion and 32 (21%) were diagnosed with no 
CIN. 15 (10%) cytology-positive women did not comply with colposcopy advice; three 
had both normal cytology and a negative hrHPV test in follow-up, and 12 were lost 
to follow-up. CIN2 or worse detection with methylation triage was non-inferior to 
cytology triage: the relative risk (RR) of detection of CIN2 or worse with methylation 
triage versus cytology triage was 1.19 (95% CI 0.90–1.57), with the lower bound of the 
CI above the hypothesised non-inferiority margin of 0.80. CIN3 or worse detection 
was similar between groups (RR 1.03; 0.72–1.47), although the CIs were wider than 
with CIN2 or worse. We detected no significant effect of age cohort on the detection 
of CIN2 or worse (p=0.13), or CIN3 or worse (p=0.54) lesions.
Table 1.  Baseline characteristics
Cytology triage 
(n=509)
Methylation 
triage (n=515)
Mean age (range) 42.4 (33–63) 42.6 (33–63)
30–34 years 128 (25%) 126 (24%)
35–39 years 128 (25%) 129 (25%)
40–44 years 94 (18%) 94 (18%)
45–49 years 63 (12%) 63 (12%)
50–54 years 51 (10%) 50 (10%)
55–59 years 27 (5%) 37 (7%)
60–64 years 18 (4%) 16 (3%)
Region
Mid-west 411 (81%) 414 (80%)
East 98 (19%) 101 (20%)
Mean time to previous cytology smear, years (IQR) 6.1 (2.9–8.6) 6.0 (2.8–8.4)
Data are n (%) unless otherwise specified.
Methylation-marker testing versus cytology as a triage test in hrHPV positive women | 
C
H
A
P
T
E
R
.8
175
T
a
b
le
 2
. D
et
ec
ti
on
 o
f 
h
is
to
lo
gi
ca
ll
y 
co
n
fi
rm
ed
 c
er
vi
ca
l i
n
tr
ae
p
it
h
el
ia
l n
eo
p
la
si
a 
an
d
 c
an
ce
r 
in
 t
w
o 
tr
ia
ge
 g
ro
u
p
s
S
tr
a
te
gy
R
el
a
ti
v
e 
d
et
ec
ti
o
n
T
ri
a
ge
 t
es
t 
(b
a
se
li
n
e)
E
x
it
 t
es
t 
(6
 m
o
n
th
s)
N
o
 C
IN
C
IN
1
C
IN
2 
o
r 
w
o
rs
e
C
IN
3 
o
r 
w
o
rs
e
C
a
n
ce
r
C
yt
ol
og
y 
tr
ia
ge
 
gr
ou
p
 (
n
=5
09
)
C
yt
ol
og
y
..
32
 (
6%
)
27
 (
5%
)
75
 (
15
%
)
53
 (
10
%
)
5 
(1
%
)
..
C
yt
ol
og
y 
+ 
h
rH
P
V
67
 (
13
%
)
47
 (
9%
)
26
 (
5%
)
15
 (
3%
)
2 
(<
0·
5%
)
C
yt
ol
og
y
C
yt
ol
og
y 
+ 
h
rH
P
V
99
 (
19
%
)
74
 (
15
%
)
10
1 
(2
0%
)
68
 (
13
%
)
7 
(1
%
)
M
et
h
yl
at
io
n
 
tr
ia
ge
 g
ro
u
p
 
(n
=5
15
)
M
et
h
yl
at
io
n
..
96
 (
19
%
)
50
 (
10
%
)
90
 (
17
%
)
55
 (
11
%
)
6 
(1
%
)
..
C
yt
ol
og
y 
+ 
h
rH
P
V
37
 (
7%
)
29
 (
6%
)
34
 (
7%
)
24
 (
5%
)
0
M
et
h
yl
at
io
n
C
yt
ol
og
y 
+ 
h
rH
P
V
13
3 
(2
6%
)
79
 (
15
%
)
12
4 
(2
4%
)
79
 (
15
%
)
6 
(1
%
)
D
at
a 
ar
e 
n
 o
r 
n
 (
%
).
 C
IN
=c
er
vi
ca
l i
n
tr
ae
pi
th
el
ia
l n
eo
pl
as
ia
 (
n
u
m
be
r 
in
di
ca
te
 g
ra
de
).
  H
P
V
=h
u
m
an
 p
ap
il
lo
m
av
ir
u
s.
 h
rH
P
V
=h
ig
h
 r
is
k 
H
P
V
T
a
b
le
 3
. S
en
si
ti
vi
ty
 a
n
d
 p
os
it
iv
e 
p
re
d
ic
ti
ve
 v
al
u
e 
of
 c
yt
ol
og
y 
tr
ia
ge
 a
n
d
 m
et
h
yl
at
io
n
 t
ri
ag
e
S
en
si
ti
v
it
y
P
o
si
ti
v
e 
p
re
d
ic
ti
v
e 
v
a
lu
e
U
n
a
d
ju
st
ed
A
d
ju
st
ed
*
n
/N
%
 (
95
%
 C
I)
n
/N
%
 (
95
%
 C
I)
%
 (
95
%
 C
I)
C
IN
2 
o
r 
w
o
rs
e
C
yt
ol
og
y 
tr
ia
ge
75
/1
01
74
.3
%
 (
65
.7
–8
2.
8)
70
.8
%
 (
66
.1
–7
5.
4)
75
/1
49
50
.3
%
 (
42
.3
–5
8.
4)
M
et
h
yl
at
io
n
 t
ri
ag
e
90
/1
24
72
.6
%
 (
64
.7
–8
0.
4)
70
.5
%
 (
66
.1
–7
5.
0)
90
/2
84
31
.7
%
 (
26
.3
–3
7.
1)
C
IN
3 
o
r 
w
o
rs
e
C
yt
ol
og
y 
tr
ia
ge
53
/6
8
77
.9
%
 (
68
.1
–8
7.
8)
74
·8
%
 (
70
.3
–7
9.
2)
53
/1
49
35
.6
%
 (
27
.9
–4
3.
3)
M
et
h
yl
at
io
n
 t
ri
ag
e
55
/7
9
69
.6
%
 (
59
.5
–7
9.
8)
67
.5
%
 (
62
.9
–7
2.
0)
55
/2
84
19
.4
%
 (
14
.8
–2
4.
0)
C
IN
=c
er
vi
ca
l i
n
tr
ae
pi
th
el
ia
l n
eo
pl
as
ia
 (
n
u
m
be
rs
 in
di
ca
te
 g
ra
de
).
* 
A
dj
u
st
ed
 fo
r 
th
e 
n
u
m
be
r 
of
 w
om
en
 w
h
o 
di
d 
n
ot
 c
om
pl
y 
w
it
h
 t
h
e 
tr
ia
ge
 o
r 
ex
it
 t
es
t
| Chapter 8
C
H
A
P
T
E
R
.8
176
The mean time from arrival of self-sampled specimen in the laboratory to CIN2 or 
worse diagnosis was longer in women with an abnormal cytology test (158 days, 
range 71–222) than in women with a positive methylation test (96 days, 44–101; 
p=0.00084).
Sensitivity for the detection of CIN2 or worse and CIN3 or worse, adjusted for loss to 
follow-up, was similar in both groups (Table 3). PPV was higher in the methylation 
group than in the cytology group for both CIN2 or worse (p<0.0001) and CIN3 or 
worse (p=0.00021; Table 3). More women in the methylation group were diagnosed 
with CIN1 than in the cytology group (50 with methylation vs 27 with cytology; RR 
1.83, 95% CI 1.16–2.88).
In the methylation triage group, 230 (45%) women with a negative triage test were 
advised to visit their physician for an exit test. At this exit assessment, 24 (10%) had 
CIN3, ten (4%) had CIN2, 29 (13%) had CIN1, and 37 (16%) had no CIN; 55 (24%) women 
had both normal cytology and an hrHPV-negative result and 75 (33%) women did not 
reach a study endpoint. In the cytology triage group, 351 (69%) women were advised 
to undergo an exit test after a negative triage test. At this exit assessment, two (1%) 
had squamous cell carcinoma, 13 (4%) had CIN3, 11 (3%) had CIN2, 47 (13%) had 
CIN1, and 67 (19%) had no CIN; 91 (26%) women had both normal cytology and an 
hrHPV-negative result and 120 women did not reach a study endpoint.
The cumulative RR for lesion detection in women in the methylation versus the 
cytology group was 1.21 (95% CI 0.96–1.53) for CIN2 or worse and 1.15 (0.85–1.55) 
for CIN3 or worse. The cumulative RR for CIN1 detection was much the same in both 
groups (79 with methylation vs 74 with cytology; RR 1.06, 0.79–1.41).
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Discussion
Our findings show that direct triage by combined promoter methylation analysis 
of MAL and miR-124-2 genes on hrHPV-positive self-samples of non-attendees of 
organised cervical screening is feasible. Direct molecular triage on self-samples 
has similar sensitivity for CIN2 or worse as indirect cytology triage on a physician-
taken smear. Direct molecular triage detects CIN2 or worse lesions earlier than 
cytology triage, is easier for patients because they do not have to visit a physician, 
and is logistically simpler because no reminder letters have to be sent. 509 visits 
to the physician were avoided by methylation marker testing at the cost of 135 
extra colposcopy referrals. Of the extra referrals, 15 led to a diagnosis of CIN2 or 
worse, meaning that 120 of the 135 extra colposcopy referrals could be considered 
as unnecessary. Thus, a drawback of the methylation marker test in this trial is its 
lower PPV compared with cytology triage. Nonetheless, the PPV of methylation triage 
(19.4% for CIN3 or worse) is still higher than the risk threshold for CIN3 or worse of 
10% as has been previously proposed to identify women in need of direct colposcopic 
assessment.30 A related issue is whether the capacity of gynaecology departments is 
sufficient to meet the increase in colposcopy referrals in the Netherlands. Our study 
population of non-attendees comprises about a fifth of the total Dutch population of 
non-responders. In view of the fact that the number of active gynaecologists in the 
country is about 1000, this direct triage strategy would result in no more than one 
extra woman for colposcopy on average per gynaecologist per year.
We did our study in the Netherlands, where the standard of cytology screening 
is high. Because substantially more women were referred to colposcopy with 
molecular triage compared with cytology triage, while detection of CIN2 or worse 
and CIN3 or worse were much the same with both methods, cytology triage is still 
an attractive triage test in countries with a good quality of cytology screening. In 
countries without a quality-assured cytology infrastructure, methylation marker 
testing might be an alternative triage method for women testing hrHPV-positive on 
self-samples.31 Moreover, large variability in cytology results has been seen in some 
high-income and medium-income countries,11 and an objective methylation marker 
analysis could lead to more homogeneous results.
Although findings from our previous study showed that the marker panel in our 
study performed well as a triage test for hrHPV-positive women,22 we realise that it 
has not been assessed by other groups. Additionally, methylation markers discovered 
by other groups, which include both DNA methylation of host-cell genes18,19,33 and 
HPV DNA methylation34, have not been tested on self-sampled specimens in a 
screening setting. Nevertheless, with the aid of bisulphite treatment and the sample 
control (ie, β-actin housekeeping gene) to establish proper quantity, the methylation 
markers tested in this study have previously shown good reproducibility on clinical 
samples.17,22
In our study, most hrHPV-positive women complied with the advice to visit a 
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gynaecologist after an abnormal triage test. Also, in the cytology triage group, 99% 
of the hrHPV-positive women had a cytological triage test taken, indicating that a 
positive hrHPV test encourages former non-attendees to visit a physician. A plausible 
explanation for this finding is that an hrHPV-positive test changes the perception 
of the risk of cervical disease and motivates women to visit the physician. In the 
Netherlands, the number of general-practice physicians is high—in countries with 
fewer general-practice physicians, direct triage with methylation testing seems the 
most obvious approach to ensure good compliance. Moreover, the 99% compliance 
to cytology triage is very high for former non-attendees. In our study, the compliance 
increased from 91% to 99% by sending a reminder letter to women and their 
physicians. However, in a routine setting, this compliance could be somewhat lower 
as already seen in two earlier studies in non-responders to cervical screening in the 
Netherlands.4,5
Strengths of our study are its large size, the randomised design, the setting within a 
representative non-responder population in a country with organised screening, and 
the availability of a nationwide registry for cytology and histological diagnoses. Local 
histological diagnoses were done in line with clinical practice in the Netherlands, but 
some variation of histological classification in different participating laboratories 
cannot be ruled out. However, concordance of original CIN3 or worse diagnoses in an 
earlier trial has been shown to be 97%,35 suggesting low inter-laboratory variation.
A limitation of our study is that we did not further characterise the detected 
CINs. Although a similar number of CIN2 or worse was detected with both triage 
tests, further research is needed to assess whether the CIN2 or worse lesions in the 
methylation group are similar to those in the cytology group. In an earlier study,36 
we showed that promoter methylation levels proportionally increase with the 
duration and degree of CIN lesions, and are very high in samples of women with 
cervical cancer. Blinded methylation testing of self-samples of the two women whose 
carcinomas were missed by cytology at baseline showed a positive test result (data 
not shown). Moreover, no carcinomas were missed by methylation marker analysis 
in the molecular triage group. If substantiated in other studies, this finding would 
greatly underscore the value of molecular triage over cytology triage. Furthermore, 
methylation marker analysis can also be used on cervical smears and therefore as a 
triage test for women with an HPV-positive cervical smear.17
Our findings suggest that methylation marker analysis is an objective method 
for direct molecular triage of HPV-positive self-collected cervicovaginal specimens. 
This molecular approach obviates the need for a visit to a physician and reduces 
time to CIN2 or worse diagnosis—but at the cost of more colposcopy referrals. HPV 
self-sampling combined with molecular triage opens the possibility of full molecular 
cervical cancer screening, minimising the need for visiting a physician.
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Panel: Research in context
Systematic review
Cytomorphological triage of leftover self-collected cervicovaginal material 
of HPV-positive women for colposcopy referral is unreliable.15,16 In 2009, 
when our trial was initiated, a PubMed search with the keywords “HPV”, 
“self-sampling”, and (“triage” or “methylation”) revealed no relevant studies 
about alternative triage markers that are directly applicable to self-sampled 
material. Tests to detect DNA methylation of promoter regions of (candidate) 
tumour suppressor genes have emerged as promising candidate triage tests 
that are feasible on self-sampled material.21,22,32 However, no prospective 
studies had been done that compared triage by direct methylation marker 
testing on self-samples with triage by cytology on an additional physician-
taken smear.
Interpretation
To our knowledge, this is the first randomised trial in non-attendees of 
screening that compared methylation marker analysis on self-sampled 
material with cytology as triage test for the detection of CIN2 or worse. We 
showed that direct triage by combined promoter methylation analysis of 
MAL and miR-124-2 genes on self-collected cervicovaginal material revealed 
a similar sensitivity for CIN2 or worse as cytology triage on an additional 
physician-taken smear. Women who received molecular triage showed a 
better compliance and shorter diagnostic track, at the cost of more colposcopy 
referrals. Therefore, molecular triage of HPV-positive women by MAL/miR-
124-2 methylation analysis on self-collected specimens opens the way to 
full molecular screening as a feasible alternative for cervical screening by a 
physician-taken sample.
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Appendix : Non-inferiority testing
The sample size of the study was set such that the power of a non-inferiority test 
was at least 80 percent. The study end-point was cervical intraepithelial neoplasia 
(CIN) grade 2 or worse (CIN2+).
The null and alternative hypothesis of the non-inferiority test (H0 and H1) were 
defined as
 Ho: sensitivity methylation test ≤ 0.8 × sensitivity cytology test,
 Ha: sensitivity methylation test > 0.8 × sensitivity cytology test.
The null hypothesis can be written as
  
sensitivity methylation test
 Ho:   ≤ 0.8 .
  
sensitivity cytology test
The relative sensitivity can be estimated by the proportion of women in the 
intervention group that present with a positive methylation test and CIN2+ divided 
by the proportion of women in the control group that present with positive cytology 
and CIN2+. Hence, a suitable test statistic is
where n1 and n2 are the number of women included in the methylation and cytology 
triage group, and x1 and x2 are the number of CIN2+ detected in the respective 
study groups after a positive triage test. Under Ho, T follows a standard normal 
distribution. Substituting x1 = 90, x2 = 75, n1 = 515, n2 = 509 gives T = 2.72.
Hence, the one-sided p-value is 0.0033.
The secondary end-point in the study is CIN3+ instead of CIN2+. Furthermore, a 
secondary threshold is 0.9 instead of 0.8. The threshold 0.9 in combination with 
end-point CIN2+ has been recommended for comparison of the sensitivities of 
different HPV DNA tests.1
For end-point CIN3+, T = 1.35, and the p-value is 0.088.
For end-point CIN2+ and threshold 0.9 instead of 0.8, T = 1.92, and the p-value is 
0.027.
Reference:
1. Meijer CJ, Berkhof J, Castle PE et al. Guidelines for human papillomavirus DNA test requirements 
for primary cervical cancer screening in women 30 years and older. International journal of cancer. 
2009;124:516-20.
√T= ,x1 (n1 - x1) / n13   + 0.82 x2 (n2 - x2) / n23
x1  / n1 - 0.8 x2 / n2
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General discussion 
Screening for HPV has proven to be an important step forward in improving cervical 
cancer prevention. Primary testing for hrHPV will be increasingly incorporated into 
national programs for cervical cancer screening on a worldwide level, starting with 
programs in The Netherlands and Australia in 2016. Apart from the sensitivity of 
the screening test, the success of prevention programs depends extensively on the 
participation rate and the reduction of unwanted side effects. This thesis shows that 
primary screening via hrHPV self-sampling increases participation and discusses 
possible solutions in reducing unwanted side effects of primary HPV screening. 
Although vaccination for HPV will soon be widespread, cervical cancer screening 
will remain an important topic in the coming years. This discussion focuses on the 
uncertainties, possible threats, and possible opportunities of primary HPV screening.
Improving screening participation: self-sampling for non-responders
Despite organized screening programs, half of the women with invasive cervical 
cancer have never been screened, or they have histories of inadequate screening.1-4 
The main barriers to attendance in the Dutch regular cervical screening program 
are practical or organizational, rather than emotional or other.5 Offering devices for 
self-collection of cervicovaginal specimens for HPV testing (HPV self-sampling) may 
overcome these barriers. The most important reasons for using the self-sampling 
device are being able to take a sample at a time of one’s own choosing, do it alone, 
and do it with less effort and in less time than having a physician take a smear.5 
Indeed, about one-third of the invited (primarily non-responding) women do respond 
when offered a self-sampling device.6-9 Furthermore, the yield of high-grade lesions 
was greater for non-responder women who participated in self-sampling than for 
compliant screening participants.6-9
In these studies, so far only direct mailing of a self-sampling device6,7 or an opt-
out invitation8,9 has been used to approach the women who had not yet attended 
cervical screening. With direct mailing, all women receive a self-sampling device 
along with the invitation. In an opt-out approach, it is assumed that the women will 
participate, but they are sent a pre-invitation that provides for opting out. If they do 
not opt out, they receive a self-sampling device at home. An opt-out approach can 
reduce waste and costs of unused devices compared with direct mailing.
Recently, the Dutch Minister of Health decided to introduce hrHPV testing of self-
sampled specimens in the regular population-based screening in 2016 for women who 
are reluctant to participate: the non-responders.10 The decision favors the strategy of 
an opt-in invitation to ensure the autonomy of these women. An opt-in approach 
requires women to actively order a self-sampling device, perhaps via a website or 
an e-mail request to the regional screening organization. A clear advantage of opting 
in is that the costs are lower than the costs of opting out or direct mailing. However, 
with the opt-in strategy, it is unclear what participation rates with self-sampling will 
| Chapter 9
C
H
A
P
T
E
R
.9
190
be achieved in the Dutch screening program since no population-based studies in 
the Netherlands have compared opting in with direct mailing or using an opt-out 
invitation. In an Italian study, an opt-in approach resulted in significantly lower 
participation rates than direct mailing (8.7% vs. 19.6%).11 It is likely that only women 
whose objections can be removed by self-sampling and who are otherwise motivated 
to attend screening will opt in for self-sampling. Additionally, opting in might be 
that extra organizational step that women neglect to take (organizational barriers 
being the main reason for non-attendance), which would minimize the effect of self-
sampling on the participation rate. In the high-risk population of non-responding 
women, opting in instead of opting out may result in less participation and therefore 
less health benefit. Consequently, more cases of high-grade cervical intra-epithelial 
lesions (CIN) and cervical cancer will remain undetected.
To conclude, self-sampling for hrHPV testing among current non-responders – to 
start in 2016, as the Minister decided – has the additional value of increasing the 
uptake in the screening program and has a significant health benefit in detecting 
high-grade CIN and cervical cancer. The chosen opt-in procedure may reduce 
costs and waste of unused self-sample packages and respects the autonomy of 
non-participating women. However, it can be expected that this approach will not 
increase the participation rates as much as direct mailing or an opt-out approach 
would, and as a consequence, fewer CIN and cervical cancer cases will be detected.
Improving screening participation: hard-to-reach populations
Although self-sampling increases participation and reaches an extra one-third 
of the original non-responders, there still remains a substantial group of women 
(two-thirds) who do not respond to either regular screening or self-sampling. The 
objections of this group of persistent non-responders are apparently of such a nature 
that they cannot be dispelled by the offer of a self-sampling device. Their reasons are 
probably emotional, ethical, cultural, religious, or on principle. However, hard-to-
reach subgroups are also hard to study. Chapter 3 shows that only 2.3% of the women 
who neither participate in the regular screening program nor in a self-sampling 
program are willing to fill in a questionnaire about why they do not participate in 
either program.5
It is generally known that special subgroups are hard to reach in the target 
population for screening. These subgroups include young women, women with a 
low social economic status, and immigrants.12,13 In addition, fewer immigrants than 
native Dutch non-responders come forward when they are offered a self-sampling 
device for HPV screening.14 In-depth studies are necessary to determine why these 
persistent non-responders do not participate and how the participation rates in these 
specific subgroups can be increased. 
Primary HPV screening: how to reduce false positives
HPV infections are common among sexually active women – about 4–5% in the 
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normal Dutch screening population. The presence of hrHPV is age dependent, and it 
decreases from approximately 12% at 30 years to 2.5% at 60 years.15-17 Women who 
do not respond to the regular screening program have a greater HPV prevalence, 
namely 8–10%, which is also age dependent.6-9 An HPV-positive woman has a low 
risk of developing precancer and cancer, since most HPV infections are transient; 
the prevalence of CIN 2–3 is less than 2% in the general population. In order to 
avoid unnecessary referrals of women with transient, clinically irrelevant hrHPV 
infections, an optimal hrHPV test should identify the hrHPV-positive women 
with cervical precancer or cancer and simultaneously minimize the detection of 
hrHPV infections not associated with cervical precancer and cancer. Therefore, 
it is important to use a clinically validated hrHPV test in primary screening. The 
requirements are described in guidelines on how to assess the performance of a new 
assay in the setting of cervical screening.18 For their use in nationwide screening 
programs, it is imperative that HPV assays have high throughput, have regular 
internal controls, and are applicable to self-collected samples. Furthermore, it is 
important that both the HPV assay and the self-sampling device be validated, not 
only individually, but also in a combined method. Especially PCR-based HPV tests 
with vaginal self-sampling devices showed a test accuracy similar to physician-taken 
samples in detecting CIN2+ lesions.19
Although well-balanced tests have been developed, HPV screening in general 
remains less specific than cytology screening and yields more false positives. This 
results in unnecessary referrals, and possibly in treatment of regressive lesions, and 
a higher number of repeat screening tests. This, in turn, may lead to unnecessary 
high costs, high levels of anxiety, and negative emotional responses from the referred 
women, all of which could be prevented.20-23 
One method for improving the overall specificity of HPV testing is to adjust the 
definition of a positive HPV test. Rebolj et al. report that raising the cut-off level of the 
viral load for a positive HPV test can increase the specificity and PPV with no loss, or 
only a small loss, in sensitivity. This controversial method seems reasonably safe; the 
high effectiveness in preventing cervical cancer could be attained, but the frequency 
of false-positive tests would be kept low.24
Another possible and more common way to further reduce the false positivity 
rate is to use a secondary test (i.e. a triage test) after an HPV-positive result, so that 
a decision can be made as to which HPV-positive women need to be referred for 
colposcopy. Due to the quite high specificity of cytology testing, the Dutch Minister of 
Health has proposed additional triage with cytology testing for the renewed screening 
program. However, although cytology testing is an appropriate triage tool for hrHPV-
positive women, it remains subjective and has a rather low reproducibility.
Knowledge about the molecular genesis of cervical precancer and cancer is 
expanding; therefore, in the near future, tests other than reflex cytology testing 
could also fulfill the role of an additional triage test for HPV-positive women. New 
molecular assays such as p16/Ki-67 have greater sensitivity than cytology testing, 
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and their specificities are comparable to that of cytology testing.25,26 The results of 
the p16/Ki-67 assay are promising. However, this assay is still sensitive to smear-
taking (sampling) errors and is dependent on subjective laboratory interpretation. 
Errors in laboratory reading could be partially reduced by automatic screening, 
which excludes normal parts of the slides from manual reading and selects only 
the abnormal cells for the cytotechnologist’s interpretation. Currently, studies are 
evaluating automatic screening for p16/Ki-67 dual staining.
It would be even better to entirely eradicate any subjectivity in test analysis, 
especially in the near future, when an increasing immunization rate will lower the 
PPV of the screening test and analysts will be less alert to finding abnormalities. This 
thesis describes several triage tests that are objective and more reproducible; they 
include HPV genotyping for HPV16 and HPV18, and promoter methylation analysis 
of tumor suppressor genes. The HPV types 16 and 18 are strongly associated with 
an increased risk of CIN2 lesions or worse. The advantage of HPV genotyping as a 
triage test is that it enables detection and monitoring of HPV-positive women with 
specific, persistent, oncogenic HPV.27 However, the best results have been reported 
for a combination of genotyping and cytology testing as a triage test; the single use 
of genotyping as triage test has not yet been proven feasible. The relative balance 
between benefit and harm of cytology testing versus HPV16/18 genotyping must be 
further determined.
Another strategy described in this thesis that may hold great promise as a 
triage test is the promoter methylation analysis of tumor suppressor genes. With 
DNA methylation analysis, early and advanced transforming CIN lesions can be 
distinguished on the basis of epigenetic changes.28 This method is completely 
objective, non-morphological, and molecular-based. Moreover, we have found 
that DNA methylation analysis as a triage test is just as reliable with self-collected 
specimens (both lavage based and brush based) as the cytology testing of physician-
collected samples (Chapters 7 and 8). Methylation triage analysis directly on self-
collected specimens makes an additional office visit to the physician unnecessary, 
which helps reduce loss to follow-up. At this moment, only a small set of panels of 
methylation markers have been validated in large population-based studies.8,29 More 
prospective studies are needed to indentify and validate the best genes and panels. 
These marker panels should be validated in large population-based screening studies 
to prove their clinical value. 
Other potential biomarkers that are on the horizon include microRNAs (miRNAs) 
and markers that are concerned with genetic events, such as aberrations involving 
chromosome 3. Binding to the miRNAs negatively regulates the gene expression and 
prevents its translation.30 Several studies have highlighted significant correlations 
between miRNA expression patterns in a number of tumors, including cervical 
tumors.31,32 Changes in expression also occur in early, precancerous lesions, and studies 
with miRNA expression in premalignant lesions are upcoming.33-35 Discrepancies 
have been found in the results of various studies. While miRNAs are interesting as 
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biomarkers for cervical cancer screening, it will be necessary to further validate and 
study these markers in multiple larger cohorts before miRNAs can be introduced 
into practice. Furthermore, amplification of important genes located in the region of 
chromosome 3, such as hTERC and/or polysomy of chromosome 3, has been detected. 
This may be an adjunct to cytology screening and HPV testing, since it can identify 
which low-grade squamous intraepithelial lesions (LSILs) and atypical squamous 
cells of undetermined significance (ASC-US) may give HPV-positive patients a risk of 
progressing to high-grade lesions and cancer. However, these tests have not yet been 
validated for clinical usage.36,37
All in all, several new markers for the expression levels of genes, proteins, and 
miRNAs, and markers that are concerned with epigenetic events (DNA methylation) 
and genetic events (amplifications, deletions, insertions, and translocations) are 
widely being studied at this moment. The advantage of such markers is that they 
should be detectable irrespective of the HPV type, potentially obviating the vagaries 
of shifting HPV prevalence in a post-vaccination era.38
In the near future, it is likely that a completely molecular-based, objective, and 
automated form of cervical cancer screening with primary HPV testing and new 
biomarkers as secondary tests will be implemented. More validation studies and 
large longitudinal studies with economic evaluations for various triage biomarker 
candidates should be conducted so that solid conclusions can be drawn with regard 
to the participation grades and clinical applicability of triage tests other than cytology 
testing as a secondary test. The results of such studies will be available within the 
next decade.
Primary HPV screening: loss to follow-up after negative triage
The inevitable triage test after primary HPV screening has another aspect that should 
be taken into account. As already mentioned, participation is vitally important for the 
effectiveness of a screening program. After the first difficulties in involving as many 
women as possible in the primary screening, participants may also be lost in the 
follow-up after triage. For the time being, HPV-positive samples will be triage tested 
with cytology screening. If the outcome of this triage test is negative (normal result), 
there is clearly a loss to follow-up. Adherence to follow-up after cytology screening 
has been reported at 57–75% in both a responder population (physician-taken 
samples) and a non-responder population (self-sampling).6-8,15,16 Women apparently 
feel protected and reassured by their negative triage result. Nonetheless, these HPV-
positive women are still at increased risk: there is a chance of 2–10% that they will 
develop CIN3 or worse before the next screening round. A more intensive follow-up 
with a shorter interval to rescreening is advisable for this group.39 
Basically, there are currently three options for management: (1) routine screening 
intervals, (2) more intensive follow-up with a shorter interval to rescreening, and (3) 
colposcopy with or without biopsy or treatment. The ideal situation would be one 
in which a follow-up test is rendered superfluous, thereby obliterating the problem 
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of loss to follow-up. In that scenario, we could screen one sample on which one or 
a combination of reliable triage tests can be performed, so that women who have 
cervical precancer or cancer will be distinguished from women who definitely have 
not. 
Currently, such an all-in-one test without any need for follow-up is not available. 
None of the currently available triage strategies is adequate for the safe referral of 
HPV-positive, triage test-negative women back to regular screening without some 
residual risk, however small. There is always a group of HPV–positive, triage test-
negative women who should be kept in follow-up. The currently available triage 
techniques only differ in the resulting proportion of this group. In the proposed 
screening starting from 2016, extra attention should be paid to ensuring that this 
group will not be lost to follow-up. This could be realized by adequate counseling, 
sending reminders, and keeping the participation barrier as low as possible by 
offering a follow-up test that is easy, accessible, and woman-friendly.
All in all, the best step forward is to strive for a screening situation in which a 
follow-up test can be abolished and women with a negative triage test result can 
safely be referred back to the regular screening program. 
HPV vaccination: cervical cancer screening in the (near) future
Two prophylactic vaccines against HPV are currently available, and their use has 
become an attractive strategy for preventing cervical cancer. The quadrivalent 
Gardasil (Sanofi Pasteur MSD) protects against infection by the low-risk genotypes 6 
and 11 and the high-risk genotypes 16 and 18. The bivalent Cervarix (GlaxoSmithKline) 
protects against infection by genotypes 16 and 18. HPV16/18 are considered to be 
responsible for approximately 70% of the cervical cancers worldwide.40 Results 
for both vaccines have shown remarkably good and similar efficacy, partial cross-
protection against some non-vaccine types, and excellent safety and immunogenicity 
profiles.41,42 However, the duration of protection and the adverse effects for a period 
longer than 9 years have not yet been established. The planned long-term follow-
up of vaccinated cohorts should provide more information about these aspects 
of vaccination. Currently, the efficacy of a second-generation HPV prophylactic 
vaccine against nine HPV subtypes is being studied in phase III studies. This 9-valent 
(nonavalent) vaccine contains the subtypes available in the current quadrivalent 
vaccine (low-risk types 6/11, and high-risk types 16/18) and additionally the high-risk 
HPV types 31/33/45/52/58. This nonavalent vaccine could prevent almost 90% of the 
invasive cervical cancer cases worldwide.43,44 If the nonavalent vaccine achieves the 
same degree of efficacy as previous vaccines, it might be able to minimize world 
incidence rates of cervical cancer in vaccinated women.44 
The first Dutch women vaccinated with the bivalent vaccine will enter the 
cervical cancer screening program in the Netherlands in 2023.45 Screening remains 
important to prevent these vaccinated women from developing cervical cancer 
caused by types other than the HPV16/18 high-risk types and to ensure prevention 
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for non-vaccinated women. Concerns have been raised about a potential decrease 
in screening participation among vaccinated women. Such a possibly reluctant 
population is the very population for which an easily accessible, low-effort, and 
objection-free screening method is needed to ensure that women continue to attend 
screening. Self-testing is such a method. It is important that these vaccinated women 
understand their need to comply with screening after vaccination and to continue 
protecting themselves against sexually transmitted infections. This applies to 
vaccinated individuals; however, there are also additional benefits at the population 
level.
In the current, early years of HPV vaccination, the vaccines in use do not contain 
all the HPV types, and vaccination rates are still relatively low (about 60% in 2013). 
Over time, the vaccination of successive cohorts of girls will continually reduce 
the average lifetime risk of developing invasive cervical cancer in the population, 
and as a result, existing screening practices will eventually become less and less 
cost-effective.42 Screening will have to be continually adjusted to the then current 
situation. To that end, it will be important that immunization records are linked to 
the screening program so that it is certain who is protected and who is not.46 The 
goal in future screening is to achieve synergy between vaccination at a young age 
and an individual-based screening program at an older age. Such a program is easily 
accessible, the costs are relatively low, and it provides the optimal benefit for both 
the vaccinated and the non-vaccinated women. Women vaccinated with a bi- or 
quadrivalent vaccine might then be given another screening algorithm, possibly 
to be used only two or three times in their lives. Especially when new-generation 
vaccines that protect against nine (or more) types of hrHPV become available, the 
subject of whether vaccinated women need screening at all can be revisited.
Regardless of how comprehensive the vaccination program becomes in the 
future, it will never completely obviate the need for secondary screening. Even with 
the availability of several easy-access screening tools, including HPV vaccination 
and screening with self-sampling devices, there will still be women who decide 
not to participate in any form of cervical cancer prevention. These women remain 
the Achilles’ heel in the effectiveness of the future screening programs. National 
screening organizations and governments should therefore continue their efforts to 
provide an organized and high-quality, population-based, screening program that 
will continue to pursue high coverage with adequate treatment and follow-up of any 
detected precancer and cancer. 
Future perspectives
Cervical cancer prevention has come to a turning point in our times. The near future 
will bring a rapid transition to entirely HPV-focused screening. The two central 
pillars in this transition will be the widespread implementation of HPV vaccination 
programs to prevent HPV infections (primary prevention), and the use of HPV 
screening to detect precancerous and cancerous lesions (secondary prevention) that 
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will include an important role for HPV self-sampling. 
It has been shown that offering HPV self-sampling increases participation rates 
among non-responders to the regular screening. It is likely that HPV self-sampling 
will soon become the primary screening tool for the entire population. Women will 
ideally receive a self-sampling device at home, use it, and return it for HPV testing. 
Alternatively, it might become possible to buy a self-test that is easy to use and 
from which the result can be read, once the test has been completed. This might 
be comparable to the current pregnancy tests, for example. Only HPV-positive 
women may need additional follow-up with a more robust test such as a physician-
taken sample. The advantages would be a reduction of anxiety and a reduction of 
laboratory work and thus costs. One disadvantage would be the extra step required 
in the case of a positive test result. Another disadvantage is that the availability 
of such a do-it-yourself test would make it more difficult to maintain high-quality 
screening registries, while monitoring the vaccination grade and virus mobility will 
remain two of the objectives of future screening.
When the self-sample reaches the laboratory, it will be tested for HPV and then, 
if necessary, the same sample will be triage tested with a fully automated, objective, 
and very specific test. However, before such an efficient, low-cost, and woman-
friendly scenario can be realized, several hurdles need to be taken. 
In the Netherlands, self-sampling will be offered to non-responders from 2016 
onward. This may lead to a reduction in overall screening attendance in the first 
years after the introduction of the renewed HPV screening program. It is to be 
expected that women invited for regular screening will ignore the invitation and 
wait for a chance to opt in for self-sampling. This “substitution” can be expected 
in an evaluation some time (possibly 2 years) after starting the new HPV screening 
program. Self-sampling has proven to increase participation among non-responders, 
but it has never been assessed in a normal responder population. We need head-on 
comparisons between physician-sampling and self-sampling for HPV screening to 
assess the impact on participation, as well as the cost-effectiveness and accuracy of 
both methods. An intermediate step might be that all women are offered the choice 
between physician-sampling and self-sampling. 
An advantage of a self-sample screening program is the circumvention of the 
physician, which reduces practical, organizational, and probably also emotional 
barriers, as well as costs. In a self-sample program with direct triage, the physician 
may only have a role in informing and reassuring women in cases such as an 
abnormal result or the like, and possibly also in motivating women to participate. A 
point of concern may be that in an HPV screening program, the causal relationship 
between sexual intercourse, HPV infection, and cervical cancer is more prominent 
than in a cytologic screening program. The invited women should receive extensive 
health education to inform them and to destigmatize HPV as a sexually transmitted 
infection in order to ensure participation and to minimize any negative impact of a 
positive test result on the women’s well-being.
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Surely there will be difficulties in switching over to new screening methods 
in which HPV vaccination, HPV testing with triage testing, and self-sampling play 
an important role. However, for both primary and secondary screening, it is a 
step forward to further prevent the incidence of cervical cancer and to reduce the 
occurrence of cancer deaths.
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Summary
Cervical cancer is the fourth most common cancer and the fourth leading cause 
of cancer death among women worldwide. It is a significant health care problem, 
particularly in the developing countries. Since the introduction of cytological 
screening for cervical cancer in many developed countries, the incidence and 
mortality rate of cervical cancer have markedly diminished. Although the Netherlands 
has a well-organized program for cervical cancer screening, there are ways in which 
cervical cancer prevention can be improved to further reduce the numbers of newly 
diagnosed cases (700 per year) and deaths due to cervical cancer (200–250 per year). 
Recently, the Dutch Minister of Health decided to reshape the Dutch screening 
program for cervical cancer. Testing for high-risk human papillomavirus (hrHPV) 
on a physician-taken smear will replace cytology testing as the primary screening 
method in 2016. Non-responders (women who do not attend cervical screening) 
will have the opportunity to opt for self-sampling for HPV in this new screening 
programme. 
A brief outline of the considerations that led to the implementation of primary 
HPV screening for cervical cancer is given in Chapter 1. Here we also address 
opportunities for the further improvement of prevention of cervical cancer by HPV 
screening, which is the main objective of the research described in this thesis. We 
introduce in this first chapter the research aims of this thesis.
In Chapter 2 we present a thorough overview of the efficacy of the current cervical 
cancer screening, of promising future screening strategies with primary HPV testing 
and of additional triage strategies for HPV-positive screening results. 
Participation is the most important factor in the success of a screening program. 
Increasing the participation rate is the simplest and best way of improving the 
screening effectiveness. In this chapter, we show that participation rates highly 
differ between countries. This depends partly on the organization of screening 
(opportunistic vs organized). We give an overview of reasons for non-participation 
mentioned and suggestions how to increase participation. 
A second important factor in the success of a screening program, mentioned 
in this chapter, is the accuracy of the primary screening test. Cytology screening 
has dramatically reduced cervical cancer mortality in most high-income settings. 
However, the test performance (sensitivity, specificity, and positive predictive 
value) could be improved. In this chapter an overview is given of the advantages 
of HPV testing compared with cytology testing. HPV testing is less specific but much 
more sensitive in detecting high-grade precancerous lesions. Another advantage of 
HPV testing is the objectivity of the test, and its reproducibility in comparison with 
cytology. As a triage test for HPV positive cases, cytology is expected to perform with 
sufficient accuracy. This approach and much other promising triage techniques are 
mentioned in this chapter. 
| Chapter 10
C
H
A
P
T
E
R
.1
0
206
In the last part of this chapter, HPV self-sampling is addressed. Offering HPV 
self-sampling to non-responders increases participation rates. Finally, HPV positive 
self-sampled material needs additional triage, either directly on self-sampled 
cervicovaginal specimens or on additional physician-collected cervical samples. In 
this chapter we discuss several promising future techniques for direct molecular 
testing on self-sampled material. 
Chapter 3 describes a questionnaire study on reasons why non-responders do not 
attend regular screening, and why they do or do not participate when offered a 
self-sampling device. As part of the PROHTECT (PRotection by Offering HPV TEsting 
on Cervicovaginal specimens Trial) 3B study, a total of 30,130 women received a 
questionnaire and self-sampling device. The analysis in this study was based on 
9484 returned questionnaires (31.5%) with a self-sample specimen, and 682 (2.3%) 
without. Among women who returned both, the main reason for non-attendance to 
cervical screening was that they forgot to schedule an appointment (3068; 32.3%). 
The most important reason to use the self-sampling device was the opportunity to 
take a sample in their own time-setting (4763; 50.2%). A total of 30.9% of the women 
who did not use the self-sampling device, preferred after all to have a cervical 
smear taken instead. This chapter shows that organizational barriers are the main 
reason for non-attendance in regular cervical screening. Important reasons for non-
responders to the regular screening to use a self-sampling device are convenience 
and self-control.
In Chapter 4 we investigated a new cervicovaginal self-sampling device: the Evalyn 
Brush. The aims of this study were to investigate agreement of HPV detection by 
two HPV tests between the Evalyn Brush and physician-obtained samples, and to 
study women’s acceptance of this self-sampling device. Each of 134 women visiting 
the gynecology outpatient clinic collected a self-obtained sample and completed a 
questionnaire. After self-sampling, a trained physician obtained a conventional 
cervical cytology specimen in ThinPrep medium. HPV detection was performed 
using the SPF10-DEIA-LiPA25 and GP5+/6+-LQ-test. The overall agreement for HPV 
detection using SPF10-DEIA-LiPA25 between the self-sample and the physician-taken 
sample was 85.8% (kappa value, 0.715; 95% confidence interval (CI), 0.597 to 0.843; 
p=1.000). The overall agreement for hrHPV detection using GP5+/6+-LQ between the 
self-sample and the physician-taken sample was 86.6% (kappa value, 0.725; 95% CI, 
0.607 to 0.843; p=0.815). Ninety-eight percent of the women rated their experience as 
good to excellent. Moreover, 95% of the women preferred self-sampling to physician 
sampling. From this study is concluded that self-sampling using the Evalyn Brush 
system is as good as a physician-taken sample for HPV detection and is highly 
acceptable to women. 
 
In Chapter 5 we describe the findings of the PROHTECT 3B study. In this study a 
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cervicovaginal lavage-based HPV self-sampling device (Delphi Screener) is compared 
with a brush-based device, which is validated in Chapter 4 (Evalyn Brush). The 
aims of this study were to determine, whether the participation rate for a brush-
based cervicovaginal self-sampling device is non-inferior to the participation rate 
for a lavage-based one. Additionally, the efficacy of the clinical performance and 
the acceptability of both self-sampling methods were determined. A total of 35,477 
non-responders to the regular cervical screening programme aged 33-63 years were 
invited to participate. Eligible women (n=30,130) were randomly assigned to receive 
either a brush-based or a lavage-based device, and all received a questionnaire for 
reporting user convenience. Self-sampling responders testing HPV-positive were 
invited for a physician-taken sample for cytology; triage-positive women were 
referred for colposcopy. A total of 5218 women participated in the brush-based 
sampling group (34.6%) and 4809 women in the lavage-based group (31.9%), i.e. 
an absolute difference of 2.7% (95%CI 1.8–4.2). The HPV-positivity rates in the two 
groups were identical (8.3%, relative risk (RR) 0.99, 95%CI 0.87–1.13). The detection 
of cervical intraepithelial neoplasia grade 2 or worse and grade 3 or worse in the 
brush group (2.0% for CIN2 or worse; 1.3% for CIN3 or worse) was similar to that in 
the lavage group (1.9% for CIN2 or worse; 1.0% for CIN3 or worse) with a cumulative 
RR of 1.01, 95%CI 0.83–1.24 for CIN2 or worse and 1.25, 95%CI 0.92–1.70 for CIN3 
or worse. The two self-sampling devices performed similarly in user comfort. From 
this study, it is concluded that offering a brush-based device to non-responders is 
non-inferior to offering a lavage-based device in terms of participation. The two self-
sampling methods are equally effective in detecting hrHPV, CIN2 or worse and CIN3 
or worse, and are both well accepted.
Primary HPV testing in cervical cancer screening shows relatively low specificity. 
Triage testing is necessary to prevent high referral rates and overtreatment of HPV 
positive women. Cytology is a widely used method of triaging women who test 
positive for HPV. However, specimens taken by self-sampling – which can, as shown 
in previous chapters, substantially increase participation in screening programmes 
– are not suitable for accurate cytological assessment. Therefore, either an additional 
physician-taken smear is needed for cytological or other triage testing, or new ways 
of triage testing should be developed which apply directly on the self-sampled HPV 
positive specimens.
Chapter 6 presents the results of a study in which we compared the clinical value of 
HPV genotyping with the current, accepted triage strategy, cytology testing as a triage 
test for hrHPV-positive women. A total of 520 hrHPV-positive women were included 
from the randomized controlled self-sampling trial (PROHTECT 3B; 33-63 years). 
Eighteen baseline triage strategies were evaluated for cytology and HPV genotyping 
(Roche Cobas 4800 system) on physician-sampled triage material. Cytology with an 
atypical squamous cells of undetermined significance (ASC-US) threshold was used 
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as reference strategy. The sensitivity, specificity, positive predictive value (PPV), 
negative predictive value (NPV), referral rate, and number of referrals needed to 
diagnose (NRND) were calculated for CIN2+ and CIN3+ as outcome measure. A triage 
strategy was considered as feasible, as it met the NPV criterion of at least 98%, had 
similar sensitivity, and significantly better specificity and PPV for CIN3+ than the 
reference triage strategy. Three triage strategies met the criteria: HPV16+ or low-
grade squamous intraepithelial lesions or worse (≥LSIL); HPV16+ or high-grade 
squamous intraepithelial lesion  or worse (≥HSIL); (HPV16+ and/or HPV18+) or 
≥HSIL. Combining HPV16+ and ≥HSIL cytology testing gave the highest specificity 
(74.9%, 95% CI 70.5–78.9) with a sensitivity (94.4%, 95% CI 89.0–97.7) similar to that 
of the reference strategy (93.5%, 95% CI 87.7–97.1). Of these strategies, HPV16+ with 
≥HSIL cytology testing had the lowest colposcopy referral rate (39.5%) compared with 
that of the reference strategy (52.2%). In conclusion, our study shows that triage by 
cytology testing can be improved by combining it with HPV genotyping. The addition 
of HPV16 and/or 18 genotyping and raising the threshold of cervical cytology testing 
from ASC-US or worse to ≥LSIL or ≥HSIL improves the referral rate and the specificity 
for detecting CIN3+ lesions while maintaining adequate sensitivity.
In Chapter 7, DNA methylation analysis on an additional physician-taken smear was 
compared with cytology on an additional physician-taken smear for triage testing 
in HPV positive women. Moreover, feasibility of DNA methylation analysis directly 
on brush-based self-sampled specimens was assessed. Non-responding women from 
population-based screening were invited to self-collect a cervicovaginal specimen 
for HPV testing; HPV positive women were referred to a physician for an additional 
physician-taken triage smear. DNA methylation analysis was performed on 128 
HPV positive triage samples and 50 matched Evalyn Brush self-samples with QMSP 
for C13ORF18, EPB41L3, JAM3 and TERT. In physician-taken triage material, DNA 
methylation analysis of JAM3 showed the highest specificity (88%) combined with 
high sensitivity (82%) for detection of CIN3 or worse, whereas cytology showed 
a specificity of 48% and a sensitivity of 91%. Out of 39 women with abnormal 
cytology and normal histology (false-positive by cytology), 87% were negative for 
JAM3 and 90% for C13ORF18 methylation. Agreement between DNA methylation 
analysis performed directly on the matched self-sampled material and physician-
taken samples was 88% for JAM3 (kappa value, 0.75, p<0.001) and 90% for C13ORF18 
(kappa value, 0.77; p<0.001). We concluded  that DNA methylation analysis as a triage 
test in HPV positive women outperformed cytology due to higher specificity without 
losing sensitivity. Furthermore, it shows that DNA methylation is feasible directly 
on brush-based self-sample material and shows high correlation with matched 
physician-taken samples. 
In Chapter 8 we studied whether direct DNA methylation-based molecular triage 
on self-sampled cervicovaginal specimens was non-inferior to cytology triage on 
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additional physician-collected cervical samples in the detection of CIN2 or worse. 
This study shows the results of a large randomized controlled non-inferiority trial 
in women who did not attend cervical screening programmes. A total of 46,001 
women (aged 33–63 years) registered as non-attendees of cervical screening in the 
Netherlands in 2007 were invited to submit a self-collected cervicovaginal sample 
for HPV testing. 12,819 of these women returned self-sampled material. A total of 
1038 women who tested positive for high-risk HPV on a self-sample were randomly 
allocated to either triage by cytology on an additional physician-taken smear or 
direct triage on the self-sample by methylation analysis of MAL and miR-124-2 genes. 
Triage-positive women in either group were referred for colposcopy. The primary 
endpoint was detection of CIN2 or worse and the study is analyzed by intention 
to treat. The non-inferiority margin was 0.80. The detection of CIN2 or worse with 
methylation triage was non-inferior to that with cytology triage (90 (17%) of 515 
women vs 75 (15%) of 509 women; relative risk 1.19, 95% CI 0.90–1.57). Referral 
for colposcopy was more common in the molecular group (284 (55%) women) than 
in the cytology group (149 (29%) women; p<0.0001). Mean time to CIN2 or worse 
diagnosis was shorter in the molecular triage group (96 days, range 44–101) than 
in the cytology triage group (158 days, 71–222; p=0.00084). We concluded that DNA 
methylation analysis of MAL and miR-124-2 genes on HPV-test-positive self-samples 
is non-inferior to cytology triage in the detection of CIN2 or worse. The results of this 
study open the way to full molecular screening.
Primary HPV screening, with an additional role for HPV self-sampling, together with 
HPV vaccination will have a considerable impact on future cervical cancer screening. 
Chapter 9, the general discussion, focuses on the uncertainties, possible threats, 
and possible opportunities for future screening. Because of the rapid technological 
innovations and new discoveries, the evidence base in the area of cervical cancer 
prevention remains subject to change. Therefore, screening guidelines need to be 
regularly re-evaluated and readjusted.
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Samenvatting
Wereldwijd vormt baarmoederhalskanker een substantieel gezondheidsprobleem, 
vooral in ontwikkelingslanden. Slechts drie soorten kanker komen vaker voor bij 
vrouwen en er zijn maar drie waaraan vrouwen vaker overlijden. Sinds de introductie 
van cytologische screening op baarmoederhalskanker in veel westerse landen zijn 
de incidentie en de sterfte aanmerkelijk afgenomen. Hoewel Nederland een goed 
screeningsprogramma op baarmoederhalskanker kent, zijn er nog mogelijkheden 
om de preventie te verbeteren om zo het aantal nieuwe diagnoses (700 per jaar) en 
sterftegevallen (200-250 per jaar) verder te verminderen. Recent heeft de Minister 
van Volksgezondheid besloten tot een herstructurering van het Nederlandse 
bevolkingsonderzoek op baarmoederhalskanker. Vanaf 2016 zal het bij de huisarts 
afgenomen uitstrijkje niet meer primair op cytologie (onderzoek naar losse cellen) 
getest worden, maar in plaats daarvan op de aanwezigheid van hoog-risicotypes van 
het humaan papillomavirus (hrHPV). Non-responders (vrouwen die niet gereageerd 
hebben op de herhaalde uitnodiging voor screeningsdeelname) zullen in dit nieuwe 
bevolkingsonderzoek de mogelijkheid krijgen om een HPV-zelfafnameset aan te 
vragen.
Een beknopt overzicht van de overwegingen die geleid hebben tot de invoering van 
primaire HPV-screening voor baarmoederhalskanker is te lezen in Hoofdstuk 1. Hier 
gaan we ook in op de mogelijkheden voor verdere verbetering van HPV-screening 
– de centrale doelstelling van het onderzoek dat in dit proefschrift gepresenteerd 
wordt. De onderzoeksdeelvragen in dit proefschrift worden in dit eerste hoofdstuk 
geïntroduceerd.
Hoofdstuk 2 biedt een grondig overzicht van de effectiviteit van het huidige 
bevolkingsonderzoek op baarmoederhalskanker, van veelbelovende primaire HPV-
screeningsstrategieën voor de toekomst en van verschillende triagestrategieën na 
een HPV-positief screeningsresultaat.
Deelname is de belangrijkste factor voor het welslagen van een 
screeningsprogramma. Het verhogen van de deelnamegraad is de meest eenvoudige 
en doeltreffende manier om de effectiviteit van de screening te verbeteren. In 
dit hoofdstuk laten wij zien dat de deelnamegraad van land tot land verschilt. De 
deelnamegraad is deels afhankelijk van de organisatievorm van de screening 
(opportunistisch of  georganiseerd). Wij geven een overzicht van de redenen van 
vrouwen om niet deel te nemen – genoemd in de literatuur –, en doen suggesties 
hoe de deelnamegraad verhoogd kan worden. Een tweede belangrijke factor voor 
het succes van een screeningsprogramma is de nauwkeurigheid van de primaire 
screeningstest. Screening door middel van cytologie heeft het sterftecijfer voor 
baarmoederhalskanker in de meeste welvarende landen significant verminderd. 
Desalniettemin kan de kwaliteit van de test (sensitiviteit, specificiteit en positieve 
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voorspellende waarde) verbeterd worden. Dit hoofdstuk geeft een overzicht van de 
voordelen van testen op HPV in vergelijking met cytologie. Een HPV-test is minder 
specifiek, maar veel sensitiever in het opsporen van hooggradige voorstadia van 
kanker. Een ander voordeel van testen op HPV is de objectiviteit van de test en 
de reproduceerbaarheid vergeleken met cytologie. Cytologie heeft wel bewezen 
secundair als triagetest voor HPV-positieve gevallen voldoende accuraat te zijn. Deze 
benadering en vele andere veelbelovende triagetechnieken op materiaal afgenomen 
door een arts worden besproken in dit hoofdstuk.
In het laatste deel van dit hoofdstuk komt de HPV-zelfafnameset aan de orde. 
Het aanbieden van een HPV-zelfafnameset aan non-responders verhoogt de 
deelnamegraad. Uiteindelijk is er bij een HPV-positieve uitslag van zelf afgenomen 
materiaal nog triage nodig, ofwel direct op het reeds zelf afgenomen materiaal, ofwel 
op een extra uitstrijkje dat hiervoor alsnog afgenomen moet worden bij de huisarts. 
In dit hoofdstuk bespreken wij verscheidene technieken die ontwikkeld worden voor 
het direct moleculair testen van het zelf afgenomen materiaal.
Hoofdstuk 3 beschrijft een vragenlijst-studie naar de redenen waarom non-
responders niet deelnemen aan de reguliere screening en waarom zij wel of 
niet deelnemen wanneer aan hen een zelfafnameset wordt aangeboden. In het 
kader van de PROHTECT (PRotection by Offering HPV TEsting on Cervicovaginal 
specimens Trial) 3B studie ontvingen in totaal 30.130 vrouwen een vragenlijst en 
een zelfafnameset. De analyse in deze studie is gebaseerd op 9.484 geretourneerde 
vragenlijsten mét geretourneerd zelf afgenomen materiaal (31,5%), en 682 zonder 
zelf afgenomen materiaal (2,3%). Onder de vrouwen die beiden terugstuurden, was 
de voornaamste reden om niet deel te nemen aan de reguliere screening dat zij 
vergeten waren een afspraak te maken (3.068; 32,3%). De belangrijkste reden om 
een zelfafnameset te gebruiken was de gelegenheid om de test op een door henzelf 
gekozen moment te doen (4.763; 50,2%). Van de vrouwen die de zelfafnameset niet 
gebruikten, gaf 30,9% er de voorkeur aan om alsnog een uitstrijkje te laten maken. Uit 
dit hoofdstuk wordt duidelijk dat organisatorische bezwaren de voornaamste reden 
vormen waarom vrouwen niet deelnemen aan het reguliere bevolkingsonderzoek. 
Belangrijke redenen voor non-responders om wel de zelfafnameset te gebruiken zijn 
gemak en het feit dat ze alles rondom de afname in eigen hand kunnen houden.
In Hoofdstuk 4 hebben wij een nieuwe zelfafnameset onderzocht: de Evalyn Brush. 
Doel van deze studie was het onderzoeken van de overeenkomst in HPV-detectie 
tussen de Evalyn Brush en uitstrijkjes gemaakt bij de huisarts. Ook onderzochten wij 
de acceptatie van deze zelfafnameset onder de deelnemende vrouwen. Elk van de 134 
deelnemende vrouwen die de polikliniek gynaecologie bezochten, nam zelf materiaal 
af door middel van de zelfafnameset en vulde een vragenlijst in. Na de zelfafname 
nam een arts een regulier uitstrijkje af dat geconserveerd werd in ThinPrep medium. 
De HPV-detectie werd uitgevoerd door middel van twee HPV-testmethodes, de SPF10-
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DEIA-LiPA25 en de GP5+/6+-LQ-test. De overeenkomst in hrHPV-detectie met SPF10-
DEIA-LiPA25 tussen het zelf afgenomen materiaal en het door de arts afgenomen 
uitstrijkje was 85.8% (kappa-waarde, 0.715; 95%-betrouwbaarheidsinterval (95%-
BI), 0.597 tot 0.843; p=1.000). De overeenkomst in hrHPV-detectie met de GP5+/6+-LQ-
test tussen het zelf afgenomen materiaal en het door de arts afgenomen uitstrijkje 
was 86.6% (kappa-waarde, 0.725; 95%-BI, 0.607 tot 0.843; p=0.815). Achtennegentig 
procent van de vrouwen beoordeelden hun ervaring met de zelfafnameset als goed 
tot uitstekend. Bovendien gaf 95% van de vrouwen de voorkeur aan zelfafname 
boven een uitstrijkje gemaakt door een arts. Uit deze studie concludeerden wij dat 
zelfafname met gebruik van de Evalyn Brush even goed is als een uitstrijkje gemaakt 
door een arts wat betreft de HPV-detectie en zeer acceptabel is voor vrouwen.
In Hoofdstuk 5 beschrijven wij de bevindingen van de PROHTECT 3B studie. 
In deze studie is een lavagemethode (Delphi Screener) vergeleken met een 
brushmethode (Evalyn Brush, gevalideerd in Hoofdstuk 4) voor het zelf afnemen 
van cervicovaginaal materiaal. Het doel van de studie was om te bepalen of de 
participatiegraad bij brushmethode non-inferieur is aan de participatiegraad 
bij de lavagemethode. Daarnaast werden ook de klinische prestaties van beide 
zelfafnamemethodes vastgesteld, evenals de acceptatie. In totaal werden 35.477 
vrouwen, allen non-responders van het reguliere bevolkingsonderzoek en 33-63 jaar 
oud, uitgenodigd voor deelname. De 30.130 vrouwen die zich beschikbaar stelden, 
ontvingen na randomisatie ofwel een Delphi Screener, ofwel een Evalyn Brush. 
Tevens ontving iedere vrouw een vragenlijst waarop zij het gebruikersgemak van de 
betreffende zelfafnameset kon beoordelen. Deelneemsters die HPV-positief testten 
werden uitgenodigd om door een arts een uitstrijkje te laten maken, dat cytologisch 
beoordeeld werd; triage-positieve vrouwen werden verwezen voor colposcopie. In 
totaal namen uit de brushgroep 5.218 vrouwen deel (34,6%) en uit de lavagegroep 
4.809 vrouwen (31,9%), dat is een absoluut verschil van 2,7% (95%-BI 1,8–4,2). Het 
aantal HPV-positieve uitslagen was gelijk in beide groepen (8,3%, relatief risico (RR) 
0,99, 95%-BI 0,87–1,13). De detectie van cervicale intraepitheliale neoplasie (CIN) 
graad 2 of hoger en graad 3 of hoger was in de brushgroep (2,0% voor CIN2 of hoger; 
1,3% voor CIN3 of hoger) gelijk aan dat in de lavagegroep (1,9% voor CIN2 of hoger; 
1,0% voor CIN3 of hoger) met een cumulatief RR van 1,01, 95%-BI 0,83–1,24 voor 
CIN2 of hoger en 1,25, 95%-BI 0,92–1,70 voor CIN3 of hoger. De twee zelfafnamesets 
presteerden even goed op gebruikersgemak. Uit deze studie trekken wij de conclusie 
dat het aanbieden van een brushmethode aan oorspronkelijke non-responders non-
inferieur is aan het aanbieden van een lavagemethode wat betreft de deelnamegraad. 
De twee zelfafnamemethoden zijn even effectief in het detecteren van hrHPV, CIN2 
of hoger en CIN3 of hoger, en zijn beide zeer geaccepteerd.
Primair testen op HPV in het bevolkingsonderzoek baarmoederhalskanker 
heeft een relatief lage specificiteit. Er is een triagetest nodig om hoge aantallen 
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verwijzingen en overbehandeling van HPV-positieve vrouwen te voorkomen. 
Cytologie is een veelgebruikte triagemethode na een positieve HPV-test. Echter, 
materiaal afgenomen met een HPV-zelfafnameset is niet geschikt voor betrouwbare 
cytologische beoordeling. Daarom is 1) alsnog een door een arts afgenomen 
uitstrijkje nodig waarop cytologie of een andere triagetest uitgevoerd kan worden, 
of 2) een triagemethode nodig die direct op het zelf afgenomen materiaal toegepast 
kan worden.
Hoofdstuk 6 presenteert de resultaten van een studie waarin wij de klinische waarde 
van HPV-genotypering als triagetest voor hrHPV-positieve vrouwen vergeleken 
hebben met cytologie met als drempelwaarde ASC-US (Atypical Squamous Cells of 
Undetermined Significance). Voor deze studie includeerden wij 520 vrouwen met 
een positieve HPV uitslag vastgesteld in het zelf afgenomen materiaal. Deze vrouwen 
werden doorverwezen naar een arts om een extra triage-uitstrijkje te laten maken. 
Achttien strategieën werden toegepast op dit triagemateriaal en geëvalueerd. 
Het triagemateriaal werd geanalyseerd met cytologie en met HPV-genotypering 
(Roche Cobas 4800 systeem). De sensitiviteit, specificiteit, positieve en negatieve 
voorspellende waarde (PVW en NVW), het percentage verwijzingen en het aantal 
doorverwezen vrouwen die gediagnosticeerd moesten worden (NRND) werden 
berekend voor CIN2 of hoger en CIN3 of hoger. Vier triagestrategieën kwamen 
overeen met het NVW-criterium van 98% of hoger, hadden een vergelijkbare 
sensitiviteit en een significant betere specificiteit en PVW voor CIN3 of hoger dan de 
controle-triagemethode (cytologie, ASC-US of hoger). Deze vier methoden bestonden 
allen uit een combinatie van HPV-genotypering en cytologie: HPV16+ of ≥Low-
grade Squamous Intraepithelial Lesion (LSIL); HPV16+ of ≥High-grade Squamous 
Intraepithelial Lesion (HSIL); (HPV16+ of 18+) of ≥LSIL; (HPV16+ of 18+) of ≥HSIL. Met 
de gecombineerde uitslag HPV16+ met een cytologische uitslag die groter of gelijk 
was aan HSIL werd de hoogste specificiteit verkregen (74,9%, 95%-BI 70,5-78,9), met 
een vergelijkbare sensitiviteit (94,4%, 95%-BI 89,0-97,7) als de controlestrategie (ASC-
US of hoger). Van deze vier strategieën had HPV16+ met een cytologische uitslag die 
groter of gelijk was aan HSIL het laagste verwijzingspercentage voor colposcopie 
(39,5%) vergeleken met de controlestrategie (52,2%). Al met al toont onze studie 
aan dat een combinatie van HPV-genotypering met cervixcytologie, waarbij de 
drempelwaarde is verhoogd, de voorkeur zou kunnen hebben boven triage door 
enkel cytologie met ASC-US als drempelwaarde.
In Hoofdstuk 7 is DNA-methylatie-analyse op een extra uitstrijkje vergeleken met 
cytologie op een extra uitstrijkje als triagetest voor hrHPV-positieve vrouwen. 
Bovendien is onderzocht of DNA-methylatie-analyse direct toepasbaar is op 
zelf afgenomen materiaal met een brush. Non-responders van het reguliere 
bevolkingsonderzoek baarmoederhalskanker werden uitgenodigd om een HPV-
zelfafnameset (Evalyn Brush) te gebruiken; HPV-positieve vrouwen werden verwezen 
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naar een (huis)arts voor een extra triage-uitstrijkje. DNA-methylatie-analyse met 
QMSP voor C13ORF18, EPB41L3, JAM3 en TERT werd uitgevoerd op materiaal van 
128 hrHPV-positieve vrouwen en op materiaal van 50 bijbehorende zelfafnamesets. 
In het door de arts uitgestreken triagemateriaal leverde DNA-methylatie-analyse met 
JAM3 de hoogste specificiteit (88%) op gecombineerd met een hoge sensitiviteit (82%) 
voor de detectie van CIN3 of hoger, terwijl cytologische analyse een specificiteit van 
48% en een sensitiviteit van 91% opleverde. Van de 39 vrouwen met abnormale 
cytologische uitslag en een normale histologische uitslag (vals-positief door cytologie) 
was 87% negatief voor JAM3 en 90% voor C13ORF18. De overeenkomst tussen DNA-
methylatie-analyse op de door de arts gemaakte uitstrijkjes en het bijpassende 
materiaal van de zelfafnameset was 88% voor JAM3 (kappa-waarde, 0,75; p<0,001) 
en 90% voor C13ORF18 (kappa-waarde, 0,77; p<0,001). Wij concluderen hieruit dat 
DNA-methylatie-analyse als triagetest voor hrHPV-positieve vrouwen beter presteert 
dan cytologie, vanwege de hogere specificiteit zonder verlies van sensitiviteit. 
Verder toont deze studie aan dat DNA-methylatie-analyse direct toepasbaar is op 
zelf afgenomen materiaal met een brush. Deze zelfafnamemethode vertoont een 
hoge correlatie met dezelfde analyse op het bijbehorende door de arts afgenomen 
materiaal.
In Hoofdstuk 8 onderzochten wij of directe moleculaire triage op basis van DNA-
methylatie op zelf afgenomen materiaal non-inferieur is aan cytologie-triage op 
door de huisarts afgenomen triage-uitstrijkjes voor wat betreft de detectie van 
CIN2 of hoger. Dit hoofdstuk toont de resultaten van een grote gerandomiseerde 
gecontroleerde non-inferioriteitsstudie onder vrouwen die niet hadden deelgenomen 
aan het bevolkingsonderzoek. In totaal werden 46.001 vrouwen (leeftijd 33–63 
jaar), die geregistreerd stonden als non-responder van het bevolkingsonderzoek 
baarmoederhalskanker in 2007, uitgenodigd om materiaal in te sturen afgenomen 
met een HPV-zelfafnameset. 12.819 vrouwen retourneerden zelf afgenomen 
materiaal. De in totaal 1.038 vrouwen die positief testten op HPV op hun zelf 
afgenomen materiaal werden willekeurig toegewezen aan ofwel triage door cytologie 
op een door de huisarts af te nemen uitstrijkje, ofwel aan directe triage op het zelf 
afgenomen materiaal door middel van methylatie-analyse van MAL en miR-124-2 
genen. De triage-positieve vrouwen uit beide groepen werden doorverwezen voor 
colposcopie. Het primaire eindpunt was de detectie van CIN2 of hoger en de studie 
is geanalyseerd op basis van intention to treat. De non-inferiority marge was 0,80.
De detectie van CIN2 of hoger met methylatie-triage was non-inferieur aan die met 
cytologie-triage (90 (17%) van 515 vrouwen vs 75 (15%) van 509 vrouwen; RR 1,19, 
95%-BI 0,90–1,57). Verwijzing voor colposcopie kwam meer voor in de moleculaire 
groep (284 vrouwen, 55%) dan in de cytologiegroep (149 vrouwen, 29%; p<0,0001). 
De gemiddelde tijd tot de diagnose CIN2 of hoger was korter in de moleculaire 
triagegroep (96 dagen, range 44–101) dan in de cytologie-triagegroep (158 dagen, 
range 71–222; p=0,00084). Wij concludeerden dat DNA-methylatie-analyse van MAL 
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en miR-124-2 genen op HPV-positief zelf afgenomen materiaal non-inferieur is aan 
cytologie-triage wat betreft de detectie van CIN2 of hoger. De resultaten van deze 
studie maken de weg vrij naar volledige moleculaire screening.
Primaire HPV-screening, met een aparte rol voor HPV-zelfafnamesets, zal samen 
met HPV-vaccinatie de vorm van de toekomstige baarmoederhalskankerscreening 
bepalen. In Hoofdstuk 9, de algemene discussie, worden de onzekerheden, 
mogelijke bedreigingen en mogelijke kansen voor de toekomstige baarmoeder-
halskankerpreventie besproken. Door de snelle technologische innovatie en nieuwe 
ontdekkingen zal de kennis op het gebied van baarmoederhalskankerpreventie 
blijven veranderen. De screeningsrichtlijnen zullen daarom voortdurend geëva-
lueerd en aangepast moeten worden.
Samenvatting | 
C
H
A
P
T
E
R
.1
0
217

Zusammenfassung | 
C
H
A
P
T
E
R
.1
0
219
Zusammenfassung
Weltweit gibt es bei Frauen nur drei Formen von Krebserkrankungen, die häufiger 
vorkommen als Gebärmutterhalskrebs. Lediglich drei Arten von Krebs haben eine 
höhere Sterblichkeitsrate bei weiblichen Patienten. Dies macht Gebärmutterhalskrebs 
zu einem signifikanten Gesundheitsproblem, vor allem in Entwicklungsländern. 
Seit der Einführung von zytologischen Screenings in vielen westlichen Ländern ist 
sowohl die Anzahl der Neuerkrankungen an Gebärmutterhalskrebs als auch die 
Sterblichkeit daran merklich gesunken.
Obwohl in den Niederlanden ein gutes Screening-Programm für Gebärmutter-
halskrebs besteht, sind weitere Verbesserungen in der Prävention möglich um 
die Neuerkrankungen (700 pro Jahr) und Todesfälle (jährlich 200 - 250) weiter 
zurückzudrängen. Der Gesundheitsminister hat kürzlich eine Neustrukturierung 
des niederländischen Vorsorgeuntersuchungsprogramms für Gebärmutterhalskrebs 
beschlossen. Ab 2016 wird der beim Hausarzt genommene Abstrich nicht mehr 
primär auf zytologischer Ebene untersucht werden. Der Nachweis des humanen 
Papillomavirus (hrHPV) wird an erster Stelle stehen. Non-Responders (Frauen, die 
trotz Erinnerung nicht auf die Einladung zur Untersuchung reagiert haben) werden 
im neuen Modell der Vorbeugeuntersuchung die Möglichkeit bekommen, ein 
Selbstentnahmeset zum HPV-Nachweis (HPV-Selbsttest) zu bestellen.
Eine kurze Übersicht von Überlegungen, die zur Einführung der HPV-Untersuchung 
für Gebärmutterhalskrebs geführt haben, ist in Kapitel 1 zu finden. Hier behandeln 
wir auch die weiteren Verbesserungsmöglichkeiten für HPV-Screenings. Dies ist der 
eigentliche Zweck der Forschungsarbeit, die in dieser Dissertation präsentiert wird. 
Die Teilfragestellungen dieser Studie werden ebenfalls im ersten Kapitel vorgestellt.
Kapitel 2 bietet eine gründliche Übersicht über die Effektivität der momentanen 
Vorbeugeuntersuchungen für Gebärmutterhalskrebs, über vielversprechende 
Strategien bei der HPV-Untersuchung in der Zukunft und über unterschiedliche 
Triagestrategien nach einem HPV-positiven Untersuchungsresultat.
Die Teilnahmequote an sich ist der wichtigste Faktor für ein erfolgreiches 
Screening-Programm. Das Vergrößern des Beteiligungsgrades ist die einfachste und 
effektivste Methode um die Effektivität des Screenings zu verbessern. In diesem 
Kapitel zeigen wir die Schwankungen der Beteiligungsgrade im multinationalen 
Vergleich auf. Diese Schwankungen sind teilweise abhängig von der Aufstellung 
des Screenings (opportunistisch vs. organisiert). Wir geben einen Abriss von in der 
Literatur genannten Beweggründen, die Frauen von einer Teilnahme am Programm 
abhalten und machen Vorschläge zur Verbesserung der Teilnehmerzahlen.
Ein zweiter wichtiger Faktor für die Wirksamkeit eines Screening-Programms, 
so lesen wir in diesem Kapitel, ist die Genauigkeit des angewendeten Screening-
Tests. Das Screening auf Zytologie-Ebene hat die Anzahl der Todesfälle aufgrund 
von Gebärmutterhalskrebs in der Bevölkerung der meisten Wohlstandsländern 
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drastisch verringert. Dennoch kann die Qualität dieses Tests (Sensitivität, Spezifität, 
positiver Vorhersagewert) weiter verbessert werden. Des Weiteren veranschaulicht 
Kapitel 2 die Vorteile von HPV-Tests im Vergleich zu zytologischen Tests. Ein HPV-
Test ist weniger spezifisch, er ist jedoch wesentlich sensitiver in Hinsicht auf das 
Nachweisen von hochgradigen Vorstadien von Krebserkrankungen. Ein anderer 
Vorteil beim HPV-Nachweis ist die Objektivität des Tests und die Reproduzierbarkeit 
im Vergleich zu zytologischen Tests. Zytologie ist nachweislich ausreichend akkurat 
als Triagetest bei HPV-positiven Fällen. Neben dieser Herangehensweise werden in 
diesem Kapitel noch andere aussichtsreiche Triagetechniken besprochen.
Im letzten Teil des Kapitels wird der Selbsttest angesprochen. Das Bieten der 
Möglichkeit zum Selbsttest bei Non-Responders vergrößert den Beteiligungsgrad. 
Letztendlich ist bei einem HPV-positiven Ergebnis, auch bei selbst entnommen 
Material, eine Triage notwendig. Diese kann entweder direkt beim entnommenen 
Material oder bei einem weiteren Abstrich, der durch den Hausarzt genommen 
wurde, stattfinden. Dieses Kapitel behandelt verschiedene zukunftsträchtige 
Techniken, die für das direkte molekulare Testen des selbst entnommenen Materials 
entwickelt werden.
Kapitel 3 beschreibt eine Fragebogen-Studie zur Nicht-Teilnahme von Non-
Responders am regulären Screening-Programm und deren Teilnahmeverhalten bei 
gebotener Möglichkeit zum HPV-Selbsttest. Im Rahmen der PROHTECT 3B-Studie 
(PROHTECT = PRotection by Offering HPV TEsting on Cervicovaginal specimens 
Trial) bekamen 30.130 Frauen einen Fragebogen nebst Selbsttest. Die Analyse dieser 
Studie ist auf 9.484 zurückgesendeten Fragebögen mit selbst entnommenem Material 
(31,5%) und 682 ohne Material (2,3%) basiert. Bei den Rücksenderinnen, die sowohl 
Material als auch den Fragebogen einreichten, wurde als häufigster Grund zur Nicht-
Teilnahme am regulären Screening-Programm angegeben, dass man vergessen hatte 
einen Termin beim Hausarzt zu machen (3.068; 32,3%). Vornehmlichster Grund 
zur Nutzung des Selbsttests war, dass der Zeitpunkt des Tests frei gewählt werden 
werden kann (4.763; 50,2%). Von den Frauen, die den Selbsttest nicht benutzt hatten, 
gaben 30,9% an, lieber doch noch einen Abstrich machen zu lassen. Aus diesem 
Kapitel geht hervor, dass der organisatorische Aufwand die überwiegendste Ursache 
für eine Nicht-Teilnahme am regulären Vorsorgeprogramm ist. Wichtige Gründe, um 
dennoch den Selbsttest zu gebrauchen, sind seine Gebraucherfreundlichkeit und die 
Tatsache, die Ausführung des Tests selbst in der Hand zu haben.
In Kapitel 4 untersuchten wir ein neues Set zur HPV-Selbstentnahme: die Evalyn 
Brush. Zweck dieser Studie war eine Untersuchung der Übereinstimmungen im HPV-
Nachweis zwischen der Evalyn Brush und durch Hausärzte gemachten Abstrichen. 
Auch die Akzeptanz der Sets zur HPV-Selbstentnahme unter den Teilnehmerinnen 
wurde untersucht. Jede der 134 teilnehmenden Frauen, die die gynäkologische 
Ambulanz besuchten, entnahm selbst mittels Selbsttest Material und füllte einen 
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Fragebogen aus. Nach der Selbstentnahme nahm ein Arzt einen regulären Abstrich, 
der in ThinPrep medium konserviert wurde. Der HPV-Nachweis wurde mittels zweier 
HPV-Testmethoden ausgeführt: der SPF10-DEIA-LiPA25 und der GP5+/6+-LQ-Test. Die 
Übereinstimmung beim hrHPV-Nachweis mit dem SPF10-DEIA-LiPA25-Test zwischen 
dem selbstentnommen Material und dem durch den Arzt gemachten Abstrich war 
85,8% (Kappa-Wert, 0,715; 95%-Konfidenzintervall (95%-KI, 0,597-0,843; p=1,000)). 
Die Übereinstimmung beim hrHPV-Nachweis mit dem GP5+/6+-LQ-Test zwischen 
dem selbstentnommen Material und dem durch den Arzt gemachten Abstrich 
war 86,6% (Kappa-Wert, 0,725; 95%-KI, 0,607-0,843; p=0,815). Achtundneunzig 
Prozent der Frauen bewerten ihre Erfahrungen mit dem Selbsttest als ‚gut‘ bis 
‚hervorragend‘. Darüber hinaus bevorzugen 95% der teilnehmenden Frauen die 
Selbstentnahme gegenüber dem ärztlichen Abstrich. Aus dieser Studie schließen wir, 
dass die Selbstentnahme mittels Evalyn Brush genau so gut ist wie ein durch einen 
Arzt gemachter Abstrich und außerdem sehr akzeptabel ist für Frauen.
In Kapitel 5 beschreiben wir die Erkenntnisse aus der PROHTECT 3B-Studie. In dieser 
Studie wurde eine Lavage-Methode (Delphi Screener) mit einer Bürstenabstrich-
Methode (Evalyn Brush) zur Selbstentnahme cervicovaginalen Materials verglichen. 
Ziel der Studie war es, zu ermitteln ob der Beteiligungsgrad bei der Bürstenabstrich-
Methode nicht-inferior ist gegenüber dem Beteiligungsgrad bei der Lavage-Methode. 
Außerdem wurden auch die klinischen Leistungen beider Selbstentnahmemethoden 
sowie deren Akzeptanz festgestellt. Insgesamt wurden 35.477 Frauen, allesamt 
Non-Responders beim regulären Vorsorgeprogramm im Alter von 33 bis 63 Jahren, 
zur Teilnahme eingeladen. Die 30.130 Frauen, die sich zur Teilnahme meldeten, 
empfingen per Zufallsprinzip jeweils entweder einen Delphi Screener oder eine 
Evalyn Brush. Darüber hinaus bekamen sie einen Fragebogen mit dessen Hilfe 
sie die Gebraucherfreundlichkeit des betreffenden Selbsttests bewerten konnten. 
Teilnehmerinnen, deren HPV-Test positiv ausfiel, wurden dazu eingeladen, durch 
einen Arzt einen Abstrich machen zu lassen, der zytologisch beurteilt wurde. Triage-
positive Frauen wurden zur Kolposkopie überwiesen. Insgesamt nahmen 5.218 
Frauen (34,6%) aus der Bürstenabstrich-Gruppe und 4.809 Frauen (31,9%) aus der 
Lavage-Gruppe an der Studie teil, dies führt zu einer absoluten Differenz von 2,7% 
(95%-KI 1,8-4,2). Die Zahl der HPV-positiven Ergebnisse war in beiden Gruppen gleich 
(8,3%, relatives Risiko (RR) 0,99, 95%-KI 0,87-1,13). Der Nachweis von cervicaler 
intraepithelialer Neoplasie (CIN) zweiten Grades oder höher und dritten Grades oder 
höher war in der Bürstenabstrich-Gruppe (2,0% für CIN2 oder höher; 1,3% für CIN3 
oder höher) ebenso groß wie in der Lavage-Gruppe (1,9% für CIN2 oder höher, 1,0% 
für CIN3 oder höher) bei einem kumulativen RR von 1,01, 95%-KI 0,83-1,24 für CIN2 
oder höher und 1,25, 95%-KI 0,92-1,70 für CIN3 oder höher. Beide Selbsttests erzielten 
gleich gute Bewertungen zur Gebraucherfreundlichkeit. Aus dieser Studie schließen 
wir, dass das zur Verfügung stellen der Bürstenabstrich-Methode an ursprüngliche 
Non-Responders hinsichtlich des Beteiligungsgrades nicht-inferior ist gegenüber der 
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Lavage-Methode. Beide Methoden zur Selbstentnahme sind effektiv im Nachweis 
von hrHPV, CIN2 oder höher und CIN3 oder höher, und beide sind akzeptiert.
Primäre Tests auf HPV im Rahmen eines allgemeinen Vorsorgeuntersuchungs-
programms für Gebärmutterhalskrebs haben eine relativ niedrige Spezifität. Ein 
Triagetest ist notwendig um große Mengen Überweisungen und Überbehandlungen 
von HPV-positiven Frauen zu verhindern. Zytologie ist eine oft gebrauchte 
Triagemethode im Falle eines positiven HPV-Tests. Selbst entnommenes Material 
ist jedoch nicht geeignet für eine zuverlässige zytologische Beurteilung. Deshalb 
wird 1) nach wie vor ein durch einen Arzt gewonnener Abstrich gebraucht um eine 
zytologische Untersuchung oder einen anderen Triagetest auszuführen, oder 2) eine 
Triagemethode benötigt, die direkt am selbst entnommenen Material angewendet 
werden kann.
Kapitel 6 präsentiert die Resultate einer Studie, bei der die klinischen Werte der HPV- 
Genotypisierung als Triagetest für hrHPV-positive Frauen mit einem zytologischen 
Befund verglichen wurden; Schwellenwert war ASC-US (Atypical Squamous Cells 
of Undetermined Significance). Diese Studie schloss 520 Frauen mit positivem HPV-
Ergebnis bei selbst entnommenem Material ein. Diese Frauen wurden für einen 
weiteren Triage-Abstrich zum Arzt überwiesen. Achtzehn Strategien wurden anhand 
dieses Triagematerials evaluiert. Das Triagematerial wurde mittels Zytologie und 
HPV- Genotypisierung (Roche Cobas 4800 System) analysiert. Sensitivität, Spezifizität, 
positiver und negativer Vorhersagewert (PPV und NPV), der Prozentsatz der 
Überweisungen und die Anzahl der überwiesenen Frauen die positiv diagnostiziert 
werden mussten (NRND) wurden berechnet für CIN2 oder höher und CIN3 oder 
höher. Vier Triagestrategien erreichten das NPV-Kriterium von >98%, hatten eine 
ähnliche Sensitivität und eine signifikant bessere Spezifität und PPV für CIN3 oder 
höher als die Referenz-Triagestrategie (Zytologie mit ASC-US als Schwellenwert). 
Diese vier Strategien bestanden allesamt aus einer Kombination von sowohl HPV-
Genotypisierung als auch Zytologie: HPV16+ oder ≥LSIL; HPV16+ oder ≥HSIL; (HPV16+ 
oder 18+) oder ≥LSIL; (HPV16+ oder 18+) oder ≥HSIL. Kombinierte Ergebnisse von 
HPV16+ mit einem zytologischen Befund der gleich groß oder größer war als HSIL 
erreichten die höchste Spezifität (74,9%, 95%-KI 70,5-78,9) bei einer vergleichbaren 
Sensitivität (94,4%, 95%-KI 89,0-97,9) wie die Referenz-Strategie (ASC-US oder höher). 
Von diesen vier Strategien hatte HPV16+, mit einem zytologischen Befund der  gleich 
groß oder größer war als HSIL, den niedrigsten Prozentsatz bei den Überweisungen 
zur Kolposkopie (39,5%) im Vergleich zur Referenz-Strategie (52,2%). Alles in 
allem belegt diese Studie, dass eine Kombination von HPV-Genotypisierung und 
Cervixzytologie, wobei der Schwellenwert erhöht wurde, bevorzugt werden kann 
gegenüber einer Triage, die ausschließlich eine zytologische Untersuchung mit ASC-
US als Schwellenwert beinhaltet.
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In Kapitel 7 wurde als Triagetest bei HPV-positiven Frauen die DNA-Methylierungs-
Analyse eines zusätzlichen, ärztlich entnommenen Abstrichs mit einer zytologischen 
Untersuchung eines ebenfalls ärztlich entnommenen Abstrichs verglichen. 
Weiterhin wurde die Anwendbarkeit der DNA-Methylierungs-Analyse bei mittels 
Bürstenabstrich selbst entnommenem Material untersucht. Non-Responders beim 
regulären Vorsorgeuntersuchungsprogramm für Gebärmutterhalskrebs wurden 
dazu eingeladen, einen Selbsttest (Evalyn Brush) zu gebrauchen; HPV-positive 
Frauen wurden für einen Triage-Abstrich zum (Haus-)Arzt überwiesen. Bei 128 
hrHPV-positiven Abstrichen und 50 daran gekoppelten Selbsttests wurde eine 
DNA-Methylierungs-Analyse ausgeführt mit QSMP für C13ORF18, EPB41L3, JAM3 
und TERT. Im durch einen Arzt gewonnenen Triagematerial lieferte die DNA-
Methylierungs-Analyse mit JAM3 die höchste Spezifität (88%) in Kombination mit 
einer hohen Sensitivität (82%) beim Nachweis von CIN3 oder höher, während 
zytologische Analysen eine Spezifität von 48% und eine Sensitivität von 91% 
erbrachten. Von den 39 Frauen mit abnormalem zytologischen Ergebnis und einem 
normalen histologischen Befund (falsch positiv bei der Zytologie) waren 87% 
negativ bei JAM3 und 90% bei C13ORF18. Die Übereinstimmung zwischen der DNA-
Methylierungs-Analyse bei den durch einen Arzt gemachten Abstrichen und dem 
gekoppelten Material aus dem Selbsttest lag bei 88% für JAM3 (Kappa-Wert, 0,75; 
p<0,001) und bei 90% für C13ORF18 (Kappa-Wert, 0,77; p<0,001). Hieraus schließen 
wir, dass die DNA-Methylierungs-Analyse als Triagetest für hrHPV-positive Frauen 
bessere Leistung erbringt als eine zytologische Untersuchung. Ausschlaggebend ist 
hierbei die höhere Spezifität ohne Verlust an Sensitivität. Weiterhin belegt diese 
Studie, dass die DNA-Methylierungs-Analyse direkt angewendet werden kann auf 
Material, das mittels Bürstenabstrich selbst entnommen wurde. Diese Methode 
der Selbstentnahme liefert eine hohe Korrelation mit derselben Analyse beim 
zugeordneten Material, das durch den Hausarzt entnommen wurde.
In Kapitel 8 erforschten wir, ob eine direkte molekulare Triage auf Basis von DNA-
Methylierung bei selbst entnommenem Material nicht-inferior ist gegenüber einer 
zytologischen Triage bei Triage-Abstrichen die durch den Hausarzt gewonnen wurden, 
wenn es darum geht, CIN2 oder höher nachzuweisen. Dieses Kapitel beinhaltet die 
Resultate einer großen randomisierten kontrollierten Nicht-Inferioritätsstudie unter 
Frauen, die nicht am regulären Vorsorgeprogramm teilgenommen hatten. Insgesamt 
wurden 46.001 Frauen (im Alter von 33 bis 63 Jahren), die als Non-Responders beim 
Vorsorgeprogramm für Gebärmutterhalskrebs im Jahre 2007 registriert worden 
waren, dazu eingeladen, Material einzusenden, das mittels Selbsttest entnommen 
worden war. 12.819 Frauen lieferten selbst entnommenes Material. Die insgesamt 
1.038 Frauen, deren Testergebnis beim selbst entnommenen Material HPV-positiv 
war, wurden willkürlich in zwei Gruppen eingeteilt: Entweder wurde 1) eine Triage 
auf Basis von einem durch den Hausarzt gemachten Abstrich mit zytologischer 
Untersuchung vorgenommen, oder es wurde 2) eine direkte Triage mittels 
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Methylierungs-Analyse von MAL und miR-124-2 Genen am selbst entnommenen 
Material ausgeführt. Die Triage-positiven Frauen aus beiden Gruppen wurden zur 
Kolposkopie überwiesen. Primärer Endpunkt war der Nachweis von CIN2 oder 
höher, die Studie wurde anhand des Intention-to-treat-Prinzips analysiert. Die Marge 
für die Nicht-Infiorität war 0,80.
Der Nachweis von CIN2 oder höher mittels Methylierungs-Triage war nicht-inferior 
gegenüber der zytologischen Triage (90 von 515 Frauen (17%) vs. 75 von 509 Frauen 
(15%); relatives Risiko 1,19, 95%-KI 0,90-1,57). Überweisungen zur Kolposkopie waren 
in der molekularen Gruppe häufiger (285 Frauen (55%)) als in der zytologischen 
Gruppe (149 Frauen (29%); p<0,0001). Die durchschnittliche Zeitspanne bis zur 
Diagnose CIN2 oder höher war in der molekularen Triagegruppe kürzer (96 Tage, 
Spannweite 44-101) als in der zytologischen Triagegruppe (158 Tage, Spannweite 
71-222; p=0,00084). Wir folgern hieraus, dass die DNA-Methylierungs-Analyse von 
MAL und miR-124-2 Genen bei selbst entnommenem, HPV-positivem Material beim 
Nachweis von CIN2 oder höher nicht-inferior ist gegenüber der Zytologie-Triage. Die 
Resultate dieser Studie ebnen den Weg zu einem vollständig molekularen Screening.
Primäres HPV-Screening mit einer besonderen Rolle für Selbsttests, wird 
zusammen mit der HPV-Schutzimpfung die Form des zukünftigen Screenings 
für Gebärmutterhalskrebs bestimmen. In Kapitel 9, der Diskussion, werden 
Unsicherheiten, eventuelle Bedrohungen und denkbare Chancen für die 
Prävention von Gebärmutterhalskrebs in der Zukunft besprochen. Durch schnelle 
technologische Innovationen und neue Entdeckungen wird das Wissen auf dem 
Gebiet der Vorsorge von Gebärmutterhalskrebs sich kontinuierlich verändern. Die 
Richtlinien für Screenings werden darum laufender Evaluierung und Anpassung 
unterliegen müssen.
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List of abbreviations
ASC-H Atypical squamous cells cannot exclude high-grade squamous 
intraepithelial lesion
AGC   Atypical glandular cells
ASC-US   Atypical squamous cells of undertermined significance 
BMD   Borderline or mild dyskaryosis
CONSORT  CONsolidated Standards Of Reporting Trials
CADM1  Cell adhesion molecule 1
CI    Confidence interval
CIN   Cervical intraepithelial neoplasia
CIN2+  CIN2, CIN3 or cancer
CIN3+  CIN3 or cancer
CISOE-A  Composition, Inflammation, Squamous epithelium, Other and 
endometrium, Endocervical columnar epithelium and Adequacy 
of the smear
DEIA   DNA enzyme immuno assay
DNA   Desoxyribo nucleic acid
E   Early region (E1-E7 in HPV genome)
et al.  et alii, and others
FDA  Food and Drug Administration
GP   General practitioner
GP 5+/6+ PCR  General primer 5+/6+ Polymerase Chain Reaction
HC2   Hybrid capture 2 HPV DNA test
HPV   Human papillomavirus 
hrHPV   High-risk human papillomavirus 
HSIL   High-grade squamous intraepithelial lesion 
IQR  Interquartile range
κ  Kappa-value
L   Late region (L1 and L2 in HPV genome)
LBC  Liquid-based cytology
LCR   Long control region
LiPA  Line probe assay
LSIL   Low-grade squamous intraepithelial lesion 
MAL  T-lymphocyte maturation associated protein
mRNA   Messenger RNA
MCM-2  Minichromosome maintenance protein 2
MiR-124-2 MicroRNA-124-2
miRNA  MicroRNAs
NA  Not applicable
NILM  Negative for Intraepithelial Lesion or Malignancy
NPV   Negative predictive value 
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NRND   Number of referrals needed to diagnose 
PAP Papanicolaou
PCR  Polymerase Chain Reaction
PPV   Positive predictive value 
pRb  Retinoblastoma protein
PALGA  Pathologisch anatomisch landelijk geautomatiseerd archief
PROHTECT  PRotection by Offering HPV TEsting on Cervicovaginal specimens 
Trial
QMSP  Quantitative methylation-specific PCR
OR  Odds ratio
RCT   Randomized controlled trial
ROC  Receiver operating characteristic
RR  Relative risk
SD  Standard deviation
SPF  Short PCR fragment
SPSS  Statistical Package for the Social Sciences
TBS  The Bethesda System
TOP2A   Topoisomerase II-α
VIA   Visual inspection with acetic acid
VIAM   Visual inspection with Lugol’s iodine combined with low-level 
magnification 
VILI   Visual inspection with Lugol’s iodine 
WBO  Wet op het bevolkingsonderzoek
WHO    World Health Organization
List of abbreviations | 
C
H
A
P
T
E
R
.1
0
229

Bibliography | 
C
H
A
P
T
E
R
.1
0
231
Bibliography
van Baars R, Bosgraaf RP, ter Harmsel BW, Melchers WJ, Quint WG, Bekkers RL. Dry 
storage and transport of a cervicovaginal self-sample by use of the Evalyn Brush, 
providing reliable human papillomavirus detection combined with comfort for 
women. Journal of clinical microbiology. 2012;50:3937-3943. 
Verhoef VM, Dijkstra MG, Bosgraaf RP, Hesselink AT, Melchers WJ, Bekkers RL, 
Berkhof J, van Kemenade FJ. A second generation cervico-vaginal lavage device 
shows similar performance as its preceding version with respect to DNA yield and 
HPV DNA results. BMC women’s health. 2013;13:21. 
Bosgraaf RP, Mast PP, Struik-van der Zanden PH, Bulten J, Massuger LF, Bekkers 
RL. Overtreatment in a see-and-treat approach to cervical intraepithelial lesions. 
Obstetrics and gynecology. 2013;121:1209-1216. 
Bosgraaf RP, de Jager WC, Servaes P, Prins JB, Massuger LF, Bekkers RL. Qualitative 
insights into the psychological stress before and during colposcopy: a focus group 
study. Journal of psychosomatic obstetrics and gynaecology. 2013;34:150-156. 
Bosgraaf RP, Mast PP, Struik-van der Zanden PH, Bulten J, Massuger LF, Bekkers 
RL. In reply: Overtreatment in a see-and-treat approach to cervical intraepithelial 
lesions. Obstetrics and gynecology. 2013;122:1304-1305. 
Bosgraaf RP, Siebers AG, De Hullu JA, Massuger LF, Bulten J, Bekkers RL, Melchers 
WJ. The current position and the future perspectives of cervical cancer screening. 
Expert review of anticancer therapy. 2014;14:75-92. 
Verhoef VM, Bosgraaf RP, van Kemenade FJ, Rozendaal L, Heideman DA, Hesselink 
AT, Bekkers RL, Steenbergen RD, Massuger LF, Melchers WJ, Bulten J, Overbeek 
LI, Berkhof J, Snijders PJ, Meijer CJ. Triage by methylation-marker testing versus 
cytology in women who test HPV-positive on self-collected cervicovaginal specimens 
(PROHTECT-3): a randomised controlled non-inferiority trial. The lancet oncology. 
2014;15:315-322. 
Bosgraaf RP, Ketelaars PJ, Verhoef VM, Massuger LF, Meijer CJ, Melchers WJ, Bekkers 
RL. Reasons for non-attendance to cervical screening and preferences for HPV self-
sampling in Dutch women. Preventive medicine. 2014;64:108-113. 
Bosgraaf RP, Verhoef VM, Massuger LF, Siebers AG, Bulten J, de Kuyper-de Ridder 
GM, Meijer CJ, Snijders PJ, Heideman DA, IntHout J, van Kemenade FJ, Melchers WJ, 
Bekkers RL. Comparative performance of novel self-sampling methods in detecting 
| Chapter 10
C
H
A
P
T
E
R
.1
0
232
high-risk human papillomavirus in 30,130 women not attending cervical screening. 
International journal of cancer. 2014, doi: 10.1002/ijc.29026. 
Bosgraaf RP, Boers A, van Leeuwen RW, Schuuring E, Heideman DA, Massuger LF, 
Verhoef VM, Bulten J, Melchers WJ, van der Zee AG, Bekkers RL, Wisman GB. DNA 
methylation analysis in self-sampled brush material as a triage test in hrHPV-positive 
women. British journal of cancer. 2014;111:1095-1101.
Bosgraaf RP, de Kuyper – de Ridder GM, Massuger LF, IntHout J, Verhoef VM, 
Heideman DA, Snijders PJ, Meijer CJ, van Kemenade FJ, Bulten J, Siebers AG, Bekkers 
RL, Melchers WJ. The clinical value of HPV genotyping in triage for women with 
high-risk-HPV-positive self-sampled specimens. In preparation. 
Verhoef VM, van Kemenade FJ, Rozendaal L, Heideman DA, Bosgraaf RP, Hesselink 
AT, Massuger LF, Bekkers RL, Berkhof J, Snijders PJ, Meijer CJ. Follow-up of high-risk 
HPV positive women by bi-marker CADM1/MAL methylation analysis and cytology 
on cervical smears. Submitted.
Verhoef VM, Heideman DA, van Kemenade FJ, Rozendaal L, Bosgraaf RP, Hesselink 
AT, Bekkers RL, Massuger LF, Steenbergen RD, Snijders PJ, Berkhof J, Meijer CJ. 
Methylation marker analysis and HPV16/18 genotyping in high-risk HPV positive 
self-sampled specimens to identify women with high grade CIN or cervical cancer. 
Gynecologic oncology. 2014, doi: 10.1016/j.ygyno.2014.08.003. 
Other publications
Aronson DC, Bosgraaf RP, van der Horst C, Ekkelkamp S. Nuss procedure: pediatric 
surgical solution for adults with pectus excavatum. World journal of surgery. 
2007;31:26-29; discussion 30. 
Aronson DC, Bosgraaf RP, Merz EM, van Steenwijk RP, van Aalderen WM, van 
Baren R. Lung function after the minimal invasive pectus excavatum repair (Nuss 
procedure). World journal of surgery. 2007;31:1518-1522. 
Bosgraaf RP, Aronson DC. Treatment of flaring of the costal arch after the minimally 
invasive pectus excavatum repair (Nuss procedure) in children. Journal of pediatric 
surgery. 2010;45:1904-1906. 
Bibliography | 
C
H
A
P
T
E
R
.1
0
233

Dankwoord | 
C
H
A
P
T
E
R
.1
0
235
Dankwoord
Het was een grote uitdaging: een nieuw baan in een nieuwe stad. Het waren 
mooie jaren, waarin ik op heel veel vlakken veel heb geleerd en die uiteindelijk 
hebben geresulteerd in dit proefschrift. Ik wil iedereen bedanken die hieraan heeft 
bijgedragen, in het bijzonder:
Prof. Massuger, beste Leon, jij bewaakte de grote lijnen, hield het overzicht en stuurde 
bij waar nodig. Bedankt voor de verhelderende gesprekken, jouw waardevolle input 
en de kans die je mij hebt gegeven om onderzoek te doen op de al lang bestaande 
cervixlijn.
Dr. Bekkers, beste Ruud, jij was het die me de kans gaf me verder te ontwikkelen 
op onderzoeksgebied. Met klapperende oren kwam ik na onze eerste kennismaking 
uit jouw kamer. Je maakte me enthousiast voor een heel mooi promotietraject. 
Jouw ideeën bleven zich maar aandienen. Ik wil je bedanken voor je geduld, je 
inspirerende begeleiding en de gezellige tijd. 
Dr. Melchers, beste Willem, je had altijd oprechte interesse en een duidelijke, snelle en 
eerlijke manier van communiceren. Dank voor je kritische noten, de verhelderende 
gesprekken en het vertrouwen om mij los te laten in jouw lab.
De afdeling Pathologie was nauw betrokken bij het onderzoek. Dr. Siebers, beste Bert, 
bedankt dat ik mocht delen in jouw onderzoekservaring en jouw specifieke kennis 
over PALGA en de ins en outs van het bevolkingsonderzoek baarmoederhalskanker. 
Dank voor jouw belangrijke bijdrage aan hoofdstuk 2. Dr. Bulten, beste Hans, hartelijk 
dank voor jouw bijdrage aan de verschillende hoofdstukken. Ik heb het gewaardeerd 
dat jij er soms voor zorgde dat mijn PROHTECT-glaasjes boven op de stapel werk 
kwamen te liggen. Jouw specifieke pathologische kennis was van grote waarde.
Alle coauteurs wil ik bedanken voor de samenwerking, hulp en ieders bijdragen 
aan de afzonderlijke hoofdstukken. Beste collega’s van het PROHTECT-team van het 
VUmc, in het bijzonder Viola Verhoef, Peter Snijders, Chris Meijer, Daniëlle Heideman, 
Folkert van Kemenade (nu Erasmusmc), Johannes Berkhof en Lawrence Rozendaal. 
De besprekingen waren altijd bijzonder constructief en de samenwerking heeft 
geleid tot mooie projecten. Viola Verhoef, counterpartner aan het VUmc, bedankt 
voor de goede en leuke samenwerking. Onze grote projecten hebben geresulteerd in 
tal van mooie publicaties. Jij hebt ook een proefschrift om trots op te zijn. Veel succes 
met jouw verdediging en de opleiding tot gynaecoloog!
Romy van Baars, Bram ter Harmsel en Wim Quint, bedankt voor jullie hulp 
en feedback bij hoofdstuk 4. Joanne de Hullu en Kim Meeuwis, dank voor het 
kritisch lezen van hoofdstuk 2. Kim, jij was vaak mijn vraagbaak. Bedankt voor je 
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betrokkenheid. Joanne In ’t Hout, met jouw uitgebreide statistische kennis heb je 
mij goed geholpen. Dank hiervoor. Aniek Boers, Bea Wisman, Ate van der Zee, Ed 
Schuuring, bedankt voor de plezierige samenwerking die uiteindelijk heeft geleid tot 
een mooi gezamenlijk hoofdstuk, hoofdstuk 7. Aniek, succes met jouw opleiding tot 
gynaecoloog!
Alle medewerkers uit het Radboudumc die betrokken waren bij de organisatie van de 
studies wil ik hartelijk danken. Muriël van Bergen – Verkuijlen, Annelies Hoebers  en 
Bart van den Bosch, analisten van de medische microbiologie, heel erg bedankt voor 
alles wat ik van jullie heb mogen leren in het lab en voor jullie inzet bij het testen van 
de duizenden samples. Ik wil alle analisten van de cytopathologie bedanken voor de 
organisatie en de analyse van alle samples uit de PROHTECT studie. Mike van der 
Kolk van de afdeling CRCN, het bouwen en managen van de PROHTECT database 
was een hele klus, dank hier voor. Marc Padros Goossens en Dennis Pasveer van 
de afdeling IQ Health Care, bedankt voor jullie hulp en expertise bij de opzet en 
het management van het vragenlijstonderzoek, jullie expertise was onmisbaar. Nel 
Struik-van der Zanden, bedankt voor je inzet bij de inclusie van hoofdstuk 4. Met 
jouw hulp was dat in een vloek en een zucht gebeurd.
Beste studenten en stagiaires, Caroline, Femke, Fraukje, Gea, Karen, Laura, Linda, 
Marit, Martijn, Michiel, Mieke, Mine, Najiba, Peter-Paul en Willemieke. Wat een 
goed werk hebben jullie verricht. Dank jullie wel! Marieke de Kuyper – de Ridder, 
jouw stage heb je zelfs uitgebreid en in korte tijd heb je heel veel werk verzet voor 
hoofdstuk 5 en 6.
Pleun Ketelaars, dank voor je inzet voor de PROHTECT-3B studie en je vrolijke 
gezelschap bij tal van congressen. Je was de vrolijke noot en voelde je vanaf het 
begin verantwoordelijk voor de organisatie in het PROHTECT-crisiscentrum, later 
omgedoopt tot ‘Chateau Remko’. Je hebt duizenden thuistesten, ordners vol met 
vragenlijsten, opt-out- en informed consent-formulieren door je handen zien 
gaan. Jouw inzet heeft mede geleid tot de totstandkoming van hoofdstuk 3 en 7 
in dit proefschrift. Veel succes met jouw promotietraject. Renée Ebisch, je hebt 
een vliegende start gemaakt met tal van (vervolg)projecten. Veel succes met het 
voortzetten van een mooie onderzoekslijn! 
Lieve (ex-)kantoortuincollega’s. Het was een mooie tijd! Bedankt voor de introductie 
in Nijmegen en bedankt voor alle gezelligheid. 
Beste gynaecologen, arts-assistenten, verloskundigen en verpleegkundigen uit het 
Jeroen Bosch Ziekenhuis. Bedankt voor jullie warme welkom. Ik voel me er op mijn 
plek en ervaar het als een zeer gezellige, veilige en vertrouwde leeromgeving. Ik ben 
in het JBZ met veel plezier begonnen aan mijn opleiding tot gynaecoloog.
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Vera Grossmann und Patric Steinmetz, herzlichen Dank für die Hilfe bei der deutschen 
Zusammenfassung. Roel en Christine, bedankt voor jullie hulp bij de Samenvatting. 
Lieve paranimfen, lieve Renske en lieve Myrtille,
Myrtille, wij zijn bijna gelijk begonnen aan onze onderzoekstijd, samen als ANIOS 
en de komende jaren nog als collega-AIOS. Zie je wel, wij komen er wel! Ik herinner 
me de gesprekjes op de gang waarin we onze blijdschap en frustraties konden delen. 
Nu en dan konden we even bijtanken in een goed restaurant met een goed glas wijn. 
Bedankt dat ik af en toe jouw Thijs even mocht lenen om een rondje mee te fietsen. 
Geweldig dat jij mijn paranimf bent.
Renske, onze vriendschap is begonnen in het eerste jaar Geneeskunde in 
het AMC in Amsterdam en is heel waardevol voor mij. Voor mij was het dan ook 
vanzelfsprekend dat jij, kersverse specialist, naast mij staat als paranimf. 
Lieve papa en mama. Er zijn weinig mensen die zo uitgekeken hebben naar deze 
dag. Jullie onvoorwaardelijke steun en geloof in mij is onbeschrijfelijk. Wie had 
gedacht dat ik hier ooit zo zou staan? Het is een bijzonder gevoel om te weten dat 
jullie zo trots op mij zijn. Lieve Erik, je hebt een inkijkje gekregen in die voor jou rare 
onderzoekswereld. Samen gingen we naar  San Juan, Puerto Rico. Zonder blikken of 
blozen liep jij rond in jouw korte broek en jouw t-shirtje in het congrescentrum. Ik 
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Bedankt voor al je geduld en je liefde. Zonder jouw hulp en steun was het me niet 
gelukt. Je bent degene die mijn teksten het vaakst onder ogen heeft gezien en bent 
daardoor ondertussen zelf ook specialist op het gebied van baarmoederhalskanker 
en HPV. Ik hou van jou.
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Remko Bosgraaf (11 januari 1982, Smallingerland) behaalde zijn vwo-diploma aan de 
CSG Liudger in Drachten en begon aansluitend met de studie geneeskunde aan het 
Academisch Medisch Centrum (AMC) in Amsterdam. Tijdens zijn studie verrichtte hij 
onderzoek bij de afdeling kinderchirurgie in het Emma Kinderziekenhuis AMC (prof. 
dr. D.C. Aronson), wat leidde tot een drietal publicaties over de Nuss-procedure, 
een minimaal invasieve methode voor het corrigeren van een pectus excavatum 
(trechterborst). Zowel zijn reguliere coschap gynaecologie als zijn oudste coschap 
volgde hij op de afdeling verloskunde en gynaecologie van het Zaans Medisch Centrum 
in Zaandam (opleider dr. J.P.R. Doornbos). Na het behalen van zijn artsenbul in 2008 
werkte hij in datzelfde ziekenhuis als arts-assistent verloskunde en gynaecologie. Na 
een jaar maakte hij de overstap naar het Onze Lieve Vrouwe Gasthuis in Amsterdam, 
waar hij nog een jaar als arts-assistent in datzelfde specialisme werkte (opleider dr. 
D.J. Bekedam). In 2010 volgde opnieuw een overstap, ditmaal naar het Radboudumc 
in Nijmegen, om daar bij de gynaecologische oncologie promotieonderzoek te doen 
naar de mogelijkheden tot verbetering van baarmoederhalskankerscreening. Het 
laatste half jaar combineerde hij zijn onderzoek met het werk als arts-assistent 
verloskunde en gynaecologie in het Jeroen Bosch Ziekenhuis in ’s-Hertogenbosch. 
Per augustus 2014 is Remko gestart met de opleiding tot gynaecoloog in het Jeroen 
Bosch Ziekenhuis (opleiders dr. H.P. Oosterbaan en mw. dr. I.P.M. Gaugler - Senden) 
en het Radboudumc (opleider dr. R.L.M. Bekkers).
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